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Transcription by RNA polymerase II (Pol II) is an important step in cell function and regulation. 
Pol II transcription has been shown to be coupled to pre-mRNA splicing, but the underlying 
mechanisms remain poorly understood. Co-transcriptional splicing requires the assembly of a 
functional spliceosome on nascent pre-mRNA, but whether and how this influences Pol II 
transcription remains unclear.  
To investigate this, we used a human erythroleukemic cell line and performed transient 
transcriptome sequencing (TT-seq) and mammalian native elongating transcript sequencing 
(mNET-seq) upon fast inhibition of U2 snRNP function. We further studied how the 
positive transcription elongation factor b (P-TEFb) recruitment is related to the Pol II pause 
duration, using chromatin immunoprecipitation and sequencing (ChIP-seq) of the PTEF-b kinase 
cyclin T1 (CycT1) upon U2 snRNP inhibition. I performed a bioinformatics analysis of the different 
datasets generated for this study and two additional published datasets. I also conducted a multi-
omics analysis combining TT-seq and mNET-seq data to calculate and quantify transcription kinetic 
parameters such as Pol II productive initiation frequency, pause duration and elongation velocity. 
Here we show that inhibition of pre-mRNA branch site recognition by the spliceosome component 
U2 snRNP leads to a widespread and strong decrease in new RNA synthesis from human genes.  
We further show that inhibition of U2 snRNP function increases the duration of Pol II pausing in 
the promoter-proximal region, impairs recruitment of the pause release factor P-TEFb, and reduces 
Pol II elongation velocity at the beginning of genes. Our results indicate that efficient release of 
paused Pol II into active transcription elongation requires the formation of functional spliceosomes 
and that eukaryotic mRNA biogenesis relies on positive feedback from the splicing machinery to 
the transcription machinery. We further show that the fast U2 snRNP inhibition affects the 
expression of genes related to RNA synthesis and it is not related to stress response genes.  
Our new multi-omics approach for the calculation of Pol II elongation velocity can be applied to 
further study the impact on Pol II kinetics regarding different splicing and transcription factors. 
This is of great importance to unravel the mechanisms behind Pol II transcription and splicing and 
understand how the disruption of this regulation leads to several pathological cell phenotypes and 
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This chapter highlights the importance of studying co-transcriptional splicing, the main goals, 
published research manuscript details, and the dissertation organization. 
1. Transcription regulation and splicing 
Transcription is the first step in the biological process of transcribing the genomic information into 
protein. Consequently, transcription regulation is a critical process that impacts the function of the 
cell, the tissue, and the whole organism. Transcription regulation involves a series of different 
processes, including splicing (Li and Liu, 2019; Lodish et al., 2000). The complex splicing process 
requires the assembly of a functional spliceosome on nascent pre-mRNA. Splicing occurs in most 
eukaryote genes in a co-transcriptional manner. It comprises the removal of introns as the nascent 
RNA emerges from RNA polymerase II (Pol II) to generate a functional mature protein-coding 
RNA (Bentley, 2014).   
Splicing is known to have a significant impact on several processes, such as gene expression (Ding 
and Elowitz, 2019), cell cycle (Petasny et al., 2021), and immune activity (Su and Huang, 2021). 
Due to its vast importance in cell regulation, splicing has been associated with several pathologies, 
such as rare genetic diseases and cancer (Coltri et al., 2019; Tang et al., 2021). Splicing modifiers 
have been developed as therapeutic targets for many human disorders to correct for the mentioned 
aberrant splicing or to induce a reduction of the expression level of determined genes or isoforms 
(Tang et al., 2021).  
The study field of systems biology integrates different omics laboratory techniques. Several 
transcriptomics techniques were developed and can be used to study transcription regulation and 
splicing. The processing and visualization of this data require the use of computational resources. 
Thus, bioinformatics analysis is an essential pillar of the systems biology field, which comprises an 
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2. Motivation and aims of this thesis 
Splicing is a critical phenomenon in regulating gene expression, and many human diseases are 
linked to modifications in the splicing process, such as many molecular alterations observed in 
cancer (Coltri et al. 2019). Therefore, it is crucial to study the mechanisms involved in this process, 
especially how splicing and transcription are interlinked. Regarding the up-to-date knowledge, the 
effect of rapid inhibition of spliceosome function on transcription has not yet been investigated.  
 
This study aims to understand the impact of the spliceosome U2 small nuclear ribonucleoprotein 
(snRNP) on transcription and transcription regulation. For that, we used a K562 cell line (Lozzio 
and Lozzio, 1975), an immortalized chronic myelogenous leukemia cell line with many available 
multi-omics sequencing data available at the ENCODE project portal (Sloan et al. 2016; Zhou et 
al. 2019). To study how transcription and splicing are interlinked, we used three orthogonal 
approaches to inhibit U2 snRNP function and monitor RNA synthesis and splicing genome-wide 
using RNA sequencing (RNA-seq) and transient transcriptome sequencing (TT-seq). To inhibit 
U2 snRNP function we used two SF3B1 inhibitors, pladienolide B (Pla-B) and spliceostatin A 
(SSA); and an antisense morpholino oligo (AMO) against U2 snRNA. 
In addition, we studied the RNA polymerase II occupancy profile using mammalian native 
elongation transcript sequencing (mNET-seq) and chromatin immunoprecipitation (ChIP) and 
sequencing (ChIP-seq). We investigated the positive transcription elongation factor b (P-TEFb) 
recruitment through cyclin T1 (CycT1) ChIP-seq. We then performed transcription kinetics 
calculations. Productive initiation frequency was calculated using TT-seq data. A multi-omics 
approach integrating TT-seq and mNET-seq data was performed to calculate Pol II pause duration 
and elongation velocity (Figure 1).  
I performed a bioinformatics analysis of the different datasets generated for this study and the multi-
omics approach for kinetic modeling. Two published datasets were also included (Table S1).  
 
In particular, the following general questions were addressed: 
 
 
A) Does splicing inhibition affects new RNA synthesis? 
 
B) Is co-transcriptional splicing related to Pol II productive transcription initiation 
frequency and promoter-proximal pausing duration? 
 
C) Does co-transcriptional splicing influence Pol II elongation velocity? 
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Figure 1. Study design.  
(A) Overview of the experiments performed. RNA-seq, TT-seq, mNET-seq, and Pol II and CycT1 ChIP-seq were 
performed on K562 cells subjected to control or a U2 snRNA inhibitor treatment. (B) Overview of the 
bioinformatics analysis and the studied parameters with each methodology. Note that Pol II promoter-proximal 
pausing duration and elongation velocity calculations were obtained by a multi-omics approach combining TT-
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3. Publication 
Part of this work has been published as a research manuscript: 
 
Efficient RNA polymerase II pause release requires U2 snRNP function 
Caizzi, L. *, Monteiro-Martins, S. *, Schwalb, B., Lysakovskaia, K., Schmitzova, J., Sawicka, 
A., Chen, Y., Lidschreiber, M., and Cramer, P. (2021). Mol. Cell 81, 1920-1934.e9 
doi: https://doi.org/10.1016/j.molcel.2021.02.016  
(* joint first authorship) 
 
Author contributions: 
Conceptualization, LC and PC. Methodology, LC and BS. Formal Analysis, SMM. Investigation, 
LC, KL, JS, AS and YC. Data Curation: SMM. Writing – Original Draft, LC, SMM and PC. Writing 
- Review & Editing, LC, SMM and PC. Visualization, SMM, LC and PC. Supervision, LC, BS, 
ML and PC. Project Administration, PC. Funding Acquisition, LC, AS and PC. 
 
A detailed summary of items and chapters excerpted or adapted from the manuscript can 
be found in Appendix (see page IV).  
4. Dissertation organization 
The present document is structured in six (VI) chapters. The introductory chapter (I) highlights the 
importance of understanding the mechanisms behind transcription regulation and splicing and the 
motivation and aims of this study. The second chapter includes a literature overview for crucial 
topics essential to understanding the present work, such as RNA transcription cycle, splicing, co-
transcriptional splicing, an overview of transcriptomics analysis methods, and a summary of critical 
software used in the present work.  
A description of the bioinformatics methodology used can be found in the third chapter. The fourth 
chapter shows the main results regarding the impact of U2 snRNP inhibition. In chapter V, a brief 
discussion on the central questions addressed with this study and comment on the methodology 
limitations, and an insight into the remaining questions and future opportunities for this thematic 
are described. Chapter VI includes supplementary information to chapters IV and V, including a 




STATE OF THE ART 
 
I reviewed selected milestones in the transcription field to introduce the reader to the relevant 
information needed to understand this work. In section 1, I focus on the transcription cycle and co-
transcriptional regulation. In section 2, I introduce the splicing concept and focus on co-
transcriptional splicing. In section 3, I describe the most commonly used sequencing assays to study 
transcription and transcription regulation, including multi-omics approaches. In section 4, I 
summarily explain the concept of essential software used in the analysis. 
1. The transcription cycle 
Every cell of a living organism contains the same genetic code comprised of deoxyribonucleic acid 
(DNA) molecules. This genetic information is transcribed into ribonucleic acid (RNA) molecules 
according to the cell and tissue function. RNA molecules occur in different forms, and they can be 
transcribed into proteins or work in various regulatory processes in the cell (Li and Liu, 2019; 
Lodish et al., 2000). RNA transcription is carried out by enzymes named RNA polymerases (Pol). 
More than 50 years ago, three types of polymerases were discovered. Pol I synthesizes the 
ribosomal RNA (rRNA), which accounts for over 50% of the total RNA synthesized in a cell.         
Pol II transcribes messenger RNAs (mRNAs) that will be further transcribed into proteins and many 
non-coding RNAs (ncRNAs). Pol III is responsible for the synthesis of transfer RNAs (tRNAs), 
that are involved in decoding an mRNA sequence, and some other small ncRNAs (Cramer, 2019; 
Roeder, 2019). 
The present work focuses on Pol II transcription, a highly regulated process that can be roughly 
divided into initiation, promoter-proximal pausing, elongation, and termination (Schier and Taatjes, 
2020; Shandilya and Roberts, 2012). This whole process can take between a few seconds to several 
hours in human genes (Alpert et al., 2018). 
 
The transcription initiation comprises DNA opening and the incorporation of the first nucleotide to 
start the mRNA chain. This first step is determined by the formation of a functional pre-initiation 
complex (PIC) which consists of eight factors: transcription factor (TF) IIA, TFIIB, TFIID, TFIIE, 
TFIIF, TFIIH, Pol II, and Mediator complex (Figure 2A). PIC assembles on DNA sequence regions 
called promoters, which serve as binding platforms for proteins to start transcription (Haberle and 
Stark, 2018). A critical and well-defined promoter sequence is the RNA transcription start position, 
denominated transcription start site (TSS) (Roy, 2006). Promoters can be regulated by regulatory 
sequences with approximately 200 base pairs (bp) designated enhancers, which can be located 
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down or upstream the promoter or as far as several thousand bp (Schaffner, 2006). A well-studied 
core promoter sequence is the TATA-box motif positioned around 30 bp upstream of the TSS 
(Haberle and Stark, 2018). In TATA-box containing genes, the first step of PIC formation is the 
recruitment of the TFIID complex TATA-binding protein (TBP) to the TATAA sequence. TBP is 
highly regulated both positively and negatively. TFIIA recruitment will stabilize the interaction 
between TBP and the DNA; TFIIB will also recognize and bind to elements flanking the TATA 
box. Pol II and TFIIF bind to the core promoter, followed by the Mediator complex, TFIIH, and 
TFIIE (Figure 2A). TFIIH is responsible for an ATP-dependent transition between closed and open 
PIC required for productive transcription initiation (Schier and Taatjes, 2020; Shandilya and 
Roberts, 2012). Recently, reconstitution of a human Mediator-PIC complex revealed interaction 
with TFIIH cyclin-dependent kinase (CDK) 7, which is responsible for Pol II carboxy-terminal 
domain (CTD) phosphorylation and promoter-proximal Pol II escape (addressed below on sections 
1.5 and 1.2, respectively) (Rengachari et al., 2021). The Mediator complex CDK8 module impairs 
the binding to PIC, and the CDK8 kinase is responsible for facilitating Mediator dissociation from 
the CDK8 module and consequent binding to PIC (Osman et al., 2021). 
Even though the TATA-box is an extensively studied motif, TATA-less genes are predominant in 
mammalian genomes, while TATA-box-containing genes are associated with a stress response. A 
more abundant core promoter motif in mammalian genomes is the initiator (Int), which overlaps 
the TSS. Int is usually accompanied by a second motif located downstream the TSS, the 
downstream promoter element (DPE). TFIID is suggested to bind DPE (Haberle and Stark, 2018; 
Schier and Taatjes, 2020; Shandilya and Roberts, 2012). 
Another complex involved in transcription initiation is the SAGA co-activator complex. While 
TATA-containing promoters use more frequently the SAGA complex, TATA-less promoters are 
associated with TFIID recruitment. Nevertheless, SAGA and TFIID are redundantly recruited at 




Before continuing into productive elongation, Pol II often stalls 20-60 bp downstream of the TSS; 
an event defined as promoter-proximal pausing. This regulation step is suggested to work as a 
checkpoint before the assembly of elongation factors (Core and Adelman, 2019; Dollinger and 
Gilmour, 2021). Promoter-proximal Pol II pausing is mediated by the negative elongation factor 
(NELF) and the DRB sensitivity inducing factor (DSIF) proteins, which bind to Pol II after 
dissociation of TFIIB, TFIIF, and TFIIE (Figure 2B). NELF is recruited to the paused transcription 
complex by DSIF (Vos et al., 2018a). P-TEFb is part of the multi-subunit super elongation complex 
(SEC) and has a crucial role in releasing Pol II into productive elongation. P-TEFb comprises CDK9 
and cyclin T1 (CycT1) or CycT2. CDK9 phosphorylates NELF resulting in its dissociation from 
the paused transcription elongation complex. DSIF subunit Spt5 is also phosphorylated by CDK9, 
causing a transition in DSIF function from being a pausing factor into a positive elongation factor. 
Besides NELF and DSIF, some other factors were found to be important for promoter-proximal 
pausing regulation, including TFIID, GAGA factor, and Pol II-associated factor 1 (PAF) complex 
(Dollinger and Gilmour, 2021). Bromodomain-containing protein 4 (BRD4) is also associated with 
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transcription elongation and pause release both by P-TEFb recruitment and histone acetylation 
(Itzen et al., 2014; Moon et al., 2005; Yang et al., 2005). 
DNA and RNA sequences have been implicated in promoter-proximal pausing regulation, including 
the enrichment of promoter elements and pause motifs, along with GC-content. Furthermore,          
+1 nucleosome (see section 1.6 for definition) positioning may also play a role in promoting Pol II 
pausing in humans (Dollinger and Gilmour, 2021). The pre-exon junction complex (pre-EJC), 
which assembles on RNA upstream of exon-exon boundaries (Le Hir et al., 2000), is also related to 
Pol II promoter pausing and splicing. The pre-EJC subunit Mago was shown to impact promoter-
proximal pausing and be related to CDK9 occupancy in drosophila (Akhtar et al., 2019; Dollinger 
and Gilmour, 2021). 
 
The processing of Pol II into productive elongation is highly dependent on promoter-proximal 
pausing release and the formation of an active elongation complex (EC*) formed by Pol II, DSIF, 
PAF, and the transcription elongation factor SPT6 (Vos et al., 2018b). P-TEFb phosphorylates      
Pol II CTD, DSIF, and NELF. Upon phosphorylation, NELF is released, allowing the association 
of elongation factors, such as PAF and SPT6 (Dollinger and Gilmour, 2021) (Figure 2C). BRD4 
stimulates P-TEFb to phosphorylate Pol II CTD, releasing paused Pol II into productive elongation 
(Itzen et al., 2014). 
RTF1, a dissociable PAF complex subunit critical for chromatin transcription, stimulates Pol II 
elongation depending on DSIF, PAF, and P-TEFb, but not on SPT6 (Zhang et al., 2020). RTF1 and 
SPT6 bind opposite sides of Pol II (Vos et al., 2018b, 2020).  
 
The end of the transcriptional cycle is marked by Pol II dissociation from the DNA template. The 
most studied termination process depends on polyadenylation (poly(A)) sites. Most protein-coding 
genes contain a conserved poly(A)-site in eukaryotes, which includes an AAUAAA motif. The 
poly(A)-site is recognized by components of the cleavage and polyadenylation complex (CPA), 
and is cleaved by the CPSF73 endonuclease (Eaton and West, 2020; Shandilya and Roberts, 2012). 
Two different models have described poly(A)-site-dependent termination: allosteric/anti-terminator 
and torpedo models. In the allosteric/anti-terminator model, the transcription of a poly(A) will cause 
the dissociation of anti-termination factors, such as the SCAF4 and SCAF8 and a conformational 
change within Pol II that will lead to its termination. In the torpedo model, the termination is 
achieved after a nuclear 5’ → 3’ exonuclease, XRN2 in human (and Rat1 in yeast), degrades the 
Pol II-associated product of poly(A)-site cleavage and helps to dissociate Pol II from the DNA 
template. Recent findings support the existence of a combined model, where an allosteric switch 
decelerates Pol II beyond the poly(A)-site, followed by its termination by XRN2 (Figure 2D). 
However, not every transcript contains a poly(A)-site, as is the case of replication-dependent 
histones (RDH) which 3’ end is cleaved by the CPSF73 endonuclease. In this case, CPSF73 is 
recruited by U7 snRNA, which is part of the histone cleavage complex (HCC). Similarly, snRNAs 
do not contain a poly(A)-site, and its 3’ end processing has been described to be accomplished by 
the multi-subunit integrator complex (Eaton and West, 2020).  
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Recent findings show that early termination can occur in different stages of gene transcription, 
regulated by the integrator complex (Elrod et al., 2019; Tatomer et al., 2019), U1 snRNP (Berg et 
al., 2012; Chiu et al., 2018) and the exosome complex (Davidson et al., 2019). The integrator 
complex role in early termination was related to non-productive elongation regulation (Beckedorff 
et al., 2020; Lykke-Andersen et al., 2021). 
 
Figure 2. The transcription 
cycle.  
(A) Transcription initiation of a 
TATA-box containing gene, 
showing PIC assembly. TFIID 
TBP is recruited to the TATAA 
sequence. TFIIA stabilizes the 
TBP-promoter interaction. TFIIB 
recognizes and binds to elements 
flanking the TATA box. Pol II, 
TFIIF, Mediator complex TFIIH 
and TFIIE bind the core promoter. 
(B) Promoter-proximal pausing 
with DSIF and NELF binding Pol 
II after dissociation of TFIIB, 
TFIIF, and TFIIE. (C)  After P-
TEFb phosphorylates DSIF and 
NELF, Pol II is released into 
productive elongation, leading to 
the transition of DSIF to a positive 
elongation factor and the release of 
NELF. PAF and SPT6 associate 
with Pol II and DSIF to form the 
EC*. Some PIC components 
remain associated at the promoter, 
forming a reinitiating scaffold. (D) 
Termination of a poly(A)-site 
containing gene: poly(A) is 
recognized by CPA and cleavage 
by XRN2. Adapted from (Eaton & 
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RPB1 is the largest subunit of RNA polymerase II. It comprises a tail-like domain that contains a 
unique CTD consisting of heptad repeats of YSPTSPS that is central in the regulation of Pol II 
transcription, including the co-transcriptional splicing process (Harlen and Churchman, 2017; 
Schier and Taatjes, 2020). The residues in the CTD are described based on their position in the 
heptapeptide: Tyr1 Ser2 Pro4 Thr4 Ser5 Pro6 and Ser7. The number of repeats varies between 
species, comprising 26 repeats in yeast and 52 repeats in human. The CTD residues can be subjected 
to several post-translational modifications, promoting or inhibiting proteins’ binding to the CTD. 
The most study modification is phosphorylation (Harlen and Churchman, 2017). 
During transcription pre-initiation, CTD is found in a hypo-phosphorylate form, where the Mediator 
is recruited to the promoter. Pol II CTD becomes phosphorylated at the Ser5 and Ser7 position by 
the THIIH kinase CDK7, to release Pol II from the PIC. Therefore, high peaks of Ser5P and Ser7P 
are found around the TSS and promoter. In metazoans, Tyr1P peaks are also correlated with paused 
Pol II.  Elongating Pol II shows a decrease of Ser5P and an increase of Ser2P and Tyr4P (Figure 
3A). Ser2 is phosphorylated by PTEF-b kinase CDK9 (Harlen and Churchman, 2017).  
Besides its regulation regarding the residues post-translation modifications, it was also shown that 
CTD can undergo liquid-liquid phase separation and that its length is essential for Pol II clustering 
in vivo (Boehning 2018). A human CTD containing only 25 repeats out of the normal 52 will reduce 
the number of Pol II clusters in the nucleus and impacts the transcription activation of target genes 
and their putative enhancer elements (Boehing 2018, Sawicka 2021). 
Pol II CTD phosphorylation is also shown to play a critical role in co-transcriptional splicing (Maita 
and Nakagawa, 2020), which I discuss further below (see section 3.2)  
 
Figure 3. Transcription regulation.  
(A) Pol II CTD phosphorylation profile showing a peak for Ser5, Ser7, and Tyr1 phosphorylation around TSS and 
increase signal of Ser2P and Tyr4P along the gene body. Adapted from (Harlen and Churchman, 2017). (B) 
Schematic representation of the main histone modifications and the correlation with the transcription cycle. 
H3K4me3 effect on H3K9ac is shown with a dotted arrow. Adapted from (Gates et al., 2017a). 
 
Histone modifications have a substantial impact throughout the transcription cycle. The nucleosome 
is the basic unit of eukaryotic chromatin. It consists of a histone octamer: an eight-protein complex 
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formed by two copies each of H3, H4, H2A, and H2B, and 146 base pairs of DNA wrapped around 
the histones. Histones contain regions of polypeptide N-terminal to the central, globular helical 
histone fold that are exposed to broad post-translational modifications (Gates et al., 2017a). 
Different histone modifications are observed during the transcription cycle (Figure 3B). During 
transcription initiation, trimethylation on histone H3 lysine 4 (H3K4me3) is associated with TFIIH 
recruitment and PIC formation and stabilization (Vermeulen et al., 2007). Productive transcription 
elongation is associated with histone lysine acetylation (Church et al., 2017; Gao et al., 2020; Gates 
et al., 2017b). It was found that H3K4me3 triggers H3K9ac (Foulds et al., 2013) and H3K9ac was 
suggested to mediate Pol II pause release through SEC recruitment (Gates et al., 2017b). Likewise, 
H4ac promotes binding of BRD4 and is also related to pausing release (Gonzales-Cope et al., 2016; 
Zippo et al., 2009). 
H3K36me3 is also associated with productive elongation and has an essential role in transcription 
regulation processes, such as preventing cryptic start sites and splicing (Kim et al., 2011; 
Kolasinska-Zwierz et al., 2009; Neri et al., 2017). H3K36me2 and H3K36me3 are correlated with 
de novo DNA methyltransferases DNMT3a and DNMT3b (Dukatz et al., 2019; Rondelet et al., 
2016; Weinberg et al., 2019). H3K36me3 is also correlated with the MRG15 transcription factor 
(Xie et al., 2011) and the transcription repressor ZMYND11 (Guo et al., 2014; Wen et al., 2014). 
H3K79me2 and H3K79me3 were also associated with productive elongation. In humans, DOT1L 
is the enzyme responsible for H3K79 methylation and it has been associated with Pol II CTD and 
SEC (Kim et al., 2012). In addition, H3K79me2 levels are associated with elongation rates, 
suggesting that H3K79me2 can regulate gene expression through DOT1L regulation (Ljungman et 
al., 2019).  
H3K9me2 is associated with transcription termination, specifically at genes that show termination-
associated Pol II pausing. The enzyme responsible for H3K9 methylation, G9 methyltransferase, is 
required for Pol II to pause at the 3’ end and for effective termination (Skourti-Stathaki et al., 2014). 
G9 H3K9 methylation is also responsible for the recruitment of the heterochromatin protein 1 γ 
(HP1γ) that is implicated in splicing (Rachez et al., 2019; Saint-André et al., 2011; Vakoc et al., 
2005). Additionally, H3T45phos was related to termination after exposure to DNA damaging agents 
(Lee et al., 2015). 
2. Co-transcriptional processing 
Mature functional mRNA undergoes processing mechanisms and checkpoints such as 5’ capping, 
splicing, and 3’ processing (de Almeida and Carmo-Fonseca, 2010; Bentley, 2014). The splicing 
mechanism will be further discussed in section 3. 
The first mRNA processing event is the 5’ capping, which occurs shortly after the transcript 
emerges from the RNA exit channel, and it protects the newly synthesized RNA against 
5’_exonucleases. A 7-methylguanosine cap is added to the 5’ end of nascent transcripts. First, the 
triphosphate on the first nucleotide is converted to a diphosphate group. Then, a GMP molecule is 
attached, and the N7 atom of the guanosine base is methylated to produce a mature cap (Kachaev 
et al., 2020). 
The better-characterized cap-binding complexes are the cap-binding complex (CBC) and the 
eukaryotic initiation factor 4F (eIF4F) that is related to translation initiation. CBC is a heterodimer 
formed by 20 and 80 kDa subunits, denominated CBP20 and CBP80, and is related to several 
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processes such as gene expression, RNA processing mechanisms such as splicing, and 3’ end 
formation, transcript nuclear export, and translation (Gonatopoulos-Pournatzis and Cowling, 2014; 
Kachaev et al., 2020).  
Promoter-proximal pausing and 5’ capping were shown to be connected, suggesting a capping 
checkpoint model in which Pol II pausing in the promoter region will ensure the 5’ capping of 
nascent RNA (Kachaev et al., 2020). DSIF subunit SPT5 and Pol II CTD Ser5 phosphorylation 
stimulate RNA capping (Doamekpor et al., 2014; Komarnitsky et al., 2000; Wen and Shatkin, 
1999). Both P-TEFb and NELF interact with CBP, plus NELF was shown to have a role on CBC 
recruitment (Aoi et al., 2020; Lenasi et al., 2011; Narita et al., 2007; Schulze and Cusack, 2017). 
Moreover, CBC has an impact on promoter-proximal pausing release into productive elongation 
(Fujiwara et al., 2019; Lahudkar et al., 2014; Myers et al., 2002; Varshney et al., 2018). 
Regarding 3’ ending processing, most mRNAs contain a poly(A) tail. Therefore, the newly 
synthesize mRNAs undergo RNA cleavage (discussed in section 1.4) and poly(A) tail addition 
(Danckwardt et al., 2008).  The nuclear poly(A) polymerase (PAP) adds between 150 to 250               
A-nucleotides to the mRNA 3’ end in a template-independent manner (Danckwardt et al., 2008). 
However, some mRNAs lack or have a shortened poly(A) tail. Additionally, poly(A) length has 
been associated with an impact on gene expression regulation (Danckwardt et al., 2008; Jalkanen 
et al., 2014). The poly(A) is bound by the polyadenylate-binding nuclear protein 1 (PABPN1, also 
known as PABP2) in the nucleus.  PABPN1 is then replaced in the cytoplasm by the cytoplasmic 
polyadenylate-binding protein (PABPC). PABPC interacts with eIF4G protein from eIF4F 
complex, inducing translation. PABPC also interacts with the eukaryotic release factor 3 (ERF3) 
related to translation termination (Danckwardt et al., 2008).  
3. Transcription and splicing 
 
Splicing is an essential step of gene expression where the introns are removed from precursor 
RNAs, and the flanking exons are joined to generate mature transcripts. These reactions are 
catalyzed by the spliceosome, a multi-megadalton ribonucleoprotein complex. Most eukaryotes 
comprise a major spliceosome that splices U2-type introns and a less common minor spliceosome 
that splices a rarer class of U12-type introns (Will and Lührmann, 2011). Here I will focus on the 
common major spliceosome.  
The major spliceosome is formed by five snRNPs: U1, U2, U4, U5, and U6, containing associated 
snRNAs with specific and shared proteins that recognize conserved RNA elements termed splice 
sites (SS). The 5’ splice site (5’ SS) is located in the exon-intron border (donor site), and the                
3’ splice site (3’ SS) refers to the intron-exon border (acceptor site). Another important sequence is 
the branch site (BS), located from 18 to 40 nucleotides upstream of the 3’ SS. The BS contains an 
adenosine followed by a polypyrimidine tract (Will and Lührmann, 2011).  
Chemically, the splicing process occurs by two consecutive transesterification reactions. In the first 
reaction, the hydroxyl (HO) group of the BS adenosine carries out a nucleophilic attack on the 
phosphate (P) at the 5’ SS. This generates a lariat intermediate and the release of the 5’ exon with 
a HO group. In the second step, the P in the 3’ SS is attacked by the 3’ OH group of the 5’ exon, 
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removing the intron and ligating the two exons together  (Gomez-Escribano and Bibb, 2011) 
(Figure 4A). 
The spliceosome assembly pathway begins with U1 snRNP binding to the 5’ SS and the U2 
auxiliary factor (U2AF) binding to the polypyrimidine tract and the 3’ SS, resulting in the early 
spliceosome E complex. Then, U2 snRNP binds to the BS sequence forming the pre-spliceosome 
A complex. Afterwards, the tri-snRNP U4/U6·U5 is recruited to form the pre-catalytic spliceosome 
B complex. Structural arrangements, including several RNA-RNA interactions, lead to the 
destabilization of U1 and U4 snRNPs and to form the active spliceosome (Bact complex).  Then the 
spliceosome is catalytically activated by the Prp2 ATPase, generating the B* complex, which 
catalyzes the first transesterification reaction, leading to the formation of the C complex. Follows 
the C complex conversion into the activated form by Prp16 and catalyzes the second 
transesterification reaction. Finally, it results in the post catalytic P complex containing the matured 
RNA. Prp22 releases the matured RNA, and Prp43 disassembles the spliceosome (Kastner et al., 
2019; Tellier et al., 2020; Will and Lührmann, 2011) (Figure 4 B). 
 
 
Figure 4. The splicing cycle.  
(A) Schematic representation of the splicing chemical reaction. In the first transesterification reaction, the BS OH 
group attacks the P on the 5’ SS, generating a lariat intermediate. In the second transesterification reaction, the     
5’ exon OH group attacks the 3’ SS P, ligating the exons and releasing the intron. (B) Schematic representation of 
the spliceosome assembly and disassembly pathways. Complex E shows U1 snRNP (blue) bind to the 5’ SS.         
U2 snRNP (green) binds the BS in complex A. The tri-snRNP U4/U6 (pink and red) and U5 (purple) are recruited 
to form complex B, which is further activated (Bact  B*) performing the first chemical reaction. This leads to the 
formation of complex C, which after activation performs the second catalytic step, resulting in P complex. Matured 
RNA is released, and the spliceosome is disassembled. “A” represents the BS adenosine. Adapted from (Tellier et 
al., 2020; Will and Lührmann, 2011). 
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Transcription and splicing are interlinked 
both physically and functionally (Custódio 
and Carmo-Fonseca, 2016; Herzel et al., 
2017; Neugebauer, 2019; Saldi et al., 
2016; Tellier et al., 2020; Wallace and 
Beggs, 2017). More than 30 years ago, 
Beyer and Osheim showed that the introns 
being spliced from nascent transcripts are 
still attached to Pol II on the DNA 
template. This finding was directly 
observed by electron microscopic 
visualization of a Miller chromatin 
spreading method (Miller and Beatty, 
1969) in a drosophila embryo (Beyer and 
Osheim, 1988) (Figure 5).  
 
Splicing and transcription interlink is 
observed throughout the transcription 
cycle. The spliceosome is related to transcription initiation by PIC recruitment and promoter 
selection (Damgaard et al., 2008; Fiszbein et al., 2019). Differences in promoter strength and 
alternative TSS influence alternative splicing (Anvar et al., 2018; Cramer et al., 1997; Fededa et al., 
2005; Kadener et al., 2001). Mediator core component Med23 interacts with splicing factors, 
including the RNA binding protein hnRNP L, and co-immunoprecipitates (IP) with U1 and U2 
snRNAs components (Huang et al., 2012).   
Some studies have also found that splicing can influence transcription; for instance, the presence of 
introns can increase transcriptional efficiency (Brinster et al., 1988; Furger et al., 2002). Splicing 
inhibition reduces transcription from nearby promoters and impacts TSS usage (Fiszbein et al., 
2019). Additionally, a 5’ SS in close proximity with the promoter can enhance transcription in yeast 
and mammals (Furger et al., 2002).  
U1 snRNA was found to associate with TFIIH and thus be involved in transcription initiation (Kwek 
et al., 2002). It was also observed that the insertion of a 5’ SS or a complete intron into an intronless 
gene enhances mRNA production and stimulates early PIC assembly (Damgaard et al., 2008).  
Furthermore, CBC has an impact on co-transcriptional splicing and spliceosome assembly 
(Görnemann et al., 2005; Laubinger et al., 2008; Pabis et al., 2013). Additionally, studies in the 
FOS gene show an interaction between CBC and U4/U6·U5 tri-snRNP (Pabis et al., 2013). 
 
Promoter-proximally paused Pol II release into productive elongation was also observed to be 
correlated with splicing. In drosophila, a reduction in promoter-proximal pausing is observed after 
the knockdown of the pre-EJC component Mago (Akhtar et al., 2019). DSIF affects splicing in both 
S. cerevisiae and mammalian cells (Burckin et al., 2005; Lindstrom et al., 2003; Xiao et al., 2005) 
and can modulate spliceosome assembly (Maudlin and Beggs, 2019).  
Inhibition of NUAK1, a kinase involved with spliceosome activity, increases Pol II occupancy near 
the TSS and at the first exon-intron border and decreases nascent RNA synthesis (Cossa et al., 
 
Figure 5. Co-transcriptional splicing.  
“Miller spread” electron micrograph for a drosophila 
embryo gene (left) and it’s interpretive tracing with a DNA 
strand shown as a dashed line and the other as a dotted line 
(right). It is visible an DNA template with several engaged 
Pol II. Extending from either side of the DNA it’s possible 
to observe Pol II associated nascent transcripts with bound 
proteins (dark blobs). Yellow arrows mark introns spliced 
out co‑transcriptionally. Adapted from (Beyer and Osheim, 
1988) 
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2020). A high Pol II occupancy is also related to retained introns, particularly with Ser2P Pol II 
(Braunschweig et al., 2014).  
U1 snRNP inhibition cause premature cleavage and polyadenylation (PCPA); however, this is not 
observed upon U2 snRNP inhibition (Kaida et al., 2010). U1 role in protecting PCPA also impacts 
transcription, suggesting an additional U1 telescripting role separable from splicing (Berg et al., 
2012; Oh et al., 2017; So et al., 2019).  
 
Splicing occurs in the range of minutes and is limited by the rate of Pol II elongation (Wachutka 
and Gagneur, 2017), which was shown to affect splicing patterns (Aslanzadeh et al., 2018; Braberg 
et al., 2013; Fong et al., 2014; Howe et al., 2003; De La Mata et al., 2003; Maslon et al., 2019). 
Splicing factors stimulate transcription elongation, suggesting a spliceosome-dependent checkpoint 
for elongation. U2 snRNP stimulates elongation in vitro by binding the elongation factor HIV1  
Tat-specific factor 1 (TAT-SF1) that interacts with P-TEFb (Fong and Zhou, 2001). HIV1-Tat 
interacts directly with CycT1 (Garber et al., 1998; Wei et al., 1998) and associates with TFIIF 
RAP30 protein and DSIF domain SPT5 (Kim et al., 1999). Moreover, the splicing factor SKIP 
enhances HIV1-Tat transactivation through P-TEFb interaction (Brès et al., 2005). Also, the         
SR-splicing factor 2 (SRSF2 (or SC35)) influences promoter-proximal release into productive 
elongation and P-TEFb recruitment (Ji et al., 2013; Lin et al., 2008). Recently, it was shown that 
U1 snRNP interacts with elongating Pol II independent of nascent RNA on 5’ SS, suggesting the 
formation of a growing intron loop on Pol II that supports scanning for the BS and the 3’ SS (Zhang 
et al., 2021). 
 
Furthermore, Pol II CTD recruits splicing factors (Emili et al., 2002; Misteli and Spector, 1999; 
Mortillaro et al., 1996; Nojima et al., 2018; Vincent et al., 1996) and stimulates splicing in vitro 
(Hirose et al., 1999) and in vivo (Fong and Bentley, 2001; McCracken et al., 1997). The CTD 
interacts with spliceosomal proteins and regulates spliceosome assembly and splicing (Harlen et al., 
2016; Nojima et al., 2018). Phosphorylation on Ser5 was associated with the 5’ SS in humans 
(Nojima et al., 2015). Mutation of the CTD hampering the phosphorylation on Ser2 impairs 
recruitment of the splicing factor U2AF65 and U2 snRNA, but not of U1 snRNA, impairing co-
transcriptional splicing (Gu et al., 2013). Additionally, U2AF65 was found to bind to 
phosphorylated CTD in vitro (David et al., 2011). Moreover, hyperphosphorylated CTD is 
incorporated into Mediator condensates, preferentially if the condensates are formed by splicing 
factors (Guo et al., 2019). 
 
Histone modifications are also correlated with splicing, having an essential role in alternative 
splicing modulation (Luco et al., 2010). Furthermore, SRSF1 and SRSF2 overexpression and 
splicing inhibition resulted in the decrease of nucleosome occupancy, while an increase is observed 
upon overexpression of the RNA binding protein hnRNP A1 (Keren-Shaul et al., 2013). 
Additionally, splicing regulator Hu proteins can induce local histone hyperacetylation around 
alternative exons regions (Zhou et al., 2011). Splicing inhibition or intron deletion decreases RNA 
transcription and H3K4me3 levels (Bieberstein et al., 2012). Additionally, splicing factors were 
found to be related to tri-methylation of H3K36 (de Almeida et al., 2011; Kim et al., 2011), 
particularly inhibition of SF3B1 and SF3B3 reduces H3K36m3 levels (Convertini et al., 2014; Yuan 
et al., 2009).  
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4. Transcriptomics  
Several different techniques have been developed over the years to study RNA synthesis and 
processing. In vitro biochemical and single-molecule assays are used to determine the structure of 
Pol II, important TFs, and transcription and processing complexes. Fluorescent or bead-based 
assays are used in single-molecule studies; in vivo studies can also be accomplished using imaging 
and system biology (Wang and Greene, 2011; Wissink et al., 2019). Here I will focus on the 
transcription analysis using a systems biology approach with the resource of next-generation 
sequencing (NGS) techniques. 
NGS platforms can sequence millions of small fragments of DNA at the same time. In summary, 
the first step is the library preparation, where the input DNA sample is fragmented, and common 
adapters are added to the small fragments. Then, depending on the sequencing technology, clonally 
clustered amplicons can be generated by different approaches, such as in situ polonies, emulsion 
PCR, and bridge PCR (Ansorge, 2009). 
 
RNA synthesis studies can be conducted with simpler techniques to track individual transcripts, 
such as Northern blots or quantitative PCR. A high throughput analysis became possible with the 
introduction of microarray analysis. Microarray analysis uses microchips with probes to which the 
nucleic acid on the sample will hybridize. However, microarrays are limited to the detection of 
know sequences used as probes (Nelson, 2001).  
NGS technologies provide a quantitative and qualitative study of different RNA types through 
RNA-seq. Short-read cDNA sequencing has been widely used to study transcription and gene 
expression; however, long-read cDNA and direct RNA sequencing approaches are an important 
alternative (discussed in section 4.9) (Stark et al., 2019). Single-cell RNA-seq (scRNA-seq) 
technologies, which provide a transcriptional profile of thousands of individual cells, are also an 
essential resource for transcription analysis from an individual cell point of view (discussed in 
section 4.10) (Chen et al., 2019; Yasen et al., 2020). 
Some differences in RNA extraction and library preparation can be chosen concerning the 
biological questions and sample types (Stark et al., 2019). For instance, the use of a ribosomal RNA 
depletion protocol before library preparation results in greater intron enrichment than the poly(A)+ 
RNA enrichment method. However, available alternative splicing methods work better with the 
poly(A)+ RNA enrichment method (Sultan et al., 2014). 
A more precise analysis of RNA synthesis and transcription processing can be accomplished with 
the study of newly synthesized RNA, which can be achieved by metabolic labeling, where the cells 
are labeled with uridine analogs, such as 4-thiouridine (4sU), 5’-Bromouridine (BrU), and 5-ethynyl 
uridine (EU) (Wissink et al., 2019). 
In Bru-seq, the cells are exposed to BrU for 30 min, and the transcripts tagged with BrU are further 
separated from total RNA using magnetic beads coated with anti-BrdU antibodies. Then, the tagged 
transcripts are converted into a strand-specific cDNA library and subjected to deep sequencing. In 
BruChase-seq, a pulse-chase step is added before purification, permitting the study of the RNA 
stability (Paulsen et al., 2013). In 4sU-seq, cells are briefly treated with 4sU, and the labeled 
transcripts are isolated and sequenced (Garibaldi et al., 2017). To better study initiation frequencies 
and elongation rates, 4sUDRB-seq includes a treatment with DRB to inhibit RNA elongation before 
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labeling the cells with 4sU (Fuchs et al., 2014a). 4sU-seq comprises a 5’ bias due to the brief 3’ end 
labeling. To solve that, TT-seq includes a fragmentation step after labeling, which increases the 
coverage of short-lived introns (Schwalb et al., 2016). SLAM-seq (Herzog et al., 2017), TimeLapse-
seq (Schofield et al., 2018), TUC-seq (Lusser et al., 2020; Riml et al., 2017) and TUC-seq DUAL 
(Gasser et al., 2020) also use 4sU labeling but rely on the chemical conversion of the 4sU into 
cytosine, which will create single nucleotide T > C mutations that are then sequenced by deep 
sequencing. The chemical conversion has the advantage of not requiring enrichment of the labeled 
RNA.  
Several approaches had been developed to study different RNA molecules or processing processes, 
such as Start-seq (Nechaev et al., 2010) and CapSeq (Gu et al., 2012) to study TSS and capping.  
3’-seq (Lianoglou et al., 2013), PAL-seq (Subtelny et al., 2014) and TAIL-seq (Chang et al., 2014) 
are used to explore the role of the 3’ UTRs and the poly(A) tail.  
 
Besides being a DNA-seq based approach, ChIP has an important impact on transcription study. 
This technique can measure the occupancy level of proteins bound to DNA in vivo (Aparicio et al., 
2004). A ChIP assay starts with a cross-linking step (usually using formaldehyde) to stabilize DNA-
protein complexes, followed by cell lysis, chromatin DNA fragmentation/shearing to obtain 
randomized fragments, IP with the antibody of interest, followed by de-cross-linking and DNA 
purification. A ChIP assay can be combined with different technics; for instance, it can be applied 
to a microarray (ChIP-chip) (Ren et al., 2000) or it can be followed by real-time PCR (ChIP-qPCR) 
to investigate target genes (Kim and Dekker, 2018). In 2007, the combination of ChIP with the 
increasing popularity of NGS allowed the development of ChIP-seq, which allows the overall study 
of DNA-protein interactions and histone modifications profiling (Barski et al., 2007; Johnson et al., 
2007; Robertson et al., 2007). Different variations of ChIP-seq have been established since then. 
ChIP-exo and ChIP-nexus use an exonuclease, allowing near-nucleotide resolution (He et al., 2015; 
Rhee and Pugh, 2012).  
Chromatin endogenous cleavage sequencing (ChEC-seq) was developed as an alternative to ChIP-
seq. This approach comprises a DNA-binding protein of interest fused with micrococcal 
nuclease (MNase), which will cleave the DNA around the binding site, removing the need for cross-
linking (Zentner et al., 2015). Later, the same lab updated this approach to develop CUT&RUN. 
Instead of a fusion protein, it uses an antibody against the protein of interest and a pAG-MNase 
enzyme to isolate specific protein-DNA complexes (Skene and Henikoff, 2017). Techniques 
regarding chromatin-protein interactions are mentioned in section 4.7. 
 
DNA:RNA IP followed by sequencing (DRIP-seq) is used to study R-loops formation, which is 
involved in different regulatory mechanisms, such as gene expression. This technique uses a    
DNA-RNA structure-specific S9.6 antibody (Ginno et al., 2012). R-loops are formed by two 
antiparallel DNA strands and one RNA strand that is base-paired to one of the DNA strands while 
the other is unpaired, forming a DNA:RNA hybrid loop (Lieber and Chedin, 2001). 
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Ule et al. developed a cross-linking and IP (CLIP) approach to identify the interaction between 
proteins and RNA. This technique uses UV light to crosslink the proteins near the irradiated bases 
with the RNA; then, the samples are partially digested with RNAse T1 followed by protein 
degradation by proteinase K (Ule et al., 2005). The CLIP approach was further adapted to high 
throughput sequencing (CLIP-seq or HITS-CLIP) (Chi et al., 2009; Licatalosi et al., 2008). Many 
techniques have been derived from CLIP-seq to accomplish nucleotide resolution sequencing.  
PAR-CLIP includes the incorporation of 4sU, allowing for precise identification of the binding sites 
by scoring for T > C transitions in the sequenced cDNA (Hafner et al., 2010). The use of RNAse 
was removed on iCLIP. In this technique, after UV crosslinked, the RNA-protein complex is IP, 
digested by proteinase K, RNA is reverse transcribed, cDNA is truncated at the binding site and 
circularized, followed by PCR amplification and deep sequencing (König et al., 2010). eCLIP is 
another nucleotide resolution CLIP approach which ligates the cDNA to single-stranded DNA 
adapters containing an in-line random-mer sequence to serve as unique identifiers against PCR 
duplicates (Van Nostrand et al., 2016). irCLIP also provides nucleotide resolution by using on-bead 
nuclease digestion (Zarnegar et al., 2016). Some techniques using CLIP were also developed for 
specific analysis, such as AGO-CLIP to detect argonaute protein binding sites (Grosswendt et al., 
2014) or mirCLIP to target miRNA (Imig et al., 2015).  
Another approach to detecting RNA-protein interaction is RNA IP sequencing (RIP-Seq), which, 
unlike CLIP-seq, does not use UV cross-linking. In this process, the RNA-protein complex is IP 
using antibodies against target proteins, followed by RNAse digestion, RNA extraction, and reverse 
sequencing. Even though simpler than CLIP-seq, it relies on the antibody specificity to the target 
protein (Zhao et al., 2010). Targets of RNA-binding proteins identified by editing (TRIBE) 
identifies the RNA-protein interaction of interest by coupling the protein to the catalytic domain of 
the drosophila RNA-editing enzyme ADAR and further identification of the fusion protein 
(McMahon et al., 2016). 
To identify ribosome-engaged mRNAs, two techniques were developed: ribosome profiling   
(Ribo-Seq, also known as ARTseq) and targeted purification of polysomal mRNA (TRAP-Seq) 
(Ingolia et al., 2009; Jiao and Meyerowitz, 2010). In Ribo-seq, the ribosome-bound RNA is digested 
with RNAse, followed by RNA extraction and rRNA depletion, reverse transcription, and 
sequencing (Ingolia et al., 2009). TRAP-seq uses tagged ribosomal proteins that are further purified, 
and the complexed RNA is isolated, reverse transcribed, and sequenced (Jiao and Meyerowitz, 
2010) 
Protein interaction profile sequencing (PIP-seq) provides a protein-footprint based on RNA-protein 
interaction by using two sets of cells, subjected or not to UV cross-linking (Foley and Gregory, 
2016).  
 
Another technique using CLIP was developed to study mRNA secondary structures: hiCLIP 
(Sugimoto et al., 2015). Additionally, a set of different techniques using UV cross-linking were also 
established to focus on RNA-RNA interactions, such as SPLASH (Aw et al., 2016), CLASH-seq 
(Kudla et al., 2011), LIGR-seq (Sharma et al., 2016), and PARIS (Lu et al., 2018).  
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Pol II occupancy can be studied with Pol II ChIP-seq (or the ChIP variants refereed previously in 
section 4.2). The need to increase sequencing resolution led to the development of techniques using 
nuclear run-on assays. In a nuclear run-on assay, the cells are put on ice to stop Pol II transcription; 
then, the nuclei are incubated with nucleoside analogs, followed by the extraction of the run-on 
transcripts (Hirayoshi and Lis, 1999). Global run-on sequencing (GRO-seq) uses 5-bromouridine 
5’-triphosphate (Br-UTP) labeling after nuclei isolation, followed by hydrolyzation, purification, 
and isolation of the run-on transcripts RNAs that are further reverse-transcribed into a cDNA library 
and subjected to deep sequencing. GRO-seq captures the RNA bound to transcriptionally active  
Pol II (Core et al., 2008). Precision run-on sequencing (PRO-seq) includes the incorporation of 
biotin-11-NTPs which will result in the incorporation of a single nucleotide to the transcript and 
therefore improving the technique to a nucleotide resolution. Pol II initiation sites can be mapped 
using a cap selection (PRO-cap) (Kwak et al., 2013). Chromatin run-on and sequencing         
(ChRO-seq) works like a simplified version of PRO-seq that can also be applied to tissue samples. 
In ChRO-seq the nuclei isolation is replaced by an insoluble chromatin fractionation strategy (Chu 
et al., 2018). mNET-seq, adapted from yeast NET-seq (Churchman and Weissman, 2012), also 
produces nucleotide resolution Pol II occupancy. Elongating Pol II complexes are first isolated by 
fractionation, followed by an MNase digestion to break down all exposed DNA. Then, Pol II 
antibodies are used to IP the polymerase with attached RNAs. 3’ linkers are ligated to RNA that is 
then purified and processed into cDNA sequencing libraries (Nojima et al., 2015). Antibodies 
directed to different Pol II CTD states and empigen detergent, which separates RNA processing 
complexes from Pol II, allow for a better understanding of the co-transcriptional process, such as 
splicing (Nojima et al., 2015, 2018; Schlackow et al., 2017). 
 
Chromatin accessibility is an important factor in transcription analysis. In 2006, Crawford et al. 
developed DNAse-chip, a technique based on chromatin digestion with Dnase I, followed by 
hybridization to microarrays (Crawford et al., 2006). Later with the use of NGS, DNAse-seq was 
developed, generating nucleotide resolution sequencing data (Boyle et al., 2008). Formaldehyde-
assisted isolation of regulatory elements (FAIRE) assays, on the other hand, use formaldehyde for 
chromatin cross-linking, following by DNA fragmentation/shearing with sonication and phenol-
chloroform extraction (Giresi et al., 2007). MNase can be used for genomic DNA digestion and to 
study nucleosomes (Cusick et al., 1981). MNase -seq used MNase to degrade the naked DNA around 
the nucleosome, and the DNA from the nucleosome complexes is extracted and subjected to 
sequencing (Schones et al., 2008). A more recent approach, the assay for transposase-accessible 
chromatin with sequencing (ATAC-Seq), uses hyperactive Tn5 to simultaneously cut and ligate 
adapters for high-throughput sequencing at regions of increased accessibility. ATAC-seq data can 
spot both the nucleosome-free regions (shorter reads) and nucleosome positions corresponding to 
DNA fragments protected by a nucleosome (longer read) (Buenrostro et al., 2015a).  
Regarding the analysis of the spatial organization of chromatin in a cell, several techniques 
denominated chromosome conformation capture (3C) have been developed. These approaches 
comprise formaldehyde cross-linking, fragmentation, DNA extraction, and digestion with 
restriction enzymes. 3C techniques can be divided according to their scope. Techniques like 3C-seq 
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(Duan et al., 2012) can quantify interactions between two specific fragments (one-vs-one). 4C-seq 
(Zhao et al., 2006) and Capture-C (Hughes et al., 2014) can quantify interactions between one locus 
and all other genomic loci (one-vs-many). Hi-C (Lieberman-Aiden et al., 2009) allows the 
quantification of chromatin interactions genome-wide (all vs. all). Tiled-C (Oudelaar et al., 2020) 
accomplish a genome-wide interactions analysis with the possibility to precisely identify enhancer-
promoter topologically associating domains (TADs). ChIP-loop (also called CHIP-3C) (Horike et 
al., 2005), ChIA-PET (Li et al., 2014) and HiChIP (Mumbach et al., 2016) combine a 3C approach 
with an IP step using an antibody against the protein of interest. 
Regarding RNA-Chromatin Interactions, several techniques are available. ChIRP-seq (Chu et al., 
2011) and CHART-seq (Simon et al., 2011) use biotinylated probes for the target RNA, followed 
by pull-down and elution of the target complexes. More recently, developed techniques allow the 
identification of RNA-chromatin interaction genome-wide, such as GRID-seq (Li et al., 2017), 
Char-seq (Bell et al., 2018) and RADICL-seq (Bonetti et al., 2020). These approaches use an 
oligonucleotide duplex bridge to ligate at one side the chromatin-associated RNA and at the other 
side the previously digested genomic DNA.  
 
Different approaches are available for transcriptomics analysis techniques, depending on the 
biological question to address and the specific method (Table 1). Regarding RNA synthesis 
approaches, the basic analysis can be summarized as quality control, read assembly, and RNA 
synthesis quantification.  
The first step after sequencing is demultiplexing, where the sequences obtained from one lane are 
assessed to the respective samples, using the barcode information. Then, an evaluation of the raw 
sequences must be performed. A typical software used for this step is FASTQC (Andrews, 2010) 
that comprises both a graphical user interface (GUI) and a terminal version. Other tools for generic 
raw data quality analysis are available, such as FASTX-Toolkit (Hannon, 2010), NGS QC toolkit 
(Patel and Jain, 2012) and EasyQC (Rangamaran et al., 2018). Some critical aspects regarding 
quality check are sequence number, quality and length distribution, GC content, duplicate levels, 
and the presence of contaminators, such as adapters. Some tools were developed for read trimming 
and adapter removal, such as Trimmomatic (Bolger et al., 2014) and Cutadapt (Martin, 2011).  
After read quality control, the most common process is the alignment of the sequenced reads to a 
genome or a transcriptome. Several software were designed to perform the alignment of cDNA 
reads to a reference genome. As an example, a commonly used alignment software is TopHat2 (Kim 
et al., 2013), which uses Bowtie (Langmead et al., 2009) or Bowtie2 (Langmead and Salzberg, 
2012) as a first genome alignment, followed by splice junction identification. Bowtie2 is a fast 
aligner that uses Burrows-Wheeler transforms for indexing. It is mainly used for DNA sequencing 
analysis since it is not splice aware. Another common RNA-seq aligner, STAR (Dobin et al., 2013), 
uses a different strategy to account for spliced isoforms that do not rely on a continuous DNA 
aligner such as Bowtie. Instead, it uses a seed searching step that searches for the longest read that 
matches one or more genome reference sequences and does a sequential mapping until the read is 
completely mapped to the genome, considering the intronic mismatches. Then all the seeds are 
clustered, stitched together, and a local alignment scoring scheme is performed. In this study, STAR 
was used to align the TT-seq, RNA-seq, and mNET-seq sequenced cDNA reads to the genome. 
Bowtie2 was used to align ChIP-seq DNA reads. 
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After read alignment to a reference genome, transcriptome assembly can be performed, where the 
previously mapped reads will be assembled to transcripts and further gene expression 
quantification. Most of these tools use strategies based on graph theories. For example, Cufflinks 
(Trapnell et al., 2010) uses an overlap graph, where the mapped reads form the nodes, and two 
nodes will be connected regarding splicing pattern overlap. Other examples are StringTie (Pertea 
et al., 2015) and Bridger (Chang et al., 2015) that comprise the building of a splice graph. On the 
other hand, SLIDE (Li et al., 2011) uses a linear model for isoform assembly. A different way of 
achieving gene expression levels is by quantifying the number of reads that map to a defined 
sequence feature, such as full transcripts, exons, or introns, which can be achieved with HTSeq 
(Anders et al., 2015) or featureCounts (Liao et al., 2014). An alternative to transcript assembly is 
the direct coverage level study using the reads mapped to the genome. The GenomicRanges and 
GenomicAligments R packages (Lawrence et al., 2013) allow the manipulation of the mapped reads 
to output coverage profiles as well as counting read files. The same could also be achieved in python 
language using PyRanges (Stovner and Sætrom, 2019).  
 
Table 1. Overview of the developed techniques for transcriptomics analysis.  
Representative summary of techniques for transcriptomics study  
Analyses Techniques 
RNA synthesis 
total RNA RNA-seq 
newly synthesised RNA 
4sU-seq, TT-seq, TimeLapse-seq, TUC-seq, TUC-seq 
DUAL, BrU-seq, BruChase-seq,  
specific analysis CapSeq, Start-seq, 3’-seq, PAL-seq, TAIL-seq 
DNA-protein interactions ChIP-seq, ChIP-exo, ChIP-nexus, ChEC-seq, CUT&RUN 
DNA-RNA 
interactions 




CLIP-seq, PAR-CLIP, iCLIP, irCLIP, RIP-seq, TRIBE, 
eCLIP 
specific analysis AGO-CLIP, mirCLIP 
ribosome profiling Ribo-seq, TRAP-seq 
protein-footprint PIP-seq 
RNA-RNA interactions hiCLIP, SPLASH, CLASH-seq, LIGR-seq, PARIS 
Pol II occupancy 




Chromatin accessibility DNAse-seq, Mnase-seq, ATAC-seq, Char-seq 
Chromatin 
interaction  
3C 3C-seq, 4C-seq, Capture-C, Hi-C, Tiled-C, ChIP-loop 
3C + ChIP ChIP-loop, ChIA-PET, HiChIP 
RNA-Chromatin 
interactions 
ChIRP-seq, CHART-seq, GRID-seq, Char-seq, RADICL-
seq 
 
Up to date, the most widely used long-read sequencing (LRS), also known as third-generation 
sequencing, is nanopore by Oxford Nanopore Technologies (ONT) and single-molecule real-time 
(SMRT) by Pacific Biosciences (PacBio). In nanopore sequencing, a single-stranded DNA or RNA 
is passed through a 1.5 nm wide bioengineered protein channel embedded in an electrically resistant 
Chapter II: State of the art 
 21 
polymer membrane (nanopore). An ionic current is passed through this nanopore by setting a 
voltage across this membrane. The current across the channel depends on which nucleotide is 
traversing, allowing for base determination (Wang et al., 2014). In SMRT, adapters are ligated to 
double-stranded DNA, creating a circular template. Then, the DNA template is added together with 
primers and polymerase to a cell containing millions of zero-mode waveguides wells. As the Pol 
incorporates labeled nucleotides, light is immitted, allowing for base determination (Roberts et al., 
2013). However, LRS provides lower per read accuracy than short-read sequencing (Adewale, 
2021; Amarasinghe et al., 2020). LRS has an important impact on sequencing analysis since it 
allows for insight into the structural variant study, base modifications, isoform quantification, and 
splicing analysis. In the light of these advantages, several studies have been performed using LRS 
to study transcription cycle and processing (Carrillo Oesterreich et al., 2016; Drexler et al., 2020, 
2021; Ibrahim et al., 2018; Maier et al., 2020).  
 
Different cell populations within the same tissue can have different gene expressions. scRNA-seq 
permits analyze a specific cell population. A limitation of scRNA-seq is that the amount of RNA 
present in a single cell is on the scale of a picogram, which is significantly lower than necessary for 
any NGS platform. Thus, RNA amplification is a critical step on scRNA-seq. Single-cell 
approaches to study newly synthesized RNA using 4sU labeling have been developed, such as 
scSLAM-seq (Erhard et al., 2019) and NASC-seq (Hendriks et al., 2019). Additionally, chromatin 
accessibility can be studied in a specific cell population using scATAC-seq (Buenrostro et al., 
2015b). Single-cell sequencing can also be used for spatial transcriptomics analysis, allowing the 
analysis of specific cell populations (Nichterwitz et al., 2016; Wang and Greene, 2011). 
 
The integration of different omics techniques can be of great importance to address transcription 
regulation and processing. In our lab, Gressel, Schwalb et al. used a multi-omics analysis to 
calculate Pol II pause duration using TT-seq and mNET-seq (Gressel et al., 2017, 2019). This 
approach was also used in the present work and is further described in the Methods section 5.4.  
Gang et al. integrated data from ChIP-seq for TF and histone modifications with RNA-seq to further 
correlate TFs binding and histone modifications with gene expression level to further characterize 
these co-operations dynamics. They used a machine learning approach by constructing a support-
vector machines (SVM) model to identify TF or histone alterations on gene expression level (Gang 
et al., 2018). Rodrigues et al. used a ratio between TRAP-seq and RNA-seq to calculate the number 
of transcripts bound to ribosomes to the total mRNA abundance (Rodrigues et al., 2020). Zapparoli 
et al. used a multi-omics approach integrating data from ChIRP-Seq, ChIP-Seq, and RNA-Seq to 
identify direct transcriptional targets of an intergenic lncRNA expressed in epithelial tissues 
(Zapparoli et al., 2020). A muti-omics approach was used in the present study to calculate Pol II 
elongation velocity using TT-seq and mNET-seq (see Methods section 5.5). 
Multi-omics analyses are conducted in different fields of complex genetic diseases to correlate 
genetic and epigenetic features. Some of these approaches take advantage of machine learning 
analysis to unravel the causal regulatory interactions (Nicora et al., 2020). For example, for a gene-
wise characterization of cancer-related DNA variants, Kim et al., created a comprehensive Bayesian 
Chapter II: State of the art 
 22 
prior model using TF ChIP-seq, ChIA-PET, and gene expression QTL (eQTL) from breast cancer 
cells. They further tested the transcriptional causality of the previously found interactions with 
microarray and RNA-seq (Kim et al., 2015). 
5. Overview of key software used in this analysis 
The bioinformatics analysis implemented in this work made use of some published software. I will 
briefly describe the principles behind the essential software used. 
 
Salmon uses a dual-phase inference algorithm for alignment and quantification of raw reads to a 
reference transcriptome. This software can be used with both raw or previously mapped reads as 
input. In the present analysis, I used raw reads. First, indexing the transcripts in the reference 
transcriptome is performed, followed by a quasi-mapping approach (by default), determining the 
best mapping for each read. Then, Salmon uses an online (or streaming) inference algorithm to 
estimate fragment abundances using a variant of a stochastic collapsed variational Bayesian 
inference. It also calculates per-fragment conditional probabilities, which will be used to estimate 
auxiliary models and bias terms and to update the abundance estimates. 
In simplified terms, the online inference algorithm will focus on each read separately and calculates 
the alignment’s abundance and collapses reads into equivalent classes. Afterwards, an offline 
inference (also denominated batch inference) algorithm refines the previous findings based on the 
different read classes defined (Patro et al., 2017). 
 
A typical analysis performed using feature counts is the gene expression analysis commonly 
performed with DESeq2 (Love et al., 2014) or edgeR (Robinson et al., 2009) which use a negative 
binomial distribution. In the present work, I used DESeq2 (1.24.0, RRID:SCR_015687) (Love et 
al., 2014) applied to different input counts from TT-seq analysis. DESeq2 is available as a 
R/Bioconductor R package and fits a generalized linear model for each gene following a negative 
binomial distribution. It is based on the analysis of logarithmic fold changes (LFC) of a gene 
expression value. It accounts for the variability between replicates which is a critical step for the 
statistical inference of differential expression (DE) between small sample sizes, such as control vs. 
treatment (Love et al., 2014). 
In summary, it uses an Empirical Bayes shrinkage method in which the prior LFC distribution is 
estimated from the data and shrank towards zero. In that way, it solves the problem found with high 
LFC on genes with low counts. After fitting a generalized linear model to each gene, a Wald test is 
used to test if the shrink LFC divided by its standard error differs significantly from zero, by 
comparison to a standard normal distribution. It also removes outliers using Cooks’ distance which 
measures the effect of deleting a given observation (Love et al., 2014).  
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A widely used approach to highlight biological processes on a group of selected genes is the 
categorization of genes into specific ontologies. Gene ontology (GO) knowledgebase is divided into 
three categories: biological process, cellular component, and molecular function. GO has a 
hierarchical graph structure, where each GO term is a node with related nodes being connected. 
Parent terms are more generalized, while child terms are more specialized. However, one child term 
can have more than one parent term. GO analysis permits us to investigate how likely it is by chance 
that a gene group in the sample is represented in a GO term that contains n genes (Young et al., 
2010). In the present work, I used goseq R/Bioconductor package (1.36.0, RRID:SCR_017052) 
(Young et al., 2010) upon gene expression analysis to identify the enriched GOs in DE genes. Goseq 
accounts for transcript length bias by the estimation of a probability weighting function (PWF) from 
the data. First, the data is classified in a binary fashion: 1 for DE genes and 0 for the remaining 
genes in the sample. Then, a monotonic cubic spline interpolation is fitted to the gene length. 
Therefore, the PWF will quantify the probability of DE gene changes as a function of its length. 
The categories significance is calculated using an approximation obtained by approximating the 
generalized hypergeometric Wallenius distribution for the mean of the values from the PWF for 
each gene in the set and dividing by the mean of the values from the PWF for genes outside the set 






In this chapter are listed the bioinformatics methods used for data analysis. 
The methods described from section 1 to 5 have been adapted from: 
Caizzi, L. *, Monteiro-Martins, S. * et al. Efficient RNA polymerase II pause release requires U2 
snRNP function. (2021). Mol. Cell 81, 1920-1934.e9 
doi: https://doi.org/10.1016/j.molcel.2021.02.016 
(* joint first authorship) 
 
The laboratory experiments were performed by Dr. Livia Caizzi (MPI-bpc, Dept. of Molecular 
Biology), except for mNET-seq experiments which were performed by both Dr. Livia Caizzi and 
Kseniia Lysakovskaia (MPI-bpc, Dept. of Molecular Biology) and can be found in the 
Supplementary information section 1.  
 
The majority of the analysis was conducted using a computer cluster supported by the Gesellschaft 
für wissenschaftliche Datenverarbeitung mbH Göttingen (GWDG). A list of the used software can 
be found below (Table 2).  
 
Table 2. Software resources used in the present work. 
Resource Source Link/identifier 
Operating systems 
macOS High Sierra 
10.13.6 
Apple Inc. https://support.apple.com/macos 
Scientific Linux 
release 7.9 (Nitrogen) 
(cluster) 
Linux distribution https://scientificlinux.org/downloads/ 
Software/tools 
Bowtie 2 (2.3.5)  
 




Cutadapt (1.18)  
 
(Martin, 2011) https://cutadapt.readthedocs.io/en/v1.18/installation.html 
RRID:SCR_011841 
FastQC (0.11.6) (Andrews, 2010) http://www.bioinformatics.babraham.ac.uk/projects/fastqc/ 
RRID:SCR_014583 
HTSeq (0.6.1.p1)  
 
(Anders et al., 2015) https://htseq.readthedocs.io/en/master/ 
RRID:SCR_005514 




Salmon (0.13.1)  
 
(Patro et al., 2017) https://combine-lab.github.io/salmon/ 
RRID:SCR_017036 
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Samtools (1.3.1)  
 
(Li et al., 2009) https://sourceforge.net/projects/samtools/files/samtools/1.3.1
/ 
RRID:SCR_002105 
STAR (2.6.0) (Dobin et al., 2013) https://github.com/alexdobin/STAR, 
RRID:SCR_015899 
R versions and R packages 




(Morgan, 2019) https://www.bioconductor.org 
https://CRAN.R-project.org/package=BiocManager 
RRID:SCR_006442 




biomaRt (2.40.5) (Durinck et al., 2009) https://bioconductor.org/packages/biomaRt/ 
RRID:SCR_019214 
Biostrings (2.50.2) (Pagès H, Aboyoun 




DESeq2 (1.24.0) (Love et al., 2014) https://bioconductor.org/packages/release/bioc/html/DESeq2
.html 
RRID:SCR_015687 









foreach (1.5.1) (Wallig et al., 2018) https://cran.r-project.org/web/packages/foreach/index.html 
GenomicAlignments 
(1.18.1) 











goseq (1.36.0) (Young et al., 2010) https://www.bioconductor.org/packages/release/bioc/html/g
oseq.html 
RRID:SCR_017052 




LSD (4.1-0) (Schwalb et al., 2020) https://CRAN.R-project.org/package=LSD 
refGenome (1.7.7) (Kaisers, 2019) https://CRAN.R-project.org/package=refGenome 
rMATS (4.1.0)  (Shen et al., 2014) http://rnaseq-mats.sourceforge.net/ 
RRID:SCR_013049 




spliceSites (1.31.0) (Kaisers et al., 2017) https://www.bioconductor.org/packages//2.13/bioc/html/spli
ceSites.html 
Figures and document production and edition 
Microsoft Word for 






version 1.19.4  
Elsevier http://www.mendeley.com/ 
RRID:SCR_002750 
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Adobe Illustrator CS6 
version 16.0.4 




The main scripts used for this analysis are stored on GitHub:  
https://github.com/cramerlab/Efficient-RNA-polymerase-II-pause-release-requires-U2-snRNP-
function_2021 
1. Creating annotation files 
 
I downloaded an NCBI RefSeq hg38 genome assembly annotation gtf file from 
https://genome.ucsc.edu/cgi-bin/hgTables, using the following selection: clade Mammal, genome 
Human, assembly Dex.2013 GRCh38/h38, group Gene and Gene Predictions, track NCBI RefSeq, 
table RefSeq Curated. Using the biomaRt R package (2.40.5, RRID:SCR_019214) (Durinck et al., 
2009), I included a column with the feature “gene_name” using the Ensembl gene name annotation. 
I additionally calculated and added some column features, such as transcript length, exon number, 
exon order, intron number, intron order, and UTR length. 
 
In order to reduce the bias when using splice junction regions for analysis and plotting, I created an 
annotation comprising only major transcript isoforms using Salmon (0.13.1, RRID:SCR_017036) 
(Patro et al., 2017). First, I created the index using the RefSeq transcriptome (UCSC RefSeq 
GRCh38, downloaded in April 2019) using the default quasi-mapping mode. Then, the isoforms 
were quantified using RNA-seq reads for 1 h DMSO or 1 M Pla-B treatments, with automatic 
library type detection (-l A) and selective alignment (-validateMappings). 
The output quantification files were further analyzed using the R/Bioconductor environment. 
I removed the entries with transcripts per million (TPM) inferior to 0.5 in every sample and non-
curated RefSeq records. Then, I merged the information from the quantification files from Salmon 
with the general RefSeq annotation file by transcript identifier. 
For each gene, the major transcript isoform was determined as the one with maximum mean TPM 
over all samples. For each condition (DMSO and Pla-B treated samples), the percentage of each 









with TPM 𝑇𝑡𝑔 for n transcripts t in gene g. 
I excluded major transcript isoforms from further analysis if they had a P < 70% in both conditions. 
Furthermore, I used the findOverlaps function from GenomicRanges R package (1.34.0, 
RRID:SCR_000025) (Lawrence et al., 2013) to identify overlapping major isoforms, which were 
discarded from further analysis. To ensure that the definition of a splice junction site was not 
masked by the expression of an overlapping gene, I excluded major isoforms overlapping with other 
annotated gene isoforms (general annotation file). Isoforms located on chromosomes X, Y, and M 
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were removed as well. The final major isoform annotation included 6,694 isoforms containing 
65,976 exons and 59,282 introns with a median transcript length of around 23 kbp, and most 
transcripts containing 4 exons (Figure 6). 
A total of 5,535 major transcript isoforms of protein-coding genes with RPK  50 from TT-seq 
solvent control (DMSO) were included in the analysis.  
 
 
Figure 6. Major isoform annotation metrics.  
(A) Schematic representation of a transcript in the major isoform annotation showing median length for all major 
transcript isoforms (23,274 bp), first and second exon (234 and 126 bp), and first intron (3,914 bp). (B) Bar plot 
showing the number of exons per major isoform transcript.  
 
First, I defined single-exon genes as RefSeq annotated genes comprising one transcript isoform 
with one single exon (using the general annotation file). Then, I filtered the major isoform 
annotation for the defined single-exon genes, accounting for a total of 314 intronless genes. To 
avoid effects from neighboring intron-containing genes, I used the findOverlaps function from 
GenomicRanges R package (1.34.0, RRID:SCR_000025) (Lawrence et al., 2013) to find overlaps 
between intronless genes with an added length of 1 kb at both 5’ and 3’ ends and other intron-
containing annotated transcripts (strand independent). Overlapping genes were removed, leaving 
the intronless genes annotation with a remaining 180 genes. 
Moreover, because a long 3’ UTR has been recently reported to be alternatively spliced in an 
intronless gene (Le François et al., 2018), I investigated if the intronless gene UTR length has an 
impact on new RNA synthesis upon 1 h Pla-B treatment (described below). The analysis was 
performed for 116 expressed protein-coding (see below section 2.1) intronless genes. 5’ UTR and 
3’ UTR length was calculated for each transcript. If alternative start or stop codons were annotated, 
the one closer to the 5’ or 3’ end was selected, respectively.  
A higher impact on RNA synthesis was observed on the third and fourth quartile for both 5’ UTR 
and 3’ UTR (Figure 7). The same trend was not observed for intron-containing genes (Figure S1). 
Therefore, only intronless genes with UTR ≤ 100 bp were included. Thus, a total of 51 expressed 
protein-coding intronless genes were included in the final analysis. 
 






2. General analysis 
 
Paired-end 75 and 150 bp reads with an additional 6 bp of barcodes were obtained for each group 
of samples. First, I performed a quality control analysis on sequence reads using FastQC (0.11.6, 
RRID:SCR_014583) (Andrews, 2010).  
Reads were aligned to the hg38 (GRCh38) genome assembly (Human Genome Reference 
Consortium) using STAR (2.6.0, RRID:SCR_015899) (Dobin et al., 2013), with the following 
specifications: outFilterMismatchNmax 2, outFilterMultimapScoreRange 0 and alignIntronMax 
500000. The human genome was combined with the RNA spike-ins annotation information used 
for normalization (see below). BAM files were then filtered with Samtools (1.3.1, 
RRID:SCR_002105) (Li et al., 2009), to remove alignments with MAPQ smaller than 7 (-q 7), and 
only proper pairs (-f2) were selected.  
I used MarkDuplicates from Picard tools (2.20.5, RRID:SCR_006525) (Broad Institute, 2019) to 
mark duplicated reads that originated from the same DNA fragment. To make sure the duplicate 
numbers were not influencing the results, I conducted a parallel analysis removing the duplicated 
reads. Since the removal of duplicated reads did not change the overall results, we decided not to 
remove the duplicated aligned sequences for further analysis. Moreover, removing duplicated reads 
would bias the calibration strategy using RNA spike-ins, since the relation between the amount of 
initial RNA to the number of reads would be masked.  
Read counts for transcripts, exons, and introns were calculated with HTSeq (0.6.1.p1, 
RRID:SCR_005514) (Anders et al., 2015) using the major isoform annotation. Further data 
processing was carried out using the R/Bioconductor environment.  
Sequence coverage as rle lists 
Sequence coverage lists were calculated using the GenomicAlignments R package (1.18.1) 
(Lawrence et al., 2013) across the bam files to define the number of transcribed bases (tb). Coverage 
lists were stored as run-length-encoded (rle) lists, which are lists of run-length-encoded vectors. 
Rle represents the vector as a set of distinct runs with their own value, i.e. sequentially how many 
times (length) a value is repeated (Lawrence et al., 2013). For the aligned reads with a negative 
Figure 7. UTR length 
impact on Pla-B response 
of intronless genes. 
(A and B) Ratio of 1 μM   
Pla-B to DMSO antisense 
bias-corrected TT-seq read 
counts for 5’ UTR (A) and   
3’ UTR (B) in four different 
intronless gene UTR length 
quartiles. See also Figure S1. 
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inner distance between mate pairs, I calculated the number of tb using the coverage function from 
GenomicAlignments (1.18.1) (Lawrence et al., 2013). In the case of aligned reads with a positive 
inner distance between mate pairs, I used the findOverlaps function from GenomicRanges (1.34.0, 
RRID:SCR_000025) (Lawrence et al., 2013) to investigate if these inner mates overlapped with 
annotated introns (general annotation file). In this case, the inner mates not entirely overlapping 
introns were summed to the coverage calculated on the paired reads. I calculated coverage tables 
with coverage means using the sequence coverage rle lists for each feature (transcripts, exons, and 
introns) as a mean coverage between feature start and end. 
Using spike-ins HTSeq counts to calculate antisense-bias ratio 𝒄𝒋 , sequencing depth 𝝈𝒋 and 
cross-contamination 𝝐𝒋 . 
After treatment, RNA spike-ins were added to lysed cells adjusted to cell number, which allow us 
to further infer the input amount of RNA per sample. The used spike-ins are derived by the external 
RNA controls consortium (ERCC) spike-in mix (Baker et al., 2005). During library preparation, the 
same amount of input RNA (100 ng) was used for each sample to correct for different treatments 
and biological variations bias. In addition, this analysis comprises the 4sU metabolic labeling of 
RNA for the analysis of newly synthesized RNA molecules. To address the ratio of labeled RNA 
to total RNA in the cells half of the internal control spike-ins were labeled in vitro with 4sU      
(Table 3). The spike-in normalization strategy allows for the correction of antisense-bias ratio 𝑐𝑗 , 
sequencing depth 𝜎𝑗 and cross-contamination 𝜖𝑗 . 
 
Table 3. Overview of the RNA Spike-ins used in this work.  
The spike-ins used in this analysis were derived by the ERCC spike-in mix. 
Spike-ins ERCC identifier Length 4sU labeled 
Spike 2 ERCC-00043 1022 yes 
Spike 4 ERCC-00136 1032 yes 
Spike 5 ERCC-00145 1041 no 
Spike 8 ERCC-00092 1123 yes 
Spike 9 ERCC-00002 1060 no 
Spike 12 ERCC-00170 1022 no 
 
• Antisense-bias ratio 
 We used a strand-specific library preparation strategy/kit, which uses a nucleotide analog for 
strand selection. cDNA synthesis on genes overlapping on sense and antisense strands may 
induce the formation of spurious chimeric RNA (Peng et al., 2015). Therefore, the sense 
coverage is constituted by true sense reads and a small number of spurious antisense reads. To 
correct for that, I calculated antisense-bias ratios using spike-in information on sense and 
antisense strand.  
The mapped reads to the spike-ins sequences were counted with HTSeq on both sense and 
antisense strands. Antisense-bias ratios 𝑐𝑗 were calculated for each sample j according to 
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with read counts 𝑘𝑖𝑗  for all available spike-ins i in sample j. Antisense-bias ratios 𝑐𝑗 were inferior 
to 0.005 for all samples. 
• Sequencing depth and spike-in normalization 
The sequencing depth 𝜎𝑗 for each sample can be inferred by the number of reads mapped to 
spike-in sequences. Sequencing depths 𝜎𝑗 were calculated for each sample j according to  




with read counts 𝑘𝑖𝑗for all available spike-ins i in sample j for the RNA-seq samples and for the 
labeled spike-ins i in sample j for the TT-seq samples. 
 
The normalized transcribed bases 𝑁𝑡𝑏𝑖𝑗 were calculated for each sample j according to 




for each genomic position i in sample j. 
• Cross-contamination 
The total RNA found in the TT-seq samples is defined as the cross-contamination 𝜖𝑗  rate and 








with read counts 𝑘𝑖𝑗  for all the labeled spike-ins i in sample j for the TT-seq samples and was 
set to 1 for the RNA-seq samples. Cross contamination 𝜖𝑗  rates were inferior to 0.02 for all TT-
seq samples upon DMSO or Pla-B treatment and were inferior to 0.5 for TT-seq samples from 
SSA and U2 AMO treatments. 
Expression level  
HTSeq read counts were corrected for antisense bias using the previously calculated antisense bias 
ratios 𝑐𝑗 . The number corrected of read counts 𝑐𝑘𝑖𝑗 for transcript i in sample j was calculated as  
𝑐𝑘𝑖𝑗 =  
𝑘𝑖𝑗




with read counts 𝑘𝑖𝑗  for all transcripts i. 
Read counts per kilobase (RPK) were calculated by dividing the corrected read counts by transcript 
length and multiplied by 100. The expressed major isoform transcripts were defined as possessing 
more than 50 RPK in two summarized replicates of TT-seq solvent control (DMSO) for Pla-B 1 h 
treatment. An RPK of 50 corresponds to approximately a coverage of 5 per sample due to an average 
fragment size of 200 and the sum of 2 replicates. 
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Paired-end 42 bp reads with additional 6 bp of barcodes were obtained for each sample. Reads were 
trimmed for adapter content with Cutadapt (1.18, RRID:SCR_011841) (Martin, 2011) with -O 12 -
m 25 -a TGGAATTCTCGG -A GATCGTCGGACT. After adapter removal, a FastQC (0.11.6, 
RRID:SCR_014583) (Andrews, 2010) sample quality report was generated. 
To normalize the mNET-seq data with S. cerevisiae RNA spike-ins, I generated a combined genome 
using the Ensembl genome assembly for both human hg38 (GRCh38) and S. cerevisiae sacCer3 
(R64-1-1) (Table S4). Reads were aligned using STAR (2.6.0, RRID:SCR_015899)                   
(Dobin et al., 2013), with the following specifications: outFilterMismatchNmax 2, 
outFilterMultimapScoreRange 0 and alignIntronMax 500000. Bam files were filtered with 
Samtools (1.3.1, RRID:SCR_002105) (Li et al., 2009) to remove alignments with MAPQ smaller 
than 7 (-q 7) and only proper pairs (-f2) were selected. Similar to TT-seq and RNA-seq, I performed 
the analysis in parallel with and without duplicate removal using MarkDuplicates from Picard tools 
(2.20.5, RRID:SCR_006525) (Broad Institute, 2019).  
Read counts for transcripts were calculated with HTSeq (0.6.1.p1, RRID:SCR_005514) (Anders et 
al., 2015) using the major isoform annotation. Further data processing was carried out using the 
R/Bioconductor environment.  
Sequence coverage as rle lists 
To identify Pol II occupancy, I created rle lists for the mapped reads using the GenomicAlignments 
R package (1.18.1) (Lawrence et al., 2013). Since the Pol II occupancy is given by the last 
sequenced nucleotide, the polymerase occupancy (po) was calculated summing the mapped 
fragments’ endpoints at each genomic position.  
Antisense-bias ratio 
Using mapped reads (bam files) information, the antisense bias ratio was determined using positions 
in regions without antisense annotation with a coverage of at least 100 according to the defined 
major isoforms. Antisense-bias ratio values were inferior to 0.01 in all samples.  
Normalization with S. cerevisiae RNA spike-ins 
To include a spike-in normalization to the mNET-seq data, S. cerevisiae fragmented mRNA was 
added to the samples after IP, accounting for approximately 5% of total RNA.  
Normalization factors 𝑛𝑓𝑗  were calculated using the median of ratios method (Love et al., 2014) on 
antisense corrected HTSeq counts for 5639 S. cerevisiae transcripts with an RPK of 100 or higher 
in two summarized replicates of mNET-seq solvent control (DMSO). 
The normalized polymerase occupancy 𝑁𝑝𝑜𝑖𝑗 were calculated for each sample j according to 




using the calculated normalization factors 𝑛𝑓𝑗  for each genomic position i in sample j. 
Datasets for mNET-seq against CTD ser5P in HeLa cells upon 4 h DMSO or Pla-B treatments were 
obtained from (Schlackow et al., 2017), GEO:GSE81662. Empigen treatment during IP was not 
performed in this publicly available dataset.  
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Paired-end 42 or 75 bp reads with additional 6 bp of barcodes were obtained for each of the samples. 
A combined genome was generated using the Ensembl genome assembly for both human hg38 
(GRCh38) and D. melanogaster dm6 (BDGP6.28) (Table S4). Reads were mapped using         
Bowtie 2 (2.3.5, RRID:SCR_005476) (Langmead & Salzberg 2012). Bam files were filtered with 
Samtools (1.3.1, RRID:SCR_002105) (Li et al., 2009) to remove alignments with MAPQ smaller 
than 7 (-q 7) and only proper pairs (-f 2) were selected. To make sure the duplicate level did not 
affect our results, I performed the analysis in parallel with and without duplicate removal using 
MarkDuplicates from Picard tools (2.20.5, RRID:SCR_006525) (Broad Institute, 2019). Further 
data processing was carried out using the R/Bioconductor environment.  
Sequence coverage as rle lists 
I calculated ChIP-seq sequence coverage rle lists using the GenomicAlignments R package (1.18.1) 
(Lawrence et al., 2013) across mapped fragments for every genomic position. I also created a 
dedicated annotation around the TSS (- 100, + 200 bp) to compare the CycT1/Pol II ChIP-seq 
coverage ratio.  
Normalization with D. melanogaster RNA spike-ins 
To correct for global changes in DNA levels upon treatments, we included a D. melanogaster spike-
in normalization as previously described (Egan et al., 2016). An antibody against D. melanogaster-
specific histone variant H2Av was added to all samples. D. melanogaster S2 sheared cross-linked-
chromatin was added before IP, being 0.2 % of the total chromatin. Normalization factors were 
obtained by dividing the total D. melanogaster mapped reads number for each sample by the 
number of mapped reads of the sample with the lowest reads number. 
Normalized ChIP-seq coverages were obtained for each sample by dividing the ChIP-seq coverage 
by the respective normalization factor.  
3. Splicing ratio 
I performed an exon-based splice junction analysis using TT-seq. In order to reduce bias due to 
library preparation, I only included exons from major isoforms containing a first exon > 100 bp. 
Since we are aiming at exon-intron junctions, I excluded major isoforms with a single annotated 
exon.  
A window of  4 bp around the splice junction (2 bp in the exon and 2 bp in the intron) was defined 
to investigate spliced and unspliced reads employing the findOverlaps function from the 
GenomicRanges R package (1.34.0, RRID:SCR_000025) (Lawrence et al., 2013). This analysis 
was based on exon coordinates; therefore, I defined a window between the start of the exon - 2 bp 
and the start of the exon + 1 bp for 3’ SS. For analysis of the 5’ SS, I defined a window between 
the end of exon -1 bp and the end of the exon + 2 bp (as exemplified in Figure 8). Unspliced reads 
were defined as the ones overlapping at least 3 bp of the defined window and total reads (spliced 
and unspliced) the ones spanning at least 2 bp of the defined window. Afterwards, I calculated the 
number of spliced reads by the difference between total and unspliced reads. The splicing ratio was 
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calculated by dividing the number of spliced reads by the total amount of spliced and unspliced 







the definition of 
total, unspliced 
and spliced reads 





Because our preliminary analysis showed that the transcription levels were decreased upon Pla-B 
treatment, we considered only exon-based splice junctions that were covered by at least 30 total 
reads (spliced and unspliced) in Pla-B, SSA, or U2 AMO treated samples.  
The number of exon-based splice junctions included for each treatment can be found below (Table 
4). 
 
Table 4. Number of exon-based splice junctions included for each treatment 
Sample Exon-based 5’ SS Exon-based 3’ SS First exons Int. exons Last exons 
Pla-B 1 h 15,551 14,840 2,309 13,242 1,598 
Pla-B 4 h 10,041 9,550 1,658 8,383 1,167 
100 nM Pla-B 1 h 9,759 9,845 1,226 8,533 1,312 
30 ng/mL SSA 1 h  16,459 16,178 1,989 14,4470 1,708 
75 µM U2 AMO 1 h 8,928 8,916 1,245 7,683 1,233 
 
To confirm the use of this strategy, I conducted a parallel analysis based on CIGAR strings for TT-
seq transcribed bases between DMSO or 1μM Pla-B treated cells for 1 h. CIGAR stands for compact 
idiosyncratic gapped alignment report, being the representation of spliced alignments found on 
aligned sequence files (sam or bam files). I performed this analysis with the spliceSites R package 
(Kaisers et al., 2017) which focuses on align-gaps (identified by the N CIGAR tag). First, a GapSites 
alignments table was created with readTabledBamGaps function from the spliceSites R package. 
Then, the GapSites were annotated using the getSpliceTable from refGenome R package (Kaisers, 
2019). I removed GapSites with less than 5 alignments throughout all samples or which did not 
include a major isoform annotated transcript. A total of 648 major isoform transcripts were 
evaluated. I used the major isoform annotation to classify the GapSites as 5’ SS or 3’ SS splice 
junctions by matching the GapSite genomic location with exon start and/or end. A total of 7,081   
5’ SS junctions and 7,141 3’ SS junctions were identified.  
4. Identification of splicing affected and unaffected transcripts 
To identify transcripts affected or unaffected by splicing, I performed a differential expression 
analysis on the previously calculated exon-based splice junctions (Figure 9).  
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I used the DESeq2 R package (1.24.0, RRID:SCR_015687) (Love et al., 2014) to test for significant 
changes of splicing ratios between conditions, with design ~ assay + condition + assay:condition, 
where assay corresponds to the number of spliced and total amount of spliced and unspliced reads, 
and condition corresponds to DMSO and Pla-B or DMSO and SSA or Ctr AMO and U2 AMO 
treatments.  
The previously calculated sequencing depths 𝜎𝑗 were introduced as normalization size factors. 
The analysis was focused on the 5’ SS of first exons and 3’ SS of second exons in order to flank the 
first intron. To select splicing affected exons, DESeq2 results (using altHypothesis = “less”) were 
filtered with padj < 0.05 and log2FC < -1.5. To select splicing unaffected exons, DESeq2 results 
(using altHypothesis = “lessAbs” and lfcThreshold = 1.5) were filtered with padj < 0.05. 
 
 
Figure 9. Schematic representation of the analysis for the selection of splicing affected and unaffected 
transcripts.  
Exon-based spliced and unspliced read counts for the 5’ SS corresponding to the first exon and the 3’ SS of the 
second exon were subjected to DESeq2 analysis. Affected and unaffected exon-based junctions were defined. 
Transcripts containing a spliced affected or unaffected first intron were defined if included an affected or 
unaffected first exon on 5’ SS and/or a second exon on 3’ SS. The example for differential expression MA plot for 
the first exon 5’ SS was created with exon-based spliced junctions calculate for DMSO or 1 µM Pla-B treatment 
for 1 h. 
 
The analysis was conducted for 1 h and 4 h DMSO or 1 µM Pla-B treatment, 1 h DMSO or 30 
ng/mL SSA treatment, and 1 h 75 µM Ctr AMO or 75 µM U2 AMO treatment. The number of 
exon-based junctions significantly affected can be found in Table 5, and the number of exon-based 
junctions significantly unaffected can be found in Table 6. Transcripts containing a splicing 
affected first intron were defined as containing a first exon 5’ SS junction significantly affected 
and/or a second exon significantly 3’ SS junction affected (Table 5). Transcripts containing a 
splicing unaffected first intron were defined as containing a first exon 5’ SS junction significantly 
unaffected and/or a second exon significantly 3’ SS junction unaffected (Table 6). There were not 
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identified transcripts containing a first exon 5’ SS junction affected and second exon significantly 
3’ SS junction unaffected nor the other way around.  
 
Table 5. Significantly splicing affected transcripts.  
Number of exon-based splice junctions significantly affected for the 5’ SS of the first exons and 3’ SS of the 
second exon. Number of transcripts identified as having a first intron affected by splicing and number of exons 
included in the affected transcripts.  
Sample First exon 5’ SS Second exon 3’ SS Transcripts Exons from affected transcripts 
Pla-B 1 h 220 186 329 4,326 
Pla-B 4 h 536 428 784 9,771 
SSA 1 h  398 415 606 7,078 
AMO 1 h 180 276 381 5,058 
 
Table 6. Significantly splicing unaffected transcripts.  
Number of exon-based splice junctions significantly unaffected for the 5’ SS of first exons and 3’ SS of the second 
exon. Number of transcripts identified as having a first intron unaffected by splicing and number of exons included 
in the unaffected transcripts. 
Sample First exon 5’ SS Second exon 3’ SS Transcripts Exons from unaffected transcripts 
Pla-B 1 h 316 287 355 2,756 
Pla-B 4 h 187 157 194 1,082 
SSA 1 h  402 372 449 2,842 
AMO 1 h 147 145 177 1,164 
5. Initiation frequency, pause duration, and elongation 
frequency calculation 
To study genome-wide transcription kinetics we used data from TT-seq and mNET-seq experiments 
on cells treated with DMSO or 1 µM Pla-B for 1 h. For elongation velocity calculation we also 
included a published mNET-seq data on HeLa cells for 4 h (Schlackow et al., 2017), 
GEO:GSE81662. I derived the values of productive initiation frequency from TT-seq and used a 
multi-omics approach integrating data from TT-seq and mNET-seq to calculate pause duration and 
elongation velocity.  
 
To infer the productive initiation, pause duration, and elongation frequency units, such as                
cell-1 min -1, min, and bp min-1, respectively, I calculated the RNA amount per cell factor k [cell-1]. 
The calculation of k is possible using the known sequence and mixture of the used spike-ins and 
their molecular weight, and assuming a perfect RNA extraction. 
The RNA amount per cell was calculated using the RNA spike-ins as previously described (Gressel 
et al., 2017, 2019).  





with 50  10-9 g of spike-ins m, 5  107 cells 𝑛 the Avogadro number 𝑁𝐴 and the molar-mass of the 
spike-ins 𝑀 calculated as 
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𝑀 =𝐴𝑛× 329.2 + (1 −  𝜏) ×𝑈𝑛× 306.2 + 𝐶𝑛×  305.2 + 𝐺𝑛×  345.2 + 𝜏 × 𝑈𝑛× 322.26 + 159 
 
Where 𝐴𝑛, 𝑈𝑛, 𝐶𝑛 and 𝐺𝑛 are the number of each respective nucleotide within each spike-in 
polynucleotide (Table 3) calculated based on spike-in sequence (Supplementary information 
section 2). τ is set to 0.1 in case of a labeled spike-in and 0 otherwise (𝜏 × 𝑈𝑛 corresponds to the 
number of 4sU nucleotides). 159 corresponds to the molecular weight of a 5’ triphosphate added to 
facilitate in vitro transcription by T7 polymerase. 
 
Table 7. Number of each nucleotide (A, C, G, and U) and calculated molar-mass for each spike-in sequence 
Spike-ins A C G U M 
Spike 2 354 127 207 297 318331.0 
Spike 4 314 189 243 268 327586.2 
Spike 5 286 207 258 264 327385.0 
Spike 8 233 265 294 287 347569.7 
Spike 9 226 272 276 263 333378.4 
Spike 12 323 114 217 296 306827.0 
 
The conversion factor to RNA amount per cell 𝑘 [cell-1] was then calculated as 
𝑘 = 𝑚𝑒𝑎𝑛 (𝑚𝑒𝑑𝑖𝑎𝑛𝑖 (
𝑡𝑏𝑖
𝐿𝑖 ∙  𝑁
)) 
for all labeled spike-ins i with length 𝐿𝑖 . 
 
 
Pause sites were defined as described (Gressel et al., 2017, 2019) for intron-containing major 
isoforms exceeding 10 kbp in length. Normalized sequence coverage lists generated for mNET-seq 
(see section 2.2) were used to address the Pol II signal strength. The pause site was calculated 
separately for DMSO and Pla-B treated samples using mNET-seq coverage rle lists within a 
window from the TSS to the end of the first exon.  
For intronless genes, the pause site was calculated within a 100 bp window starting at the TSS. 
The pause site m was determined via the maximization of the function 
𝜌𝑖 =  𝑚𝑎𝑥𝑚Ρ𝑖𝑚 
where 𝜌𝑖 needed to exceed 5 times the median of the signal strength Ρ𝑖𝑚 for all non-negative 
antisense bias-corrected mNET-seq coverage values (Nojima et al., 2015). 
 
The initiation frequency was calculated as previously described (Gressel et al., 2017, 2019) for 
intron-containing major isoforms exceeding 10 kbp in length.  
The productive initiation frequency 𝐼𝑖  refers to the transcribed bases by Pol II that initiated and exit 
the promoter-proximal pausing site. Therefore, 𝐼𝑖  was calculated for each major isoform 𝑖 for both 
DMSO and Pla-B treated samples using spike-in normalized TT-seq coverage means (see coverage 
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means on section 2.1) corrected for antisense bias and cross-contamination for major exons, 
excluding the first exon, as 








with labeling time t = 10 and length L. For intronless genes, the productive initiation frequency was 
calculated within a window from the defined pause site on DMSO treated samples + 50 bp until the 
end of the transcript. Genes with a calculation window inferior to 100 bp were excluded from the 
analysis. 
 
Using the mNET-seq information on Pol II occupancy and the TT-seq information on productive 
initiation frequency, we defined the pause duration 𝑑𝑖
𝑐𝑜𝑛𝑑𝑖𝑡𝑖𝑜𝑛 as the time a Pol II needs to pass 
through a defined pause window located around the pause site.  
For each condition (DMSO and Pla-B treated samples), I calculated 𝑑𝑖
𝑐𝑜𝑛𝑑𝑖𝑡𝑖𝑜𝑛 in a window of             
 100 bp around the pause site m as previously described (Gressel et al., 2017, 2019) for intron-
containing major isoforms exceeding 10 kbp in length.  
For intronless genes, I calculated the pause duration 𝑑𝑖
𝑐𝑜𝑛𝑑𝑖𝑡𝑖𝑜𝑛 in a window of  50 bp around the 
pause site m.  
A spike-in corrected and antisense bias-corrected mNET-seq mean coverage for a window of              
 100 bp around the pause site (or  50 bp for intronless genes) was calculated for both conditions 
as 𝑃𝑖
𝑐𝑜𝑛𝑑𝑖𝑡𝑖𝑜𝑛 . The pause duration 𝑑𝑖
𝑐𝑜𝑛𝑑𝑖𝑡𝑖𝑜𝑛 was calculated using the previously calculated 
initiation frequency 𝐼𝑖
𝑐𝑜𝑛𝑑𝑖𝑡𝑖𝑜𝑛and 𝑃𝑖
𝑐𝑜𝑛𝑑𝑖𝑡𝑖𝑜𝑛 as  
𝑑𝑖








𝑐𝑜𝑛𝑑𝑖𝑡𝑖𝑜𝑛 to an absolute scale, Gressel et al. used a Pol II response window calculated by 
comparing CDK9 inhibition (Gressel et al., 2017) or heat shock (HS) derived elongation velocities  
(Gressel et al., 2019). For this analysis, I created a calibration factor s by comparing the median 
pause durations of our DMSO condition with the pause duration for expressed protein-coding genes 
obtained with control condition from the HS experiment on K562 cells (Gressel et al., 2019). 
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Figure 10. Schematic simplified representation of the pause duration calculation.  
Pol II pause site identified using mNET-seq coverage rle lists within the first exon as the highest signal peak (being 
5 times higher than the median). Initiation frequency calculated using TT-seq mean coverage on all exons except 
the first, so that it’s contemplating the number transcribed bases by a productive elongating Pol II. Using the 
mNET-seq mean coverage around the pause site and the calculated initiation frequency we can infer the pause 
duration.  
 
The elongation velocity estimation is based on the principle that the number of transcribed bases 
from Pol II enzymes released into productive elongation can be inferred from TT-seq and the Pol 
II occupancy can be measured with mNET-seq. Therefore, we can estimate Pol II elongation 
velocity by the ratio between the productive initiation frequency calculated with TT-seq and the Pol 
II occupancy calculated with mNET-seq (see Figure 21A). 
For each condition (DMSO and Pla-B treated samples), each feature (exon and intron) in all intron-
containing major isoforms exceeding 10 kbp in length, or intronless genes, the elongation velocity 
𝑣𝑖
𝑐𝑜𝑛𝑑𝑖𝑡𝑖𝑜𝑛  was calculated as 
 
𝑣𝑖
𝑐𝑜𝑛𝑑𝑖𝑡𝑖𝑜𝑛 =  
𝑠 
𝑡 ∙ 𝑘









with calibration factor 𝑠 (please see section 5.4). For meta-gene plotting, the formula was altered 
with a smoothing approach as follows:  
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𝑣𝑖
𝑐𝑜𝑛𝑑𝑖𝑡𝑖𝑜𝑛 =  
𝑠 
𝑡 ∙ 𝑘 ∙ 200









with calibration factor 𝑠 and a weighting vector w𝑖 = (1,2,3,4,5,6,5,4,3,2,1). 
 
Datasets for mNET-seq against CTD ser5P in HeLa cells upon 4 h DMSO and Pla-B treatments 
were obtained from (Schlackow et al., 2017), GEO:GSE81662. Empigen treatment during IP was 
not performed in this publicly available dataset. 
6. Differential expression analysis  
To investigate significant changes in gene expression between samples treated with DMSO or             
1 M Pla-B for 1 h or 4 h, or DMSO or 30 ng/mL SSA or Ctr AMO and U2 AMO, I used the 
DESeq2 R package (1.24.0, RRID:SCR_015687) (Love et al., 2014) with design ~condition on TT-
seq antisense bias-corrected HTSeq counts. The previously calculated sequencing depths 𝜎𝑗 using 
spike-ins were introduced as normalization size factors. I also performed this analysis on published 
TT-seq data from K562 cells subjected to 42 °C HS for 30 min (Gressel et al., 2019). The increased 
intronic signal due to the U2 snRNP inhibition could create a bias on differential expression 
analysis. Thus, I used the sum of the HTSeq exon counts for each transcript to perform the 
differential expression analysis. 
To select upregulated transcripts, DESeq2 results were filtered with padj < 0.05 and log2FC > 0, 
downregulated transcripts were defined as having padj < 0.05 and log2FC < 0.  
The number of defined up and downregulated transcripts for each treatment can be found below 
(Table 8). 
 
Table 8. Number of up and downregulated transcripts upon DESeq2 analysis on TT-seq summed exons 
counts. 
Sample Upregulated  Downregulated 
DMSO vs Pla-B 1 h 11 2,894 
DMSO vs Pla-B 4 h 9 3,705 
DMSO vs SSA 1 h 3 3,721 
Ctr AMO vs U2 AMO 24 2,665 
Control vs 42 °C HS 30 min  
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7. Gene Ontology enrichment analysis 
I performed a GO enrichment analysis on the output from the differential expression analysis (see 
section 6) using goseq (1.36.0, RRID:SCR_017052) (Young et al., 2010). First, I created a binary 
vector defining genes upregulated (as 1) and all other genes used in the analysis (as 0). Then, I 
created a weighting table for each transcript, depending on its length, using the fitting the 
probability weighting function (pwf) function. Goseq was run on the pwf weighting table using the 
default method (Wallenius approximation). The top 10 GO categories overrepresented amongst DE 
transcripts were then selected. I conducted this analysis for all U2 snRNP inhibition TT-seq 
experiments and the published data for HS 30 min treatment (Gressel et al., 2019) as described in 
section 6. 
8. Statistical analysis 
To investigate the correlation between paired data I used the non-parametric Spearman’s correlation 
coefficient test. 
Statistical significance was investigated using the non-parametric Wilcoxon signed-rank test to 
compare treatment and control samples, and the non-parametric Wilcoxon rank-sum test to compare 
different groups of transcripts. 
 
9. Alternative splicing analysis 
I used rMATS (4.1.0, RRID:SCR_013049) (Shen et al., 2014) to search for differential alternative 
splicing events on RNA-seq data for 1h DMSO or 1 M Pla-B treatment. rMATS retrieved a total 
of 61,515 alternative splicing events. However, there were not identified any alternative splicing 








Here are presented the main findings regarding the role of U2 snRNP inhibition in transcription. 
The results presented in section 1 to 6 have been adapted from: 
Caizzi, L. *, Monteiro-Martins, S. * et al. Efficient RNA polymerase II pause release requires U2 
snRNP function. (2021). Mol. Cell 81, 1920-1934.e9 
doi: https://doi.org/10.1016/j.molcel.2021.02.016 
(* joint first authorship) 
1. Rapid splicing inhibition in human cells 
To specifically inhibit spliceosome assembly and function at an early stage genome-wide in human 
cells, we used the splicing inhibitor Pla-B (Kotake et al., 2007). Pla-B binds the spliceosomal U2 
snRNP component SF3B (Cretu et al., 2018; Effenberger et al., 2016; Yokoi et al., 2011), which is 
essential for BS recognition (Gozani et al., 1996, 1998; Krämer et al., 1999), and inhibits usage of 
the BS (Cretu et al., 2018; Effenberger et al., 2016), thereby impairing co-transcriptional splicing 
(Drexler et al., 2020) and perturbing occupancy of genes with transcriptionally engaged Pol II 
(Nojima et al., 2015, 2018; Schlackow et al., 2017). Pla-B binds to a hinge of the SF3B subunit 1 
(SF3B1), blocking SF3B1 in an open conformation that prevents the accommodation and 
stabilization of the U2 snRNA/BS duplex (Cretu et al., 2018). Consequently, Pla-B leads to a stalled 
‘A-like’ spliceosomal complex containing U1 and U2 snRNPs, impairing further spliceosome 
assembly in vitro (Cretu et al., 2018; Effenberger et al., 2016). Consistent with these in vitro studies, 
Pla-B treatment arrests spliceosome assembly in vivo, causing cellular mobilization of the later-
stage spliceosome component U5, but not of U1 and only partially of U2 (Tresini et al., 2015).  
 
To monitor changes in RNA synthesis after spliceosome inhibition, we performed TT-seq and 
RNA-seq in K562 cells treated with 1 M Pla-B or with dimethyl sulfoxide (DMSO) as solvent 
control (Figure 11A). Both Pla-B and DMSO were added to cell media at 1:20,000 dilutions to 
prevent side effects of DMSO (Verheijen et al., 2019). RNA labeling with 4-thiouridine (4sU) was 
carried out for 10 minutes (min). After 1 h of Pla-B treatment, unspliced RT-PCR products and 
intron retention were observed (Figure S2A-B). 
TT-seq and RNA-seq data were generated from two independent biological replicates. To define 
the treatment time, a preliminary analysis was performed on TT-seq shallow sequencing using        
75 bp paired read for samples treated with 1 M Pla-B or DMSO for 30 min, 1 h, and 4 h. Total 
reads sequencing (RNA-seq) was performed for 1 h treatment. An initial quality control check was 
performed with FastQC (Andrews, 2010). On average, we obtained 40 million paired-end reads per 
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sample for TT-seq and 25 million for RNA-seq, with a minimum value of 49% of deduplicated 
reads for TT-seq and 39% for RNA-seq. The percentage of deduplicated reads defines the 
percentage of distinct reads, formed by singletons (reads found one single time) and distinct 
duplicated reads (distinct reads duplicated n times) (Table S5). 
TT-seq and RNA-seq data were mapped against the human hg38 (GRCh38) genome assembly 
(Methods section 2.1). On average, the samples showed 27% duplicated mapped paired reads, 
which had no impact on results output (Methods section 2.1) (Figure S2F-K, Table S5). The 
experiments were highly reproducible (Spearman correlation of 0.9 and 1), with the mapped reads 
showing a uniform fragment size distribution (Figure 11B-G). Since 30 min Pla-B treatment did 
not show an evident impact on new RNA synthesis, it was not used for further analysis (Figure 
S2C-G). TT-seq and RNA-seq data were globally normalized using spike-ins (Methods section 
2.1). Because splicing inhibitors may vary in activity at different introns and can cause intron 
retention or alternative splicing (Corrionero et al., 2011; Teng et al., 2017), we included in our 
analysis only major isoforms with 70 % or higher prevalence per gene in both DMSO and Pla-B 
conditions (Methods section 1.2). For further analysis, we considered 5,535 major isoforms of 
protein-coding genes that showed RPK  50 in TT-seq 1 h solvent control replicates. 
 
 
Figure 11. U2 snRNP inhibition with 1 M Pla-B 
(A) Experimental design. TT-seq was performed on K562 cells after 30 min, 1 h, and 4 h treatments with DMSO 
(solvent control) or 1 M Pla-B using a 10 min 4sU labeling time. 30 min Pla-B treatment was not used for further 
analysis since this shorter treatment time did not show an evident impact on RNA synthesis. (B, D and F) Scatter 
plots comparing TT-seq replicates using antisense bias-corrected counts for major isoforms for samples treated 
with DMSO or 1 μM Pla-B for 1 h (B) and 4 h (D) and RNA-seq for 1 h treatment (F). Spearman correlation of 
0.9 and 1. (C, E and G) Fragment size distribution for paired mapped reads for TT-seq upon 1 h (C) and 4 h (E) 
DMSO or 1 μM Pla-B treatment and for RNA-seq samples treated with DMSO or 1 μM Pla-B for 1 h (G). See 
also Figure S2A-E. 
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We analyzed our TT-seq data for the occurrence of reads spanning exon-intron junctions (5’ SS) 
and intron-exon junctions (3’ SS) (Methods section 3) for a total of 15,551 5’ SS and 14,840 3’ SS 
after 1 h treatment, and for 10,041 5’ SS and 9,550 3’ SS after 4 h treatment. The splicing ratio was 
calculated by dividing the number of spliced reads by the total amount of spliced and unspliced 
reads (Methods section 3). In accordance with our observations (Figure S2A-B), the splicing ratio 
decreased slightly but significantly (Wilcoxon signed-rank test, p-value < 2.2 × 10-16) already after 
1 h of Pla-B treatment (Figure 12A, Figure S3A-D). Splicing inhibition was readily visible at the 
first introns (Figure 12B, Figure S3B), and was observed at all introns genome-wide upon 4 h of 
Pla-B treatment (Figure 12C-D), consistent with earlier observations (Effenberger et al., 2014; 
Nojima et al., 2015). These results show that splicing was rapidly inhibited genome-wide under our 
experimental conditions.  
 
 
Figure 12. Rapid splicing inhibition in human cells  
(A) Ratio of spliced reads over total unspliced and spliced reads upon 1 h of DMSO or 1 μM Pla-B treatments. (B) 
Ratio of spliced reads over total unspliced and spliced reads upon 1 h of DMSO or 1 μM Pla-B treatments in first, 
intermediate (non-first and non-last), and last introns. 4,698 major isoforms containing at least 4 exons were 
considered in the analysis. (C) Ratio of spliced reads over total unspliced and spliced reads as in (A) upon 4 h of 
DMSO or 1 μM Pla-B treatments. (D) Ratio of spliced reads over total unspliced and spliced reads as in (B) upon 
4 h of DMSO or 1 μM Pla-B treatments. Black bars represent the median values for each group. Lower and upper 
boxes are the first and third quartiles, respectively. The ends of the whiskers extend the box by 1.5 times the 
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2. Inhibition of U2 snRNP function decreases RNA synthesis 
Following these findings, we concentrated our analysis on studying the earliest effects of splicing 
inhibition. We sequenced each sample treated with Pla-B for 1 h at a depth of up to 100 million 
paired-end reads and used the concatenated shallow and deep sequencing reads for further analysis 
with an average of 134 million paired-end reads per sample (Table S5). Metagene analysis showed 
that TT-seq coverage across the gene body was strongly reduced (Figure 13A-B, J). The level of 
this reduction was not related to the expression level of genes (Figure 13C), arguing against a direct 
effect of Pla-B on Pol II transcription. TT-seq coverage was still strongly reduced when the 
experiment was repeated with only 100 nM Pla-B (Figure S4, Table S5), a concentration that was 
recently reported to globally diminish co-transcriptional splicing (Drexler et al., 2020). A less 
pronounced decrease in RNA synthesis was observed at intronless protein-coding genes (Figure 
13D), supporting a splicing-independent role of SF3B1 (Van Nostrand et al., 2016; Wang et al., 
2019). The drastic effects of Pla-B on RNA synthesis were only observed by TT-seq, and not by 
RNA-seq (Figure 13E-F), which only detected the splicing defect through an accumulation of 
unspliced introns (Figure 13G). 
Metagene plots of the TT-seq signal upon 4 h of Pla-B treatment showed a change in the slope 
toward the 3’ regions of genes (Figure 13H-J), indicating defects in Pol II elongation or 
processivity.  
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Figure 13. Inhibition of the U2 snRNP factor SF3B1 decreases RNA synthesis.  
(A and H) Metagene analysis comparing TT-seq signal between cells treated with DMSO or 1 μM Pla-B for 1 h 
(A) and 4 h (H). TT-seq coverage was averaged for 5,535 major isoforms scaled between TSS and poly(A)-site. 
See also Figure S2H-I, K. (B and I) Metagene analysis focusing on the expression on TTS and poly(A)-site 
comparing DMSO and 1 μM Pla-B treated cells for 1 h (B) and 4 h (I). TT-seq coverage was aligned at TSS and 
poly(A)-site for 5,465 major isoforms that exceed 1 kbp in length. (C) Scatter plot comparing DMSO TT-seq RPK 
and ratio of Pla-B to DMSO TT-seq RPK upon 1 h (top) and 4 h (bottom) of DMSO or 1 μM Pla-B treatments. 
Spearman correlation of 0.36 for 1 h and 0.27 for 4 h. (D) Intronless genes meta-analysis comparing TT-seq signal 
between cells treated with DMSO and 1 μM Pla-B for 1 h. TT-seq coverage was averaged for 51 intronless genes 
scaled between TSS and poly(A)-site. (E) Metagene analysis comparing RNA-seq signal between cells treated 
with DMSO and 1 μM Pla-B for 1 h. RNA-seq coverage was averaged for 5,535 major isoforms scaled between 
TSS and poly(A)-site.  See also Figure S2J. (F) Meta-analysis comparing RNA-seq signal over exons between 
cells treated with DMSO and 1 μM Pla-B for 1 h. RNA-seq coverage was averaged for 46,243 exons scaled 
between exon start and end site. Solid lines represent the averaged signal and the shaded area represents 95 % 
confidence interval of the mean (bootstrap). (G) Boxplot comparison of antisense bias-corrected counts on 52,593 
introns between RNA-seq samples treated with DMSO and 1 μM Pla-B for 1 h. Black bars represent the median 
values for each group. Lower and upper boxes are the first and third quartiles, respectively. The ends of the 
whiskers extend the box by 1.5 times the interquartile range. Outliers are not drawn. (***) p-value < 2.2 × 10-16 
by Wilcoxon signed-rank test. (J) TT-seq coverage track of AKAP1 gene upon 1 h or 4 h of DMSO or 1 μM Pla-
B treatments (GViz R package).  
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Since long human genes can take 1 h or longer to be transcribed, RNA synthesis activity in the         
3’ regions of long genes should be less affected upon 1 h of Pla-B inhibition, and more affected 
after 4 h. To investigate this, we divided the major isoforms into different length classes and 
checked the metagene profile of short (first quartile Q1) and long (fourth quartile Q4) for both 1 h 
and 4 h DMSO or 1 μM Pla-B treatment (Figure 14A-B). In addition, we plotted the ratio of Pla-B 
to DMSO on the last exons after 1 h and 4 h of treatments. As expected, major isoforms longer than 
52 kbp showed a smaller change in transcription after 1 h of treatment when compared with shorter 
major isoforms (Figure 14A, C left). In contrast, we observed that RNA synthesis is strongly 
defective in major isoforms of all lengths after 4 h of Pla-B treatment (Figure 14B, C right). Long 
major isoforms are more affected than short major isoforms after 4 h of treatment, explaining the 
slope towards the 3’ region observed in the metagene plot (Figure 13H). To investigate whether 
the effects of Pla-B on transcription are related to splicing inhibition, we defined two groups of 
transcripts in which splicing of the first intron was affected or unaffected, based on DESeq2 (Love 
et al., 2014) analysis (Methods section 4). Indeed, RNA synthesis was significantly more decreased 
for genes where splicing of the first intron was affected for both 1 h and 4 h treatment (Figure 14D). 
Together, these results indicate that splicing has a direct positive effect on transcription. 
 
 
Figure 14. Pla-B effect on transcription is length-dependent and is related to splicing inhibition.  
(A and B) Metagene analysis for 1 h (A) and 4 h (B) DMSO or 1 μM Pla-B treated cells comparing major isoforms 
belonging to the Q1 (left) and Q4 (right) of length. TT-seq coverage aligned at TSS and poly(A)-site for 1,314 
(Q1) and 1,384 (Q4) major isoforms that exceed 1 kbp in length (C) Ratio of 1 μM Pla-B to DMSO antisense bias-
corrected TT-seq read counts for last exons upon 1 h (left) and 4 h (right) treatments in four different major 
isoforms length quartiles. (D) Ratio of 1 μM Pla-B to DMSO antisense bias-corrected TT-seq read counts for 
splicing affected and unaffected major isoforms upon 1 h (left) and 4 h (right) treatments. Outliers are not drawn. 
(***) p-value < 2.2  10-16 by Wilcoxon sum rank test.  
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To further support our findings, we performed TT-seq in K562 cells upon splicing inhibition using 
a different chemical inhibitor, SSA. Similar to Pla-B, SSA targets SF3B1 and inhibits splicing in 
vitro and in vivo, interfering with spliceosome assembly after A complex formation (Corrionero et 
al., 2011; Kaida et al., 2007; Martins et al., 2010; Roybal and Jurica, 2010). RT-PCR analysis 
showed increased intron retention already after 1 h of 30 ng/mL SSA (Figure S5A). TT-seq data 
were generated from two independent biological replicates, with the mapped reads showing a 
spearman correlation of 1 and with a uniform size distribution (Figure 15A-B). Between 44 and 53 
million paired-end reads were obtained per sample, with a minimum value of 57% of deduplicated 
reads (Table S5). In order to investigate global changes on RNA-synthesis, the data was normalized 
with spike-ins (Methods section 2.1). Sequence reads were mapped against the hg38 (GRCh38) 
genome assembly, with a maximum of 29% duplicated paired reads per sample, which had no 
impact on results output (Methods section 2.1) (Figure S5B, Table S5). We found that SSA 
inhibited splicing genome-wide after 1 h of treatment (Figure 15C). As for the Pla-B treatment, 
metagene analysis showed that new RNA synthesis was impaired genome-wide (Figure 15D-E, G) 
and that the decrease in RNA synthesis was significantly higher for genes where splicing was more 
affected (Methods section 4) (Figure 15F). 
Chapter IV: Results 
 48 
 
Figure 15. SSA treatment decreases new RNA synthesis.  
(A) Scatter plots comparing TT-seq replicates using antisense bias-corrected counts for major isoforms for samples 
treated with DMSO or 30 ng/mL SSA for 1 h. Spearman correlation of 1. (B) Fragment size distribution for paired 
mapped reads for TT-seq upon 1 h DMSO or 30 ng/mL SSA treatment. (C) Ratio of spliced reads over total 
unspliced and spliced reads upon 1 h DMSO or 30 ng/mL SSA. See also Figure S5A. (D) Metagene analysis 
comparing TT-seq signal between cells treated with DMSO or 30 ng/mL SSA for 1 h. TT-seq coverage was 
averaged for 5,535 major isoforms scaled between TSS and poly(A)-site. See also Figure S5B. (E) Metagene 
analysis focusing on the expression on TTS and poly(A)-site comparing DMSO and 30 ng/mL SSA treated cells 
for 1 h. TT-seq coverage was aligned at TSS and poly(A)-site for 5,465 major isoforms that exceed 1 kbp in length. 
Solid lines represent the averaged signal and the shaded area represents 95 % confidence interval of the mean 
(bootstrap). (F) Ratio of 30 ng/mL SSA to DMSO antisense bias-corrected TT-seq read counts for splicing affected 
and unaffected major isoforms upon 1 h. Outliers are not drawn. (***) p-value < 2.2  10-16 by Wilcoxon sum rank 
test. (G) TT-seq coverage track of AKAP1 gene upon 1 h DMSO or 30 ng/mL SSA (GViz R package).  
 
To exclude that the decrease in transcription after Pla-B or SSA treatments was due to a stress 
response pathway triggered by the chemical compounds, we performed TT-seq after treating cells 
with an antisense morpholino oligo targeting the U2 snRNA (U2 AMO) or with a control oligo   
(Ctr AMO). We used a U2 AMO that specifically blocks the RNA-RNA interactions between          
U2 snRNAs and pre-mRNA (Matter and König, 2005). RT-PCR showed that splicing was inhibited 
after treatment of cells with 75 M U2 AMO for 1 h (Figure S6A), indicating rapid splicing 
inhibition. Between 39 and 49 million paired-end reads were obtained per sample, with a minimum 
value of 49% of deduplicated reads (Table S5). TT-seq data were generated from two biological 
replicates after treatment with U2 AMO or Ctr AMO and globally normalized using spike-ins 
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(Methods section 2.1). Sequence reads were mapped against the hg38 (GRCh38) genome 
assembly, with a maximum of 35% duplicated paired reads per sample, which had no impact on 
results output (Methods section 2.1) (Figure S6B). The data were highly reproducible, with a 
Spearman correlation of 1, and a uniform fragment size distribution (Figure 16A-B). The data 
showed that 1 h treatment with U2 AMO causes a decrease in new RNA synthesis across the gene 
body (Figure 16D-E, 5G) and inhibits splicing genome-wide (Figure 16C). Again, the decrease in 
newly synthesized RNA was significantly higher for genes where splicing was more affected 
(Methods section 4) (Figure 16F). 
 
 
Figure 16. AMO U2 treatment decreases new RNA synthesis.  
(A) Scatter plots comparing TT-seq replicates using antisense bias-corrected counts for major isoforms for samples 
treated with 75 M Ctr AMO or 75 M U2 AMO for 1 h. Spearman correlation of 1. (B) Fragment size distribution 
for paired mapped reads for TT-seq upon 1 h 75 M Ctr AMO or 75 M U2 AMO. (C) Ratio of spliced reads 
over total unspliced and spliced reads upon 1 h 75 M Ctr AMO or 75 M U2 AMO. See also Figure S6A. (D) 
Metagene analysis comparing TT-seq signal between cells treated with 75 M Ctr AMO or 75 M U2 AMO for 
1 h. TT-seq coverage was averaged for 5,535 major isoforms scaled between TSS and poly(A)-site. Figure S6B. 
(E) Metagene analysis focusing on the expression on TTS and poly(A)-site comparing DMSO and 30 ng/mL SSA 
treated cells for 1 h. TT-seq coverage was aligned at TSS and poly(A)-site for 5,465 major isoforms that exceed    
1 kbp in length. Solid lines represent the averaged signal and the shaded area represents 95 % confidence interval 
of the mean (bootstrap). (F) Ratio of 75 M Ctr AMO to 75 M U2 AMO (antisense bias-corrected TT-seq read 
counts for splicing affected and unaffected major isoforms upon 1 h. Outliers are not drawn. (***)                                 
p-value < 2.2  10-16 by Wilcoxon sum rank test. (G) TT-seq coverage track of AKAP1 gene upon 1 h 75 M        
Ctr AMO or 75 M U2 AMO (GViz R package).  
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3. Inhibition of U2 snRNP function impairs early transcription 
elongation  
Our results indicated that the observed reduced RNA synthesis activity resulted from a decreased 
number of Pol II enzymes entering productive and processive elongation of genes. To investigate 
this, we performed mNET-seq of total Pol II in K562 cells treated for 1 h with 1 M Pla-B or 
DMSO. The detergent empigen was used to prevent co-IP of spliceosome-associated RNAs 
(Nojima et al., 2018a; Schlackow et al., 2017). mNET-seq data were generated from two 
independent biological replicates. To introduce a reference (spike-ins) normalization were included 
approximately 5% S. cerevisiae fragmented mRNA after IP. We obtained, on average 170 to 214 
million reads per sample, with a minimum value of 47% of deduplicated reads (Table S6).        
mNET-seq reads were mapped to a combined human hg38 (GRCh38) and S. cerevisiae sacCer3 
(R64-1-1) genome (Methods section 2.2). Between 114 to 138 million reads were uniquely mapped 
to the combined human and yeast genome. From these reads, approximately 20% mapped to the                    
S. cerevisiae genome and 80% to the human genome (Table S6). A metagene analysis over                
S. cerevisiae expressed transcripts before and after normalization confirms the use of this strategy 
(Figure S7A-C). Data were highly reproducible, with the mapped reads showing a Spearman 
correlation of 1 and a uniform fragment size distribution (Figure 17A-B). On average, the samples 
showed 54% duplicated paired reads, which had no impact on results output (Methods section 2.2) 
(Figure S7D, Table S6). 
 
Metagene plots of the mNET-seq signals over major isoforms revealed a sharp peak of Pol II 
occupancy just downstream of the TSS, indicative of promoter-proximally paused Pol II (Figure 
17C, black line). Upon 1 h of Pla-B treatment, the peak for paused Pol II strongly increased, and 
the signal in the gene body decreased (Figure 17C, red line, Figure 17D). We observed the same 
trend when we used published mNET-seq data obtained for ser5-phosphorylated (ser5P) Pol II in 
HeLa cells after 4 h of Pla-B treatment (Nojima et al., 2015) (Figure 17E). At intronless genes,   
Pol II occupancy increased also, but to a lower extent (Figure 17F). These changes in the        
mNET-seq signal indicate an increase in promoter-proximal Pol II pausing and a defect in the 
release of Pol II into elongation. 
 
Chapter IV: Results 
 51 
 
Figure 17. Inhibition of U2 snRNP function impairs early transcription elongation.  
(A) Scatter plots comparing mNET-seq replicates using antisense bias-corrected counts for major isoforms for 
samples treated with DMSO and 1 μM Pla-B for 1 h. Spearman correlation of 1. (B) Fragment size distribution 
for paired mapped reads for mNET-seq upon 1 h DMSO or 1 μM Pla-B treatment. (C) Metagene analysis 
comparing the mNET-seq signal between cells treated with DMSO or 1 M Pla-B for 1 h. mNET-seq coverage 
was averaged for 5,535 major isoforms scaled between TSS and poly(A)-site. See also Figure S7D. (D) mNET-
seq coverage track of AKAP1 gene upon 1 h of DMSO or 1 M Pla-B treatments (GViz R package). (E) Metagene 
analysis comparing the averaged mNET-seq signal for CTD ser5P between HeLa cells treated with DMSO and 1 
μM Pla-B for 4 h. mNET-seq coverage was averaged for 5,535 major isoforms scaled between TSS and poly(A)-
site. Datasets for mNET-seq against CTD ser5P in HeLa cells upon 4 h DMSO and 1 μM Pla-B treatments were 
obtained from (Schlackow et al., 2017). (F) Intronless genes meta-analysis comparing mNET-seq signal between 
cells treated with DMSO control and 1 μM Pla-B for 1 h. TT-seq coverage was averaged for 51 intronless genes 
scaled between TSS and poly(A)-site. Solid lines represent the averaged signal and the shaded area represents 95 
% confidence interval of the mean (bootstrap). 
 
A more detailed analysis of the mNET-seq data showed that Pol II accumulated not only in the 
promoter-proximal region but also further downstream in the 5’ region of the first intron (Figure 
18A-B). At about 1.3 kbp downstream of the first 5’ SS, the mNET-seq signal however dropped 
below the level observed without Pla-B treatment (Figure 17C, Figure 18B). These results are 
consistent with a strong defect in productive and processive Pol II elongation. Changes in Pol II 
occupancy were by far strongest at the beginning of the first intron (Figure 18B) and were 
independent of the length of the first intron (Figure 18C). These results argue against a simple 
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model that Pol II is paused around the 3’ end of the first intron due to the accumulation of elongating 
Pol II complexes upstream all the way back to the promoter. Instead, our findings are consistent 
with a role of the functional spliceosome in facilitating the release of promoter-proximally paused 
Pol II into active elongation. 
 
 
Figure 18. mNET-seq data reveals a defect in productive and processive Pol II elongation upon Pla-B 
treatment. 
(A) Metagene analysis comparing the mNET-seq signal upon 1 h DMSO or 1 M Pla-B treated cells aligned at 
TSS (left) and poly(A)-site (right). mNET-seq signal was averaged for 5,465 major isoforms that exceed 1 kbp in 
length. (B) Metagene analysis comparing mNET-seq signal upon 1 h DMSO or 1 M Pla-B treated cells aligned 
at the first 5’ SS. mNET-seq signal was averaged for 3,449 first introns that exceed 2 kbp in length. (C) First intron 
meta-analysis comparing the averaged mNET-seq signal between cells treated with DMSO and 1 μM Pla-B for     
1 h. First introns were divided into 4 quartiles based on the first intron length. Solid lines represent the averaged 
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4. Inhibition of U2 snRNP function increases Pol II pause 
duration 
We next investigated whether Pla-B treatment increased the duration of promoter-proximal pausing 
by Pol II. We defined Pol II pause sites as the positions of the major mNET-seq peaks with a signal 
of at least five times above the median coverage in the first exon of the intron-containing major 
isoforms or in the first 100 bp of the intronless genes (Methods section 5.2, (Gressel et al., 2017)). 
The distribution of genomic positions of these pause sites was not altered upon Pla-B treatment 
(Figure 19A). We then used our previously described approach that combines multi-omics with 
kinetic modeling (Gressel et al., 2017, 2019) to estimate the pause duration d as the ratio of the 
mNET-seq signal over the productive initiation frequency I in a pause window of ±100 bp (intron-
containing major isoforms) or ± 50 bp (intronless genes) around the Pol II pause site (Methods 
section 5.3 and 5.4). 
This quantitative kinetic analysis showed that the pause duration d was strongly increased genome-
wide after Pla-B treatment (Figure 19B). Thus, Pol II pauses longer in the promoter-proximal 
region when U2 snRNP function is compromised. Further, the productive initiation frequency I 
decreased after Pla-B treatment (Figure 19C), confirming the transcription defect. Plotting d and I 
for all expressed intron-containing major mRNA isoforms exceeding 10 kbp in length showed a 
shift to longer pause durations and to lower productive initiation frequencies upon 1 h of Pla-B 
treatment (Figure 19D-E). These observations can be explained by the existence of the previously 
described ‘pause-initiation limit’ in mammalian cells that sets a limit to the maximum Pol II 
initiation frequency at a given pause duration (Gressel et al., 2017; Shao and Zeitlinger, 2017). 
Consistent with our previous results, splicing affected genes showed significantly more increased 
pause durations and more decreased initiation frequencies than splicing unaffected genes or 
intronless genes (Methods section 4) (Figure 19F-G, p-values < 0.001, Wilcoxon rank-sum test). 
In summary, Pla-B treatment leads to an increase of the duration of promoter-proximal Pol II 
pausing, and to lower productive initiation frequencies at many genes. 
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Figure 19. Inhibition of U2 snRNP function increases Pol II pause duration.  
(A) Polymerase pause position calculated for 3,626 intron-containing major isoforms that exceed 10 kbp in length 
and had an identified pause position (Methods section 5.2) for both DMSO and 1 M Pla-B treated samples. (B 
and C) Pause duration d (B) and productive initiation frequency I (C) calculated for 3,636 intron-containing major 
isoforms that exceed 10 kbp in length and had an identified polymerase pause position (Methods section 5) for 
both 1 h DMSO and 1 M Pla-B. Outliers are not drawn. (***) p-value < 2.2  10-16 by Wilcoxon signed-rank test. 
(D and E) Correlation between the productive initiation frequency I and pause duration d upon 1 h DMSO (D) and 
1 M Pla-B (E) treated cells. The grey shaded area depicts impossible combinations of I and d considering the 
footprint of the transcribing elongation complexes a limit distance between the active sites of initiating and paused 
Pol II (Ehrensberger et al., 2013). (F and G) Ratio of Pla-B to DMSO for pause duration d (F) and productive 
initiation frequency I (G) upon 1 h of DMSO or 1 M Pla-B treatments calculated for 3,636 intron-containing, 
329 splicing affected, 355 splicing unaffected, and 29 intronless transcripts. Note that not all genes fit the criteria 
for pausing and productive initiation frequency calculation (Methods section 5). 
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5. Inhibition of U2 snRNP function impairs recruitment of 
pause release factor P-TEFb 
We next investigated the reasons for the observed increase in the duration of promoter-proximal 
Pol II pausing. Release of paused Pol II into active elongation requires P-TEFb, which contains the 
kinase CDK9 and the Cyclin T1 (CycT1) (Fujinaga et al., 2004; Marshall and Price, 1995; Marshall 
et al., 1996; Vos et al., 2018b; Wei et al., 1998). We, therefore, investigated whether increased Pol 
II proximal-promoter pausing after Pla-B treatment may be accompanied by a defect in P-TEFb 
recruitment. We used ChIP-seq to measure genome occupancy with total Pol II and with the               
P-TEFb subunit CycT1 in K562 cells treated for 1 h with 1 M Pla-B or DMSO. ChIP-seq data 
were generated from two independent biological replicates. To correct for global changes in DNA 
levels upon treatments, D. melanogaster S2 sheared cross-linked-chromatin was added before IP 
(Methods section 2.3). ChIP-seq data were mapped against a combined human hg38 (GRCh38) 
and D. melanogaster dm6 (BDGP6.28), genome (Methods section 2.3). Data were highly 
reproducible (Spearman correlation of 0.99) with a homogeneous fragment size distribution (Figure 
20A-B, Figure S8A-B). On average, 34 million paired-end reads were obtained per sample with a 
minimum value of 92% of deduplicated reads (Table S7). From these reads, on average 99.7% 
mapped to human genome and 0.3% mapped to D. melanogaster genome (Table S8). A maximum 
of 8% duplicated mapped paired reads were found, which had no impact on the results output 
(Figure S8E-F, Table S7). 
 
Analysis of these ChIP-seq data showed that Pla-B treatment resulted in increased Pol II occupancy 
just downstream of the TSS of protein-coding genes (Figure 20C). This is consistent with the 
increase in promoter-proximally paused Pol II that we had observed by mNET-seq (Figure 17C). 
In contrast, occupancy with the P-TEFb subunit CycT1 was decreased in the same region (Figure 
20D-E), indicating that the recruitment of P-TEFb to promoter-proximally paused Pol II is 
impaired. Consistent with our previous evidence, intronless genes showed similar effects, but they 
were much less pronounced (Figure 20F-G).  These data indicate that U2 snRNP inhibition impairs 
P-TEFb recruitment to the promoter-proximal region, thereby impairing the release of paused          
Pol II, increasing Pol II pause duration, and decreasing the productive initiation frequency at 
affected genes. 
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Figure 20. Inhibition of U2 snRNP function impairs P-TEFb recruitment.  
(A) Scatter plots comparing Pol II (left) and CycT1 (right) ChIP-seq replicates using counts for major isoforms 
for samples treated with DMSO and 1 μM Pla-B. Spearman correlation of 0.99. See also Figure S8A. (B) Fragment 
size distribution for paired mapped reads for Pol II (left) and CycT1 (right) ChIP-seq upon 1 h DMSO or 1 μM 
Pla-B treatment. See also Figure S8B.  (C and D) Metagene analysis comparing ChIP-seq for Pol II (C) and CycT1 
(D) between cells treated with DMSO and 1 M Pla-B for 1 h. ChIP-seq coverage was aligned at the TSS and 
averaged for 5,465 major isoforms that exceed 1 kbp in length. See also Figure S8C-F. (E) Ratio of CycT1 to Pol 
II normalized counts around TSS (from -100 to +200 bp) comparing 1 h DMSO and 1 M Pla-B treated samples. 
Outliers are not drawn. (***) p-value < 2.2  10-16 by Wilcoxon signed-rank test. (F and G) Intronless genes meta-
analysis comparing ChIP-seq signal between cells treated with DMSO and 1 μM Pla-B for 1 h. ChIP-seq coverage 
for Pol II (F) and CycT1 (G) was averaged for a total of 51 intronless genes that exceed 1 kbp in length. Solid 
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6. Inhibition of U2 snRNP function alters Pol II elongation 
velocity 
To investigate in more detail how U2 snRNP inhibition influences Pol II elongation downstream of 
the promoter-proximal region and downstream of the first intron, we estimated the Pol II elongation 
velocity at all major isoforms exceeding 10 kbp in length. We obtained the elongation velocity v 
from the ratio of the number of Pol II enzymes released into elongation, as measured by TT-seq at 
each genomic location, over the Pol II occupancy, as measured by mNET-seq (Methods section 
5.5) (Figure 21A). Metagene analysis of the cells treated with DMSO showed that the elongation 
velocity is low in the region close to the TSS, and then increases, reaching a maximum of around  
3 kbp/min (Figure 21B, black line). This agrees with previous estimates for Pol II velocity (Fuchs 
et al., 2014b; Gressel et al., 2017; Jonkers et al., 2014; Saponaro et al., 2014; Veloso et al., 2014), 
supporting our approach. 
After 1 h of Pla-B treatment, we observed a decrease in the elongation velocity in the promoter-
proximal region and at the beginning of the first intron, whereas regions further downstream were 
less affected (Figure 21B-C). This is consistent with an unaltered elongation velocity for Pol II 
enzymes that were released before Pla-B treatment.  
 
 
Figure 21. Inhibition of U2 snRNP function alters Pol II elongation velocity.  
(A) Schematic representation of Pol II elongation velocity v. The TT-seq signal (top) corresponds to the productive 
initiation frequency I. The mNET-seq signal (middle) corresponds to the ratio of the productive initiation 
frequency I to the elongation velocity v. Therefore, v (bottom) can be calculated by dividing the TT-seq signal 
over the mNET-seq signal. (B) Metagene analysis comparing the elongation velocity in cells treated with DMSO 
or 1 M Pla-B for 1 h. Elongation velocity was averaged for 5,535 major isoforms scaled between TSS and 
poly(A)-site. (C) Metagene analysis comparing the elongation velocity in cells treated for 1 h with DMSO or           
1 M Pla-B. Elongation velocity was averaged for 3,626 first exons aligned at the pause site defined on the DMSO 
treated samples (left). Elongation velocity was averaged for 5,350 first introns and aligned at the 5’ SS (middle) 
or the 3’ SS (right). Solid lines represent the averaged signal and the shaded area represents 95 % confidence 
interval of the mean (bootstrap). 
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In accordance with this and with our previous observations, short genes were already affected 
throughout their entire length after 1 h of treatment (Figure 22A). We also found that the average 
elongation velocity in the first exon was much lower than in the first intron (Figure 22B), reflecting 
Pol II pausing in the promoter-proximal region. Elongation velocity was also affected upon Pla-B 
inhibition in intronless genes but to a much lower extent (Figure 22C). After 4 h of Pla-B treatment, 
the elongation velocity decreased in all genes, as seen from a corresponding multi-omics analysis 
with the use of published mNET-seq data (Figure 22D). In summary, these results argue against a 
direct effect of Pla-B on released and processive Pol II elongation complexes. Instead, the results 
are consistent with a direct effect of spliceosome function on Pol II release from the promoter-
proximal region into efficient downstream elongation. 
 
 
Figure 22. Inhibition of U2 snRNP function alters Pol II elongation velocity.  
(A) Metagene analysis comparing the elongation velocities between cells treated with DMSO or 1 M Pla-B for 
1 h for major isoforms belonging to the lowest quartile of major isoforms length (< 9.4 kbp). Elongation velocity 
was averaged for 1,384 major isoforms scaled between TSS (left) and poly(A)-site (right). (B) Elongation 
velocities for the first exon and first intron in DMSO and 1 M Pla-B treated cells for 1 h. Elongation velocity 
distribution was calculated for 5,350 first exons and first introns (unique exons were excluded). (C) Intronless 
genes meta-analysis comparing the elongation velocity in cells treated with 1 h DMSO or 1 M Pla-B. TT-seq 
coverage was averaged for 51 intronless genes scaled between TSS and poly(A)-site. (D) Metagene analysis 
comparing the elongation velocities calculated in cells treated with DMSO or 1 M Pla-B for 4 h. Elongation 
velocity was averaged for 5,535 major isoforms scaled between TSS and poly(A)-site. Datasets for mNET-seq 
against CTD ser5P in HeLa cells upon 4 h DMSO and 1 M Pla-B treatments were obtained from (Schlackow et 
al., 2017), GEO: GSE81662. 
7. U2 snRNP inhibition with Pla-B is independent of stress 
response  
To test whether the transcription response is similar to the one obtained under stress conditions, 
such as heat shock (HS), I performed a differential gene expression analysis using the DESeq2 R 
package (Love et al., 2014) on TT-seq data from K562 cells subjected to 42 °C HS for 30 min 
(Gressel et al., 2019) and on our TT-seq data upon U2 snRNP inhibition with Pla-B, SSA and U2 
AMO (Figure 23A, C-F). TT-seq data analysis revealed that 507 transcripts are significantly 
downregulated, and 182 transcripts are significantly upregulated upon 30 min of HS in K562 cells. 
Among the upregulated ones, a GO enrichment analysis shows that within the top 10 GO terms, 6 
include “response to stress” (GO:0006950) as a parental term, in agreement with  (Gressel et al., 
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2019) (Figure 23A, B, Figure S9). On the contrary, Pla-B treatment causes mainly downregulation 
in both 1 h (2,894 transcripts downregulated versus 11 transcripts upregulated) and 4 h (3,705 
transcripts downregulated versus 9 transcripts upregulated) (Figure 23C-D). Out of the upregulated 
ones, only 1 upon 1 h (BST2) and 3 upon 4 h (ARL6IP5, MSMO1, SQLE) overlap with the 182 
transcripts activated upon HS (Table S9, Table S10), showing that different genes are affected and 
also that the response observed with Pla-B is much faster and more global. Similar to Pla-B, 1 h 
SSA treatment induces mostly downregulation of gene expression (3,705 downregulated and 9 
upregulated transcripts), without any upregulated transcript overlapping with the 30 HS upregulated 
transcripts (Figure 23E, Table S11). These findings indicate that both chemical compounds, Pla-
B and SSA, are not responsible for activating a stress pathway. To corroborate this, the treatment 
with 75 μM Ctr and 75 μM U2 AMO follows the same profile as the one from Pla-B and SSA.  In 
this case, Ctr AMO and U2 AMO would induce the same stress pathways. U2 AMO induces 
upregulation of 24 transcripts and downregulation of 2,665 (Figure 23F). Only two transcripts 
matched the ones upregulated upon 30 min HS (AZIN1 and BAG2) (Table S12). The differential 
gene expression analysis was performed only on the exonic counts for each transcript, since the 




Figure 23. U2 snRNP inhibition with Pla-B is independent of stress response   
(A) Differential expression analysis between Control and HS treatments for 30 min on K562 cells (507 
downregulated and 182 upregulated transcripts) (data from (Gressel et al., 2019), GSE123980). (B) Top 10 GO 
terms on the biological process category of upregulated transcripts on TT-seq upon control (Ctr) or 42 °C treatment 
for 30 min (Gressel et al., 2019)). GO terms belonging to “response to stress” (GO:0006950) are marked in orange. 
See also Figure S9. (C) Differential expression analysis between DMSO and 1 µM Pla-B treatments for 1 h on 
K562 cells (2,894 downregulated and 11 upregulated transcripts). See also Table S9. (D) Differential expression 
analysis between DMSO and 1 µM Pla-B treatments for 4 h on K562 cells (3,705 downregulated and 9 upregulated 
transcripts). See also Table S10. (E) Differential expression analysis between DMSO and 30 ng/mL SSA 
treatments for 1 h on K562 cells (3,721 downregulated and 3 upregulated transcripts). See also Table S11. (F) 
Differential expression analysis between 75 μM Ctr and 75 μM U2 AMO treatments for 1 h on K562 cells (2,665 
downregulated and 24 upregulated transcripts). See also Table S12. Differential expression analysis was 
performed with DESeq2 (padj < 0.05 and 0 < log2FC < 0). 
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To further characterize the downregulated genes upon U2 snRNP inhibition, a GO enrichment 
analysis was performed using the previously defined downregulated transcripts for both chemical 
compound treatments, Pla-B and SSA, and for U2 AMO. As expected, U2 snRNP inhibition for     
1 h shows downregulation of genes related to RNA biosynthesis (Figure 24A, C-D, Figure S10, 
Figure S12, Figure S13). Differences in the downregulated genes between the different inhibition 
methods can be explained by the fact that in this experiment, cells were not synchronized to reduce 
the bias these methodologies may cause on the overall physiology of the cell (Davis et al., 2001).   
Upon 4 h treatment with DMSO or 1 µM Pla-B, the overall RNA synthesis reduction impacts DNA 
metabolic process and DNA replication, as well as downregulation of genes related to positive 
regulation of gene expression and regulation of metabolic biosynthesis (Figure 24B, Figure S11).  
 
 
Figure 24. GO enrichment analysis.  
(A and B) Top 10 biological process GO terms for downregulated transcripts upon DMSO or 1 µM Pla-B 
treatments for 1 h (A) and 4 h (B). See also Figure S10 and Figure S11. (C) Top 10 biological process GO terms 
for downregulated transcripts upon DMSO or 30 ng/mL SSA treatments for 1 h. See also Figure S12. (D) Top 10 
GO terms on the biological process for downregulated transcripts upon 75 μM Ctr and 75 μM U2 AMO treatments 




DISCUSSION AND OUTLOOK 
 
Here I highlight the major findings, as well as the limitations of this study and the remaining open 
questions as future perspectives. 
The discussion present in sections 2 to 4 is adapted from: 
Caizzi, L. *, Monteiro-Martins, S. * et al. Efficient RNA polymerase II pause release requires U2 
snRNP function. (2021). Mol. Cell 81, 1920-1934.e9 
doi: https://doi.org/10.1016/j.molcel.2021.02.016 
(* joint first authorship) 
1. Open questions regarding U2 snRNP function in 
transcription 
We rapidly inactivated U2 snRNP function in human cells and monitored RNA synthesis, Pol II 
activity, productive initiation frequency, pause duration, and elongation velocity genome-wide.  
 
Question A) Does splicing inhibition affects new RNA synthesis? 
We observed by three independent U2 snRNP inhibition approaches that splicing was overall 
inhibited already upon 1 h treatment and that this impacts the amount of newly synthesized RNA. 
Even though the RNA synthesis was overall reduced, we further observed that transcripts whose 
first intron was significantly affected on 5’ SS and/or 3’ SS had a significantly higher reduction 
than the transcripts with splicing unaffected first introns. We further show that the inhibition 
strategies used are not related to stress response and that upon 1 h U2 snRNP inhibition is observed 
downregulation of genes related to RNA biosynthesis. 
 
Question B) Is co-transcriptional splicing related to Pol II productive transcription initiation 
frequency and promoter-proximal pausing duration? 
With our analysis, we account for the number of polymerases that initiate and are further released 
from promoter-proximal pause site to productive elongation. We witnessed an overall reduction in 
productive initiation frequency upon 1 h Pla-B treatment, which matches the overall decrease in 
transcription. Once again, the transcripts with a first intron significantly affected on 5’ SS and/or  
3’ SS had a significant decrease in initiation frequency when compared with the transcripts with 
splicing unaffected first introns. 
We calculated the effective pause between two Pol II initiation events that successfully lead to 
productive elongation. After 1 h Pla-B treatment, the promoter-proximal pausing duration 
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significantly increased, being once again significantly higher on splicing affected transcripts. The 
position of the pause sites was, however, not affected by the U2 snRNP inhibition.  
 
Question C) Does co-transcriptional splicing influence Pol II elongation velocity? 
The kinetics multi-omics analysis revealed a U2 snRNP impact on productive initiation frequency 
and promoter-proximal pausing duration. In agreement with these findings, our elongation velocity 
calculation shows a decrease in Pol II velocity upon Pla-B treatment. The decreased velocity was 
more visible at the beginning of the transcript upon 1 h Pla-B treatment. However, a decrease in the 
velocity throughout the full transcript body was observed for shorter genes upon 1 h treatment and 
in all genes upon 4 h treatment.  This finding can be explained by an unaltered velocity on the        
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2. Possible mechanisms under U2 snRNP requirement for 
efficient Pol II elongation activation 
We found that U2 snRNP function is important for the efficient release of paused Pol II into genes 
for active transcription elongation. Although previous reports had already shown that splicing 
inhibition has consequences for Pol II occupancy and transcription, our data now define these 
consequences genome-wide and at the level of transcription kinetics. 
Our results suggest that U2 snRNP function is important for the establishment of complete, RNA 
processing-competent, active Pol II elongation complexes in the promoter-proximal region of 




Figure 25. U2 snRNP impact on Pol II release into productive elongation.  
Our results show that upon U2 snRNP inhibition there is an increase in paused Pol II at the promoter-proximal site 
and a decrease in the elongation velocity. This suggests an impact of the formation of the spliceosomal complex 
A on the release of promoter-proximal paused Pol II into productive elongation.  
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The mechanism underlying U2 snRNP-dependent Pol II elongation activation remains to be 
elucidated. However, recent structural studies suggest a possible model for this process. It was 
recently shown that the Pol II-U1 snRNP complex is compatible with the presence of the 
transcription elongation factors DSIF, SPT6, and PAF1 complex (PAF) on the Pol II surface and 
that that U1 snRNP can remain bound to Pol II during transcription elongation. This interaction 
does neither require nascent RNA nor a 5’ SS (Zhang et al., 2021). 
Modeling further showed that U2 snRNP can be accommodated in addition to U1 snRNP to form 
the spliceosomal A complex on the Pol II surface, whereas conversion to the splicing-active B 
complex would separate Pol II and the spliceosome (Zhang et al., 2021). How such separation may 
activate further release of paused Pol II far upstream remained unclear. It was also shown that U2 
snRNP inhibition with SSA reduces the availability of U1 snRNP by retaining it on the pre-mRNAs. 
The reduced U1 availability was also related to premature cleavage and polyadenylation 
(Yoshimoto et al., 2021). Here we speculate that U2 snRNP inhibition arrests co-transcriptional 
spliceosome assembly at the stage of A complex formation on Pol II (Figure 25), and impairs the 
separation of transcribing Pol II and the spliceosome. 
Previous results suggest that U2 snRNP-dependent Pol II elongation activation may involve the 
elongation factor TAT-SF1. TAT-SF1 can bind the U2 snRNP factor SF3B1 and stimulate 
elongation in vitro (Chen et al., 2009; Fong and Zhou, 2001; Loerch et al., 2019). TAT-SF1 also 
associates with Pol II and SPT5 (Kim et al., 1999). TAT-SF1 further interacts with CycT1 (Fong 
and Zhou, 2001) and co-IP with U2 snRNP components in vivo (Abramczuk et al., 2017)  and           
in vitro (Agafonov et al., 2011). The yeast TAT-SF1 homolog Cus-2 interacts with PRP11, a subunit 
of yeast SF3a (Yan et al., 1998) and with SF3b1 (Talkish et al., 2019). Consistent with our results, 
mutation of the BS causes Cus-2 dependent Pol II accumulation over introns (Chathoth et al., 2014). 
It was recently shown that TAT-SF1 binds SF3B1 in the open conformation, and that displacement 
of TAT-SF1 must occur to allow for stable U2 snRNP-BS interaction (Zhang et al., 2020). U2 
snRNP-dependent Pol II pause release may additionally involve the splicing factor SRSF2 (or 
SC35) that is required for ATP-dependent interaction between U2 snRNP and the BS (Fu and 
Maniatis, 1992) and for normal Pol II occupancy and P-TEFb recruitment (Ji et al., 2013; Lin et al., 
2008). In conclusion, we provide strong evidence that efficient Pol II elongation activation requires 
U2 snRNP function, and speculate that this is due to co-transcriptional assembly of functional 
spliceosomes. 
3. The impact of U2 snRNP inhibition on intronless genes 
Our results further showed that inhibition of U2 snRNP function also decreased RNA synthesis 
from intronless genes, albeit to a lower extent. In terms of evolution, intronless genes are younger 
genes, mostly eukaryotic specific (Shabalina et al., 2010). Although U1 snRNP is poorly detectable 
at selected intronless genes (Listerman et al., 2006), it can be recruited to transcription units of 
splicing-deficient reporter genes (Spiluttini et al., 2010). Moreover, direct binding of U1 snRNP to 
the Pol II elongation complex does not require the presence of a 5’ SS in nascent pre-mRNA (Zhang 
et al., 2021). Furthermore, U2 snRNP can also be recruited to intronless genes (Van Nostrand et al., 
2016; Wang et al., 2019) and has a role in 3’ RNA processing at intronless histone genes (Friend et 
al., 2007; Kyburz et al., 2006). 
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Thus, our results may be explained with the presence of low levels of U1 and U2 snRNPs at 
intronless genes. Moreover, the pre-EJC subunit Mago impact in promoter-proximal pausing is also 
observed in an intronless gene (Sry-delta) in drosophila (Akhtar et al. 2019). However, we cannot 
entirely exclude indirect effects, since splicing inhibitors such as Pla-B and SSA may induce 
alternative splicing (Corrionero et al., 2011; Teng et al., 2017). Nevertheless, the rapid inhibition 
of U2 snRNP function and fast transcription readout in our experiments is expected to avoid such 
indirect effects.  
Structural studies of spliceosomes isolated from mammalian cell nuclei showed the assembly of a 
21 MDa macromolecular complex (Müller et al., 1998). The 3D structure for this macromolecular 
complex was solved at 20-Å resolution by cryo-EM in 2004 (Azubel et al., 2004) and comprised 
four active native spliceosomes connected by pre-mRNA (Azubel et al., 2004, 2006). Recently, it 
was observed that the supraspliceosome assembles in all RNAs independently of intron number or 
length, including intronless genes. Furthermore, SSA does not inhibit supraspliceosome assembly, 
being observed that affinity-purified supraspliceosomes are enriched with unspliced mRNA after 
SSA inhibition. Upon Pla-B inhibition, the unspliced mRNAs accumulate in the nucleus; however, 
SRF2 (or SC35), U1-70k, and PRP8 splicing factors are still recruited (Sebbag-Sznajder et al., 
2020). This overall recruitment of a supraspliceosome to transcribing mRNAs may explain the 
overall effect on newly RNA synthesis upon U2 snRNP inhibition, including intronless genes. 
4. Study limitations  
Our study is based on K562 cells, a human immortalized myelogenous leukemia cell line. We 
cannot exclude that we miss in our analysis signals for some RNA isoforms that are not covered by 
the RefSeq annotation. This might impact the definition of our major isoforms and intronless genes 
and the assessment of genomic positions including TSS, 5’ SS, 3’ SS, and poly(A)-site. However, 
it is not expected to alter any of our conclusions because we selected only major isoforms with.       
 70% prevalence per gene and we excluded intronless genes with UTRs longer than 100 bp.         
Pla-B could in principle have effects on transcription, but this is unlikely because orthogonal in vivo 
approaches argue against this. Pla-B treatment will also inhibit the formation of later stages of 
spliceosome assembly. Therefore, we cannot entirely exclude that Pla-B has a minor effect on cell 
viability. With respect to the TT-seq method, we cannot entirely exclude the presence of a small 
amount of unlabeled RNAs. However, we used spike-ins to estimate and correct for minor cross-
contamination by pre-existing RNAs. mNET-seq and ChIP-seq involve IP and the quality of the 
results relies on the specificity of the antibody used. ChIP-seq of splicing factors is technically 
challenging and there are few studies available, because of the indirect and transient nature of the 
binding. We performed ChIP-seq of SF3B1 and TAT-SF1 to investigate the binding sites, but 
unfortunately, we did not obtain high-quality data. I also checked the available SF3B1 eCLIP data 
obtained in (Van Nostrand et al., 2016) (ENCODE accession: ENCSR133QEA). The antibody used 
for this experiment was SF3B1-MBL, the same one we tried in our ChIP-seq experiment. To 
investigate SF3B1 binding to RNA, I downloaded the processed data, available from ENCODE 
(ENCFF887ARJ). These data were subjected to peak calling, input normalization, and 
irreproducible discovery as described in the eCLIP processing pipeline v2.2 from Yeo lab. 
Unfortunately, only 37 peaks were identified over the entire genome, indicating an issue with the 
quality of the data. The same data were used in (Wang et al., 2019) to demonstrate SF3B1 binding 
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to intronless genes, and it is not clear, from their Methods, how the processing and normalization 
were performed. Due to doubts, we did not use the published data. 
Even though was not under the scope of this work, it would be interesting to address the impact of 
alternative splicing, since SSA and Pla-B have been found to modulate alternative splicing 
(Corrionero et al., 2011; Teng et al., 2017). To allow for better detection of introns, we used 
an rRNA depletion protocol before library generation. However, alternative splicing detection tools 
work much better on poly(A)+ RNA-seq (Sultan et al., 2014). Still, I tried to detect alternative 
splicing events with rMATS (4.1.0) (Shen et al., 2014). 61,515 alternative splicing events were 
identified for 1 h Pla-B treatment. However, at a typical FDR ≤ 1 % no alternative splicing events 
were identified. We, therefore, did not include this in our analysis, since this approach is not suitable 
for alternative splicing analysis. 
5. Future perspectives 
 
As previously mentioned there are some limitations regarding this analysis concerning the available 
annotation. LRS can be a big challenge in the study of alternative isoforms or the detection of splice 
sites. With nanopore LRS it is possible to directly sequence full RNA transcripts (Wang et al., 
2014). Moreover, recent techniques show that it is possible to distinguish newly synthesized RNA 
from the total RNA using labeling strategies applied to nanopore sequencing (Drexler et al., 2021; 
Maier et al., 2020). Unfortunately, these techniques still output low-quality reads when compared 
with NGS RNA-seq related approaches (Adewale, 2021; Amarasinghe et al., 2020). The use of a 
combination of both NGS and LRS, such as the one used on the FLAIR pipeline (Tang et al., 2020) 
can help address both techniques’ limitations. The use of machine learning approaches for the 
correct identification of newly synthesized RNAs can also be of great help to study co-
transcriptional processing such as splicing (Maier et al., 2020).  
The annotations available nowadays need to be updated and eventually tuned for different cell types. 
Use of the genomic state annotation STAN R package (Zacher et al., 2014), which is based on 
Hidden Markov Models to model different types of genomic data, may be introduced to improve 
the annotation. De novo transcriptome assemblers are also powerful tools that could solve the 
annotation problem, however, these software still show some flaws, inaccurately defining gene 
isoforms (Freedman et al., 2021; Hölzer and Marz, 2019). A possible approach could be the 
implementation of a de novo transcriptome aligner with massive experimental confirmation of the 
different isoforms, using machine learning approaches to train the data against the experimentally 
confirmed isoforms. Long-read capture sequencing (lrCaptureSeq) is an interesting approach to 
annotate poorly characterized mRNA isoforms of target genes (Ray et al., 2020). 
 
Several studies show a level of promoter-proximal Pol II turnover, suggesting that several Pol II 
would not exit the pause site into productive elongation (Erickson et al., 2018; Krebs et al., 2017; 
Steurer et al., 2018). An important improvement on the kinetic analysis would be to account for  
Pol II turnover and early termination. This could be achieved by the implementation of 
mathematical modelling together with experimental procedures. Pause duration and elongation 
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frequency kinetics approaches could be calibrated by integrating TT-seq with a technique to study 
RNA 3’ end such as 3’-seq (Lianoglou et al., 2013) or TAIL-seq (Chang et al., 2014). The use of 
3’-seq upon 4sU labeling, such as performed in (Wu et al., 2020), would give the positions of newly 
synthesized RNAs 3’ ends which could be further integrated into the kinetic modelling to account 
for early terminating transcripts. The integrator complex has been associated with early termination 
(Beckedorff et al., 2020; Elrod et al., 2019; Lykke-Andersen et al., 2021; Tatomer et al., 2019). 
Therefore, integrating TT-seq and 3’-seq data using integrator depletion could also be used to 
validate the kinetics dynamics modelling.  A recent study showed that intron removal is a highly 
variable process with stochastic splice site selection, suggesting that the spliceosome may remove 
introns in chunks, instead of a whole intron unit (Wan et al., 2021). Therefore, an extensive look on 
Pol II elongation velocity around annotated and putative splice sites could help understand intron 
removal dynamics.  
 
To investigate the mechanism of U2 snRNP-dependent Pol II elongation activation, future studies 
should test whether and how splicing and elongation factors contribute to P-TEFb recruitment and 
promoter-proximal release. DNA-protein interactions studies such as ChIP-seq or CUT&RUN 
(discussed in the State of the Art section 4.2) and RNA-protein interactions studies such as eCLIP 
(discussed in the State of the Art section 4.4) against key factors involved in promoter-proximal 
pausing and pause-release, such as P-TEFb, NELF and BRD4; and factors involved in splicing such 
as SF3B1 and TAT-SF1would help understand how this mechanism works.  
As mentioned before, Pol II CTD is related to transcription regulation, including promoter-proximal 
pausing and splicing. A careful analysis of Pol II CTD phosphorylation should be performed after 
U2 snRNP inhibition. A better understanding of Pol II occupancy profiles regarding CTD 
phosphorylation could be accomplished by using mNET-seq with dedicated Pol II antibodies. 
Previous analysis of Pol II Ser5 phosphorylation upon Pla-B treatment showed a higher Ser5P peak 
on the 5’ SS for DMSO control but not for Pla-B treated cells (Nojima et al., 2015) suggesting that 
the Ser5P is related to spliceosome assembly. Further studies should include different CTD 
phosphorylation analyses, such as Ser2P. Ser2 is required for efficient splicing in vivo, being 
associated with the recruitment of the splicing factor U2AF65 and U2 snRNA (Gu et al., 2013). 
Additionally, Ser2 was shown to be decreased upon SSA treatment (Koga et al., 2015). Further 
studies could help understand the Pol II CTD role on the relation between promoter-proximal 
pausing and U2 snRNP inhibition.  
Appropriate RNA folding is essential for the spliceosome assembly and the catalytic reaction (Warf 
and Berglund, 2010). Therefore, RNA-RNA interactions assays (discussed in the State-of-the-Art 
section 4.5) should be performed upon fast U2 snRNP inhibition to understand if and how it affects 
the RNA structure.  
Histone modifications, nucleosome positioning, and chromatin accessibility are important factors 
in the splicing process (Gómez Acuña et al., 2013). Histone marks are related to exon exclusion 
(Agirre et al., 2021), and chromatin accessibility was predicted to be a regulator of intron retention 
(Petrova et al., 2021). Thus, the study of different histone marks by DNA-protein interaction 
techniques and further analysis on nucleosome positioning and chromatin accessibility (example: 
ATAC-seq) upon a rapid U2 snRNP inhibition could give important insight on the mechanism for 
Pol II elongation activation dependent on U2 snRNP.   
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Alterations in the splicing process have been linked to R-loop formation. R-loop formation is related 
to spliceosome recruitment (Bonnet et al., 2017) and point mutations in the U2 snRNP component 
U2AF1 lead to R-loop accumulation (Chen et al., 2018; Nguyen et al., 2018). On the other hand, 
R-loop formation is related to DNA instability and stress response (Tam and Stirling, 2019). In our 
analysis, we performed a fast U2 snRNP inhibition and we did not observe an impact on stress 
response genes. However, a closer look at R-loop formation upon fast U2 snRNP inhibition would 
be important to understand this mechanism. That could be accomplished by performing DRIP-seq 
(Ginno et al., 2012) upon a short U2 snRNP inhibition. A preprint from Frédéric Chédin’s lab 
(Castillo-Guzman et al., 2020), using Pla-B inhibition for 2 and 4 h followed by DRIP-seq, shows 
a reduction of R-loops formation upon treatment. Taking into consideration that we observed an 
overall decrease in transcription upon Pla-B inhibition, a normalization by expression level would 
be essential to understand the impact on R-loop formation upon treatment.   
 
In the present work, we used a human cancer cell line (K562). An interesting analysis would be the 
comparison of different cell types, including human primary cells isolated from healthy tissues, to 
check if the observed effect is cell type-specific and not influenced by cancer type mutations. Since 
response to stimuli may have a heterogeneous response on gene expression and splicing across cells 
(Shalek et al., 2013), the use of scRNA-seq could help clarify U2 snRNP function. In particular, the 
study of newly synthesized RNA and chromatin accessibility in a single cell approach (see State of 
the art section 4.10) upon fast U2 snRNP inhibition could be of great importance to further 







This chapter contains supplementary information to the Methods and Results chapters, including 
the experimental methods, Spike-ins sequence, and all the supplementary figures and tables. 
1. Experimental methods 
The laboratory experiments were performed by Dr. Livia Caizzi (MPI-bpc, Dept. of Molecular 
Biology), except for mNET-seq experiments which were performed by both Dr. Livia Caizzi and 
Kseniia Lysakovskaia (MPI-bpc, Dept. of Molecular Biology). 
 
The experimental methods presented in this section have been published: 
Caizzi, L. *, Monteiro-Martins, S. * et al. Efficient RNA polymerase II pause release requires U2 
snRNP function. (2021). Mol. Cell 81, 1920-1934.e9 
doi: https://doi.org/10.1016/j.molcel.2021.02.016 
(* joint first authorship) 
 
A list of reagents and resources used on the experimental methods can be found in Table S2. 
 
Human K562 cells (female) were obtained from DSMZ (DSMZ no.: ACC-10, RRID:CVCL_0004) 
and cultured in antibiotic-free RPMI 1640 medium (Thermo Fisher Scientific, 31870–074) 
supplemented with 10 % heat-inactivated fetal bovine serum (Thermo Fisher Scientific, 10500–
064) and 2 mM GlutaMAX (Thermo Fisher Scientific, 35050087) at 37 °C and 5 % CO2. K562 
cells were authenticated at the DSMZ Identification Service according to standards for STR 
profiling (ASN-0002). Biological replicates were grown independently. Cells were verified to be 
free of mycoplasma contamination using Plasmo Test Mycoplasma Detection Kit (InvivoGen, rep-
pt1). D. melanogaster S2 (Schneider-2) cells (used for ChIP-seq spike-ins) were obtained from 
DSMZ (DSMZ no.: ACC-130, RRID:CVCL_Z232) and cultured in Schneider´s drosophila 
medium (Biowest, L0207) supplemented with 10% heat-inactivated fetal bovine serum (Thermo 
Fisher Scientific, 10500–064) at 27°C without CO2. Yeast S. cerevisiae cells genotype BY4741 
(used for mNET-seq spike-ins) were obtained from Euroscarf (ACC-Y00000) and cultured in YP 
medium supplemented with 2% glucose to OD600 0.5 at 30°C.  
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Cells were plated the day before the experiment at a confluency of 300,000 cell/mL to obtain 
approximately 500,000-700,000 cells/mL on the next day. For Pla-B experiments, cells were treated 
with dimethyl sulfoxide (DMSO, 1:20,000 dilution, Sigma-Aldrich, D2438) as solvent control or 
with 1 M Pla-B from a DMSO-resuspended 20 mM stock (Santa Cruz, sc-391691). For SSA 
experiments, cells were treated with DMSO (1:17,000 dilution, Sigma-Aldrich, D2438) as solvent 
control or with SSA from a DMSO-resuspended 1 mM stock (gift from Vladimir Pena). 
 
Total RNA was extracted using QIAzol (Qiagen, 79306) manufacturer’s instruction. 4sU-labeled 
RNA was extracted and purified as described for TT-seq experiment (see below) except for the 
sonication of 4sU-labeled RNA which was omitted to avoid introns fragmentation. Isolated RNA 
was treated with DNAse (Qiagen, 79254) to avoid genomic DNA contamination. 400 ng of total or 
140 ng of purified 4sU-labeled RNA were reverse transcribed (Thermo Fisher Scientific, EP0751) 
using random hexamer primers. PCR was performed with Phusion High-Fidelity DNA Polymerase 
(NEB, M0530L) using the following parameters and primers: 
DNAJB1: 30 seconds (sec) at 98 °C, 28 cycles of 5 sec at 98 °C – 10 sec at 68 °C – 15 sec at 72 °C, 
and 5 minutes (min) at 72 °C. 
RIOK3: 30 seconds at 98 °C, 28 cycles of 5 sec at 98°C – 10 sec at 59 °C – 15 sec at 72 °C, and 5 
min at 72 °C. 
DNAJB1_RT-PCR_agarose gel_F: GAACCAAAATCACTTTCCCCAAGGAAGG 
DNAJB1_RT-PCR_agarose gel_R: AATGAGGTCCCCACGTTTCTCGGGTGT  
RIOK3_RT-PCR_agarose gel_F: GCTGAAGGACCATTTATTACTGGAG 
RIOK3_RT-PCR_agarose gel_R: TTCTTGCTGTGTTCTTTCTCCCACA 
Amplified cDNA was loaded in a 2 % agarose gel. Band intensity was analyzed with ImageJ (Fiji). 
 
TT-seq was performed as described (Schwalb et al., 2016; Wachutka et al., 2019) with minor 
modifications. Specifically, 5  107 cells from two biological replicates were either treated for with 
1 M of Pla-B (Santa Cruz, sc-391691) or 30 ng/mL SSA (gift from Vladimir Pena) or DMSO 
(Sigma-Aldrich, D2438) control at times indicated. Cells were exposed the last 10 min of the 
treatment time to 500 M of 4-thiouridine (4sU, Carbosynth, NT06186) at 37 °C and 5 % CO2. 300 
ng of RNA spike-ins mix were added to each sample after cell lysis in 10 mL of QIAzol (Qiagen, 
79306). Spike-ins sequences and production are described in (Wachutka et al., 2019). 150 g of 
RNAs were sonicated to obtain fragments of < 6 kb using AFA micro tubes in a S220 Focused-
ultrasonicator (Covaris). The quality of RNAs and the size of fragmented RNAs were checked using 
a Fragment Analyzer. 1 g of each of the sonicated RNAs was stored at -80 °C as total RNA (RNA-
seq). 4sU-labeled RNAs were purified from 300 g of each of the fragmented RNAs. Biotinylation 
and purification of 4sU-labeled RNAs was performed as described (Dölken et al., 2008; Wachutka 
et al., 2019). 100 ng of input RNA was used for strand-specific library preparation according to the 
Ovation Universal RNA-seq System (NuGEN, 0343-32). Libraries were prepared using random 
hexamer priming only. The size-selected libraries were analyzed on a Fragment Analyzer before 
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sequencing on the Illumina NextSeq500 (2  75 and 2  150 base paired-end for shallow and deep 
sequencing, respectively). 
 
3.2  106 of K562 cells were transfected by electroporation with 7.5 nmol/100 l (75 M) of 
antisense morpholino oligo against a control region (Ctr AMO, 
CCTCTTACCTCAGTTACAATTTATA) or U2 snRNA (U2 AMO, 
TGATAAGAACAGATACTACACTTGA) in a transfection volume of 100 μl using the NEON 
system (Invitrogen, MPK10025). The following transfection parameters were used: pulse: 1,350, 
pulse width: 10, pulse number: 4. Transfected cells were transferred to 5 mL of fresh culture 
medium, and harvested at the indicated times. For semi-quantitative PCR analysis, RNA was 
isolated and treated as previously described (see “Total and 4sU-labeled RNA extraction and 
semiquantitative-PCR”). For TT-seq experiment, cells were exposed the last 10 min of the 1 h 
transfection time to 500 μM of 4-thiouridine. RNA was isolated and treated as previously described 
(see “TT-seq and RNA-seq”). 
 
Experiments were performed as previously described (Gressel et al., 2019; Nojima et al., 2016; 
Nojima et al., 2015; Schlackow et al., 2017) with minor modifications. All buffers for the cellular 
fractionation and immunoprecipitation (IP) were supplied with protease inhibitor cocktail (Sigma-
Aldrich, P8340) and phosphatase inhibitors (Sigma-Aldrich, 4906837001). In detail, two biological 
replicates of 1  108 K562 cells were treated for 1 h with 1 M of Pla-B (Santa Cruz, sc-391691) 
or DMSO (Sigma-Aldrich, D2438) solvent. Cellular fractionation was performed according to the 
previously published protocol (Conrad and Ørom, 2017) using 1 × 107 cells per one reaction. 
Isolated chromatin was subjected to micrococcal nuclease (MNase, NEB, M0247S) digestion at 37 
°C and 1,400 rpm for 2 min. Afterwards, soluble chromatin fractions were pooled together for each 
sample and diluted 8-fold with IP buffer (50 mM Tris HCl pH 7.4, 150 mM NaCl, 0.05 % (vol/vol) 
NP-40, 0.3 % (vol/vol) empigen BB (Sigma-Aldrich, 30326)). For each sample, 30 g of RNA 
polymerase II (Pol II) antibody (Diagenode, C15200004, RRID:AB_2728744) were coupled to 
Dynabeads M-280 Sheep Anti-Mouse IgG (Invitrogen, 11201D) prior to IP step. Diluted chromatin 
was mixed with Pol II antibody-beads complexes and subjected to IP performed on a rotating wheel 
at 4 °C for 1 h. Beads were washed seven times with IP buffer (50 mM Tris HCl pH 7.4, 150 mM 
NaCl, 0.05 % (vol/vol) NP-40, 0.3 % (vol/vol) empigen BB (Sigma-Aldrich, 30326)) and one time 
with PNKT buffer (1 × T4 PNK buffer (NEB, M0236L), 0.1 % vol/vol Tween-20). For the RNA 
phosphorylation, beads were resuspended in PNK reaction mixture containing 1 × T4 PNK buffer 
(NEB, M0236L), 0.1 % vol/vol Tween-20, 1 mM ATP (Cell Signaling Technology, 9804S), T4 
Polynucleotide Kinase (phosphatase minus) (NEB, M0236L) and incubated at 37 °C and 800 rpm 
for 10 min. Beads were washed once with IP buffer and resuspended in TRIzol reagent (Invitrogen, 
15596026). At this point, 5 ng of RNA spike-ins were added to each sample. RNA was extracted 
from the beads and precipitated with GlycoBlue coprecipitant in 100 % ethanol at -20 °C. Next day, 
RNA was size-selected (25-110 nt) using a denaturing 6 % (wt/vol) polyacrylamide gel containing 
7 M urea. RNA was extracted from the gel by incubation with the elution buffer (1 M NaOAc pH 
5.5, 1 mM of EDTA pH 8.0) and precipitated with GlycoBlue coprecipitant (Invitrogen, AM9515) 
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in 100 % ethanol at -20 °C. RNA size distribution and concentration were estimated using Fragment 
Analyzer. RNA samples were used for the library preparation in equal amounts. Libraries were 
prepared using TruSeq Small RNA Library Kit (RS-200-0048) according to the manual and as 
described (Nojima et al., 2015). Purity and size distribution of the libraries were estimated using 
Fragment Analyzer. Libraries were sequenced on Illumina NEXTseq 550 (2 × 42 base paired-end). 
 
50 mL of S. cerevisiae cells (wild type strain BY4741) were grown overnight at 30°C. Cells were 
spin down, and pellet was washed 1 × with 25 mL milli-Q water. Cells from 25 mL volume pellet 
were lysed in 1.5 mL of TSNTE buffer (2 % Triton X-100, 1 % SDS, 100 mM NaCl, 10 mM Tris-
HCl pH 8.0, 1 mM EDTA pH 8.0). One volume of acidic phenol (CarlRoth, A980.2) and 1 volume 
glass beads acid washed (Sigma-Aldrich, G8772) were added to 1 volume of the lysed cells and 
TSNTE buffer mixture. Cell lysate was further homogenized in FastPrep (8 × 40 sec with 1 min on 
ice between each step). Cell lysate was centrifuged at high speed for 5 min. One volume of 
chloroform was added to 1 volume of supernatant. 0.3 M of sodium acetate was added and RNA 
was precipitated overnight in 100 % ethanol. RNA pellet was washed with 75 % ethanol and 
resuspended in 900 l of RNAse-free water. Total RNA quality was checked in Fragment Analyzer. 
200 g of total RNA were subjected to DNAse digestion (TURBO DNA-free DNAse treatment, 
Thermo Fisher Scientific, AM1907) following manufacturer’s instructions. RNA was purified with 
chloroform and precipitated overnight in 100 % ethanol at -20 °C. RNA pellet was washed with 75 
% ethanol, and pellet was resuspended in 50 l of RNAse-free water. Quality of total RNA DNAse-
treated was checked in Fragment Analyzer. 75 g of total RNA DNAse treated were subjected to 
mRNA purification using Dynabeads mRNA Purification kit (Invitrogen, cat n. 61006) following 
manufacturer’s instructions. Two rounds of mRNA purification were performed to eliminate 
possible rRNA contaminants. Approximately 0.4 % of original amount of total RNA was recovered. 
250 ng of purified mRNA was fragmented for 5 min at 94 °C using NEBNext® Magnesium RNA 
Fragmentation Module Protocol (NEB, E6150). 0.3M sodium acetate and 1 l of Glycoblue was 
added to the fragmented mRNA. mRNA was precipitated overnight in 100 % ethanol. RNA was 
washed with 75 % ethanol, and pellet was resuspended in 10 l of RNAse-free water. End-repair 
was performed following NEB manufacturer’s instruction. In details, reaction was incubated for 30 
min at 37 °C (9 l of fragmented mRNA, 5.5 l of RNAse-free water, 0.5 μl of RNAse OUT, 2 μl 
of T4 PNK buffer 10X (NEB, B0201), 1 μl of T4 PNK enzyme (NEB, M0201). 2 μl of 10 mM ATP 
were added to the mixture and the reaction was further incubated for other 30 min at 37 °C. 0.3 M 
sodium acetate and 1 l of Glycoblue was added to the reaction and RNA was precipitated overnight 
in 100 % ethanol. RNA was washed in 75 % ethanol and pellet resupended in 20 μl of RNAse-free 
water. RNA spike-ins quality and size distribution were checked in Fragment Analyzer (miRNA 
kit) and in 6 % urea gel, as described for mNET-seq protocol. Size distribution ranged between       
30 nt and 150 nt, similar to mNET-seq samples.  
 
6 × 107 cells from two biological replicates were treated for 1 h with 1 M of Pla-B (Santa Cruz, 
sc-391691) or DMSO (1:20,000 dilution, Sigma-Aldrich, D2438). Formaldehyde (16 % concentrate 
stock methanol-free, Thermo Fisher Scientific 28908) was directly added to the media to a final 
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concentration of 1 % and incubated for 8 min. 125 mM Glycine (final concentration) was added to 
quench the reaction for 5 min. Cells were spin down and pellet was washed twice with PBS at 4 °C. 
Protease (Merk Millipore, 5892970001) and phosphatase inhibitors (Merk Millipore, 4906845001) 
were added to all the buffers. A pellet from 3 x 107 cells was lysed for 10 min on ice with Farnham 
Lysis buffer (5 mM Pipes pH 8, 85 mM KCl, 0.5 % NP-40). Pellet was centrifuged for 5 min at 
1,700 g at 4 °C. Pellet was resuspended with 1 mL of sonication buffer (10 mM Tris-HCl 7.5 pH, 
1 mM EDTA, 0.4 % SDS) and incubate on ice for 10 min and transfer to AFA milliTube. Sonication 
was performed with a S220 Focused-ultrasonicator (Covaris) with the following parameters: duty 
cycle 5 %, peak incident power 140 W, cycle per burst 200, processing time 1,080 sec, degassing 
mode continuous, water run level 8. Sheared chromatin was centrifuged at 10,000 g for 15 min at 4 
°C. 15 μl of samples were de-cross-linked overnight at 65 °C and size distribution was checked in 
1 % agarose gel. 15 g of RNA polymerase II (Pol II) antibody (Diagenode, C15200004, 
RRID:AB_2728744), 20 g of Cyclin T1 (CycT1) antibody (Cell Signaling, D1B6G, 
RRID:AB_2799973) or 1 g of histone H2Av (Active Motif, 39715) were coupled to Dynabeads 
Protein G (Thermo Fisher Scientific, 10009D) for 2 h at room temperature for each sample. 100 g 
of chromatin was used for each IP. 200 ng of Drosophila S2 sheared cross-linked-chromatin 
(Covaris S200 parameters: duty cycle 5 %, peak incident power 140 W, cycle per burst 200, 
processing time 1,800 sec, degassing mode continuous, water run level 8) were added to 100 g of 
chromatin as spike-ins control. Chromatin was diluted with IP buffer (50 mM Hepes pH 7.9, 150 
mM NaCl, 1 mM EDTA, 1 % Triton X-100, 0.1 % Sodium-deoxycholate) to obtain a 0.05 % final 
concentration of SDS. 1 % of diluted chromatin was kept as input at 4 °C. Diluted chromatin was 
mixed with antibody-beads complexes and subjected to IP performed on a rotating wheel at 4°C 
overnight. Beads were washed 5 times with IP wash buffer (100 mM Tris HCl pH 7.5, 500 mM 
LiCl, 1 % NP-40, 1 % Sodium-deoxycholate) and one time with TE buffer (10 mM Tris-HCl pH 8, 
1 mM EDTA). Immuno-bound chromatin was eluted at 70 °C for 10 min with elution buffer (0.1M 
NaHCO3, 1 %SDS) and de-cross-linked overnight at 65 °C. After RNAse A treatment at 37 °C for 
1.5 h and proteinase K treatment at 45 °C for 2 h, DNA was extracted with one volume 
phenol:chloroform:isoamyl alcohol 25:24:1 (Sigma-Aldrich, P2069) and precipitated for 30 min at 
-80 °C with 200 mM NaCl and 100 % ethanol. Pellet was washed with 70 % ethanol and 
resuspended in TE buffer. DNA quality and size distribution were checked on Fragment Analyzer. 
10 ng of DNA was used for library preparation according to NEBNext® Ultra™ II DNA Library 
Prep Kit (NEB, E7645S). Purity and size distribution of the libraries were estimated using Fragment 
Analyzer. Size-selected libraries were sequenced on Illumina NEXTseq 550 (2 × 75 and 2 × 42 
base paired-end for Pol II and CycT1, respectively). 
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2. Sequence of the spike-ins used on TT-seq and RNA-seq 
experiments. 
Spike-ins are derived from ERCC Spike-in Mix with an addition of 5’ triphosphate to facilitate in 
vitro transcription by T7 polymerase. The triphosphate (GGG) is not included in the sequence. 
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3. Supplementary Figures 
 
 
Figure S1. UTR length impact on intron-containing genes. Related to Figure 7. 
(A and B) Ratio of 1 μM Pla-B to DMSO antisense bias-corrected TT-seq read counts for 5’ UTR (A) and 3’ UTR 
(B) in four different major isoforms UTR length quartiles. 
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Figure S2. TT-seq monitors the decrease of RNA synthesis activity upon Pla-B treatment. Related to Figure 
11, Figure 12 and Figure 13. 
(A) Agarose gel showing spliced and unspliced RT-PCR products for total and 4sU-labeled enriched RNAs upon 
30 min, 1 h, 2 h, and 4 h of 1 M Pla-B and 4 h DMSO treatments for regions spanning the exons 2 and 3 of 
DNAJB1 (unspliced: 597 bp, spliced: 302 bp) and exons 3 and 4 of RIOK3 (unspliced: 650 bp, spliced: 352 bp). 
See also Table S3. (B) Agarose gel band intensity (ImageJ) for spliced and unspliced RT-PCR products for total 
and 4sUlabeled RNAs. See also Table S3. (C) Scatter plots comparing TT-seq replicates using antisense bias-
corrected counts for major isoforms for samples treated with DMSO or 1 M Pla-B (batch 2) for 30 min. Spearman 
correlation of 1. (D) Fragment size distribution between samples. (E) Ratio of 1 M Pla-B to DMSO antisense 
bias-corrected TT-seq read counts for 30 min, 1 h, and 4 h treatment. (F and G) Metagene analysis comparing  
TT-seq signal between cells treated with DMSO or 1 μM Pla-B for 30 min without removing duplicated paired 
reads (F) and with duplicates removal (G). (H and I) Metagene analysis comparing TT-seq signal between cells 
treated with DMSO or 1 μM Pla-B for 1 h for shallow sequenced data without removing duplicated paired reads 
(H) and with duplicate removal (I). (J) Metagene analysis comparing RNA-seq signal between cells treated with 
DMSO or 1 μM Pla-B for 1 h with duplicated removal (as in comparison to Figure 13E without duplicate 
removal). (K) Metagene analysis comparing TT-seq signal between cells treated with DMSO or 1 μM Pla-B for 4 
h with duplicated removal (as in comparison to Figure 13H without duplicate removal). Solid lines represent the 
averaged signal and the shaded area represents 95 % confidence interval of the mean (bootstrap). See also Table 
S5. 
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Figure S3. Alternative splicing analysis using CIGAR strings. Related to Figure 12. 
Reads per million gapped alignments (RPMG) were calculated using the spliceSites R package upon 1 h DMSO 
or 1 μM Pla-B treatment. (A) RPMG for all annotated introns for a total of 7,081 5’ SS and 7,141 3’ SS splice 
junctions. (B) RPMG for 549 spliced junctions on both 5’ SS and 3’ SS of first introns. (B) RPMG for 549 spliced 
junctions on both 5’ SS and 3’ SS of first introns (not last). (C) RPMG for 538 spliced junctions on both 5’ SS and 
3’ SS of second introns (not last). (D) RPMG for 586 spliced junctions on both 5’ SS and 3’ SS of last introns. For 
B, C and D were only used identified gap alignments that comprised two consecutive exons.  
 
 
Figure S4 .TT-seq upon U2snRNP inhibition with 100nM Pla-B. Related to Results section 2 
(A) Agarose gel showing spliced and unspliced RT-PCR products for region spanning exons 2 and 3 of DNAJB1 
of total RNA (unspliced: 597 bp, spliced: 302 bp). Pla-B concentration and batch are indicated for each time point 
(batch 1: G0516, batch 2: B0420). See also Table S3. (B) Scatter plots comparing TT-seq replicates using antisense 
bias-corrected counts for major isoforms for samples treated with DMSO or 100 nM Pla-B (batch 2) for 1 h. 
Spearman correlation of 1. (C) TT-seq fragment size distribution for paired mapped reads upon 1 h DMSO or    
100 nM Pla-B treatment. (D) Ratio of spliced reads over total unspliced and spliced reads upon 1 h DMSO or     
100 nM Pla-B (batch 2). (***) p-value < 2.2 × 10-16 by Wilcoxon signed-rank test. (E and F) Metagene analysis 
comparing TT-seq signal between cells treated with DMSO or 100 nM Pla-B (batch 2) without removing 
duplicated paired reads (E) and with duplicates removal (F). TT-seq coverage was averaged for 5,535 major 
isoforms scaled between TSS and poly(A)-site. Solid lines represent the averaged signal and the shaded area 
represents 95 % confidence interval of the mean (bootstrap). See also Table S5. 
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Figure S5. TT-seq monitors decrease of RNA synthesis activity upon SSA treatment. Related to Figure 15. 
(A) Agarose gel showing spliced and unspliced RT-PCR products for total RNA upon 30 min, 1 h, 2 h and 4 h of 
75 μM U2 AMO treatment and 4 h 75 μM Ctr AMO for regions spanning the exons 2 and 3 of DNAJB1 (unspliced: 
597 bp, spliced: 302 bp) and exons 3 and 4 of RIOK3 (unspliced: 650 bp, spliced: 352 bp). See also Table S3. (B) 
Metagene analysis comparing TT-seq signal between cells treated with DMSO or 30 ng/mL SSA for 1 h with 
paired read duplicates removal (as in comparison to Figure 15D without duplicate removal). TT-seq coverage was 
averaged for 5,535 major isoforms scaled between TSS and poly(A)-site. Solid lines represent the averaged signal 









Figure S6. TT-seq monitors decrease of RNA synthesis activity upon U2 AMO treatment. Related to Figure 
16. 
(A) Agarose gel showing spliced and unspliced RT-PCR products for total RNA upon 30 min, 1 h, 2 h and 4 h of 
30 ng/mL SSA treatment and 4 h DMSO for regions spanning the exons 2 and 3 of DNAJB1 (unspliced: 597 bp, 
spliced: 302 bp) and exons 3 and 4 of RIOK3 (unspliced: 650 bp, spliced: 352 bp). See also Table S3. (B) 
Metagene analysis comparing TT-seq signal between cells treated with 75 μM Ctr AMO or 75 μM U2 AMO for 
1 h with paired read duplicates removal (as in comparison to Figure 16D without duplicate removal). TT-seq 
coverage was averaged for 5,535 major isoforms scaled between TSS and poly(A)-site. Solid lines represent the 
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Figure S7. mNET-seq S. cerevisiae spike-ins normalization. Related to Figure 17. 
(A) Scatter plots comparing mNET-seq replicates using antisense bias-corrected counts for S. cerevisiae transcripts 
for samples treated with DMSO and 1 μM Pla-B for 1 h. Spearman correlation of 1. (B)  mNET-seq fragment size 
distribution for paired reads mapped to the S. cerevisiae genome upon 1 h DMSO or 1 μM Pla-B treatment. (C) 
Metagene analysis used to verify the S. cerevisiae spike-ins normalization method, comparing mNET-seq signal 
between cells treated with DMSO or 1 μM Pla-B for 1 h before spike-ins normalization (left) and after spike-ins 
normalization (right). Replicates are shown separately. mNET-seq coverage was averaged for 5639 S. cerevisiae 
expressed transcripts between TSS and poly(A)-site. (D) Metagene analysis comparing mNET-seq signal between 
cells treated with DMSO or 1 μM Pla-B for 1 h with paired read duplicates removal (as in comparison to Figure 
17C without duplicate removal). TT-seq coverage was averaged for 5,535 major isoforms scaled between TSS 
and poly(A)-site. Solid lines represent the averaged signal and the shaded area represents 95 % confidence interval 
of the mean (bootstrap). See also Table S6. 
 
Figure S8. ChIP-seq input and duplicate removal. Related to Figure 20. 
(A) Scatter plots comparing input used on Pol II IP (left) and input used on CycT1 (right) ChIP-seq replicates 
using counts for major isoforms for samples treated with DMSO and 1 M Pla-B. Spearman correlation of 1. (B) 
Fragment size distribution for paired mapped reads for input for Pol II IP experiment (left) and input for CycT1 
(right) ChIP-seq upon 1 h DMSO or 1 μM Pla-B treatment. (C and D) Metagene analysis comparing ChIP-seq 
signal between cells treated with DMSO or 1 μM Pla-B for 1 h for input used on Pol II IP (C) and input used on 
CycT1 IP (D). ChIP-seq coverage was aligned at the TSS and averaged for 5,465 major isoforms that exceed            
1 kbp in length. (E and F) Metagene analysis comparing ChIP-seq signal between cells treated with DMSO or        
1 μM Pla-B for 1 h with paired read duplicates removal (as in comparison to  Figure 20C-D without duplicate 
removal). ChIP-seq coverage for Pol II (E) and CycT1 (F) was aligned at the TSS and averaged for 5,465 major 
isoforms that exceed 1 kbp in length. Solid lines represent the averaged signal and the shaded area represents 95 
% confidence interval of the mean (bootstrap). See also Table S7. 
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Figure S9. Graph comparing the top 10 enriched GO terms for upregulated transcripts upon Ctr or HS 
treatment for 30 min (Gressel et al., 2019) (QuickGO). Related to Figure 23B. 
 
 
Figure S10. Graph comparing the top 10 enriched GO terms for upregulated transcripts upon DMSO or 1 
µM Pla-B treatment for 1 h (QuickGO). Related to Figure 24A. 
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Figure S11. Graph comparing the top 10 enriched GO terms for upregulated transcripts upon DMSO or 1 
µM Pla-B treatment for 4 h (QuickGO). Related to Figure 24B. 
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Figure S12. Graph comparing the top 10 enriched GO terms for upregulated transcripts upon DMSO or  
30 ng/mL SSA treatment for 1 h (QuickGO). Related to Figure 24C.  
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Figure S13. Graph comparing the top 10 enriched GO terms for upregulated transcripts upon 75 M           
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4. Supplementary Tables 
 
Table S1. Overview of the datasets used in the present study. Related to Introduction section 2. 
Method Treatment Cell type GEO series       Source 
TT-seq  30 min 1 M Pla-B or DMSO  K562 GSE148433 this study 
TT-seq  1 h 1 M Pla-B or DMSO  K562 GSE148433 this study 
RNA-seq  1 h 1 M Pla-B or DMSO  K562 GSE148433 this study 
TT-seq  4 h 1 M Pla-B or DMSO  K562 GSE148433 this study 
TT-seq  1 h 100 nM Pla-B or DMSO  K562 GSE148433 this study 
TT-seq  30 ng/mL SSA or DMSO  K562 GSE148433 this study 
TT-seq  75 M U2 AMO or 75 M Ctr AMO K562 GSE148433 this study 
mNET-seq 1 h 1 M Pla-B or DMSO  K562 GSE148433 this study 
ChIP-seq Pol II 1 h 1 M Pla-B or DMSO  K562 GSE148433 this study 
ChIP-seq CycT1 1 h 1 M Pla-B or DMSO  K562 GSE148433 this study 
mNET-seq 4 h 1 M Pla-B or DMSO  HeLa GSE81662 (Schlackow et al., 2017) 
TT-seq  30 min 42°C HS (or 37°C Ctr) K562 GSE123980 (Gressel et al., 2019) 
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Table S2. Reagents and resources used for the experimental methods for the present work. Related to 
Supplementary information section 1. 
Reagent or resource Source Identifier 
Antibodies 
Mouse monoclonal against RNA polymerase II Diagenode Cat#C15200004, 
RRID:AB_2728744 
Rabbit monoclonal against Cyclin T1  Cell Signaling Cat#D1B6G, 
RRID:AB_2799973 
Chemicals, Peptides, and Recombinant Proteins 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich Cat#D2438 
Pladienolide B Santa Cruz Cat#sc-391691 
Spliceostatin A Gift from Vladimir 
Pena 
- 
4-thiouridine Carbosynth Cat#NT06186 
Empigen  Sigma-Aldrich Cat#30326 
Formaldehyde 16% concentrate stock methanol-free Thermo Fisher 
Scientific   
Cat#28908 
Critical Commercial Assays 
Plasmo Test Mycoplasma Detection Kit InvivoGen Cat#rep-pt1 
CellTiter 96® AQueous One Solution Cell Proliferation Assay  Promega Cat#G3580 
NEON system  Invitrogen Cat#MPK10025 
Ovation Universal RNA-seq System  NuGEN Cat#0343-32 
TruSeq Small RNA Library Kit  Illumina  Cat#RS-200-0048 
NEBNext® Ultra™ II DNA Library Prep Kit NEB Cat#E7645S 
Experimental Models: Cell Lines 
Human: K562 (female) DSMZ  ACC-10, 
RRID:CVCL_0004 
Human: HeLa S3 (female) GBF (Helmholtz 
Center for Infection 
Research, Brunswick) 
RRID:CVCL_0058 
Saccharomyces cerevisiae strain: BY4741 Euroscarf ACC-Y00000 
Drosophila melanogaster: Schneider 2 (S2)  DSMZ ACC-130 
RRID:CVCL_Z232 
Oligonucleotides 
Ctr AMO: CCTCTTACCTCAGTTACAATTTATA GeneTools - 
U2 AMO: TGATAAGAACAGATACTACACTTGA GeneTools - 
Recombinant DNA 
pCMV-GLuc 2 control plasmid  NEB Cat#N8081 
pGL4.10[luc2] vector Promega Cat#E6651 
pSV40-CLuc control plasmid  NEB Cat#N0318S 
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Table S3. Primers used for RT-PCR. Related to Figure S2, Figure S4, Figure S5 and Figure S6. 
Primer sequences used for total and 4sU-labeled RNA semiquantitative-PCRs 
Gene Primer sequence  
DNAJB1_RT-PCR_agarose gel_F GAACCAAAATCACTTTCCCCAAGGAAGG 
DNAJB1_RT-PCR_agarose gel_R AATGAGGTCCCCACGTTTCTCGGGTGT  
RIOK3_RT-PCR_agarose gel_F GCTGAAGGACCATTTATTACTGGAG 
RIOK3_RT-PCR_agarose gel_R TTCTTGCTGTGTTCTTTCTCCCACA 
Table S4. Names and length of Human, S. cerevisiae and D. melanogaster genomes. Related to Methods 
section 2.2 and 2.3 
chr: chromosome 
Human S. cerevisiae D. melanogaster 
chr name chr length chr name chr length chr name chr length 
chr1 248956422 I 230218 2L 23513712 
chr2 242193529 II 813184 2R 25286936 
chr3 198295559 III 316620 3L 28110227 
chr4 190214555 IV 1531933 3R 32079331 
chr5 181538259 V 576874 4 1348131 
chr6 170805979 VI 270161 X 23542271 
chr7 159345973 VII 1090940 Y 3667352 




chr9 138394717 IX 439888   
chr10 133797422 X 745751   
chr11 135086622 XI 666816   
chr12 133275309 XII 1078177   
chr13 114364328 XIII 924431   
chr14 107043718 XIV 784333   
chr15 101991189 XV 1091291   
chr16 90338345 XVI 948066   
chr17 83257441 Mito 85779   
chr18 80373285     
chr19 58617616     
chr20 64444167     
chr21 46709986     
chr22 50818468     
chrX 156040895     





Chapter VI: Supplementary information 
 89 
Table S5. Sequencing statistics for the TT-seq data used in this analysis. Related to Results section 1 and 2 
and Figure S2, Figure S4, Figure S5 and Figure S6. 
Two replicates are indicated as “rep 1” and “rep 2”. Paired-end libraries (2 x 75 bp if not stated otherwise) were 
sequenced on the Illumina NextSeq500. TT-seq samples treated with DMSO or 1 M Pla-B for 1 h were subjected 
to a shallow sequencing (2 x 75 bp) and further sequenced deeper with 2 x 150 bp reads. The two were concatenated 
(75 bp + 150 bp) for further analysis. The percentage of deduplicated reads corresponds to the percentage of 
distinct reads, formed by singletons (reads found one single time) and distinct duplicated reads (distinct reads 
duplicated n times). Uniquely mapped reads number correspond to the paired reads mapped to the genome with 
STAR (Dobin et al., 2013) and filtered with Samtools (Li et al., 2009). Duplicated paired reads were calculated 
















35 514 609 71.71, 63.44 33 943 592 19.27 - 
DMSO  
rep 2 
40 2846 911 67.03, 58.45 40 918 852 22.46 - 
Pla-B rep 1 42 925 965 65.97, 58.02 41 055 445 25.12 - 






36 784 363 66.10, 58.07 35 092 648 25.61 GSM4471381  
DMSO  
rep 2 
54 075 738 56.03, 48.65 51 362 916 36.35 GSM4471382  
Pla-B rep 1 45 519 747 60.16, 53.32 43 291 101 32.08 GSM4471383  
Pla-B rep 2 47 769 843 59.25, 52.71 45 243 934 32.99 GSM4471384  
TT-seq 




79 334 466 53.07, 46.01 




91 357 858 45.98, 38.91 
125 106 525 53.66 
GSM4471386  
Pla-B rep 1 800 34 812 50.69, 43.88 106 774 758 45.41 GSM4471387  
Pla-B rep 2 100 620 427 47.73, 41.70 127 100 081 47.73 GSM4471388  
TT-seq 1 h  
(75 bp + 
 150 bp) 
DMSO rep 
1 
116 118 829 50.43, 43.27 100 388 896 41.78 - 
DMSO  
rep 2 
145 433 596 41.87, 35.74 125 106 525 53.66 - 
Pla-B rep 1 125 554 559 47.38,41.27 106 774 758 45.41 - 





41 527 090 66.51, 57.62 39 622 355 24.54 GSM4471393  
DMSO  
rep 2 
38 030 584 66.98, 58.40 36 288 697 24.16 GSM4471394  
Pla-B rep 1 37 943 066 60.48, 52.99 36 054 517 29.75 GSM4471395  





25 555 667 54.15,51.46 21 726 274 31.86 GSM4471389  
DMSO  
rep 2 
25 352 910 41.89,39.37 21 661 759 48.99 GSM4471390  
Pla-B rep 1 26 470 018 53.83, 51.19 22 763 649 32.35 GSM4471391  
Pla-B rep 2 25 278 414 50.47, 47.84 21 336 150 39.36 GSM4471392  




Pla-B 1 h 
DMSO  
rep 1 
44 612 305 71.31, 61.83 40 971 048 18.89 GSM4970206  
DMSO  
rep 2 
59 984 807 67.21, 58.27 54 863 640 23.84 GSM4970207  
Pla-B rep 1 52 893 216 36.20, 31.97 48 186 952 65.06 GSM4970208  
Pla-B rep 2 46 519 479 48.34, 41.07 42 198 478 46.03 GSM4970209  
 
TT-seq  
SSA 1 h 
DMSO  
rep 1 
48 437 487 67.33, 58.47 44 895 714 24.73 GSM4970210  
DMSO  
rep 2 
43 831 288 65.1, 57.23 40 724 390 27.91 GSM4970211  
SSA rep 1 53 256 104 63.84, 57.33 49 148 708 28.73 GSM4970212  
SSA rep 2 50 337 889 65.36, 57.88 46 615 663 26.97 GSM4970213  
TT-seq  





48 849 741 64.95, 55.49 44 676 201 25.04 GSM4970214  
Ctr AMO 
rep 2 
43 150 243 70.5, 61.38 39 428 950 20.01 GSM4970215  
U2 AMO 
rep 1 
39 322 274 57.07, 48.79 35 628 696 35.04 GSM4970216  
U2 AMO 
rep 2 
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Table S6. Sequencing statistics for the mNET-seq data used in this analysis. Related to Results section 3 and 
Figure S7. 
Two replicates are indicated as “rep 1” and “rep 2”. Paired-end libraries (2 x 42 bp) were sequenced on the Illumina 
NextSeq500. The percentage of deduplicated reads corresponds to the percentage of distinct reads, formed by 
singletons (reads found one single time) and distinct duplicated reads (distinct reads that are duplicated n times). 
Uniquely mapped reads number correspond to the paired reads mapped to the human hg38 (GRCh38) and S. 
cerevisiae sacCer3 (R64-1-1) combined genome with STAR (Dobin et al., 2013) and filtered with Samtools (Li et 
al., 2009). Duplicated paired reads were calculated with Picard tools (Broad Institute, 2019). 
Treatment 
 
DMSO rep 1 DMSO rep 2 Pla-B rep 1 Pla-B rep 2 
Sequenced reads 213 855 281 195 923 363 185 903 379 169 665 589 
Deduplicated sequenced  
reads (% read 1, read 2) 




Total 137 746 586 125 218 396 122 226 432 113 651 005 
Human 113 284 917 101 935 180 94 567 048 85 705 434 
Human (%) 82.24 81.41 77.37 75.41 
S. cerevisiae 24 461 669 23 283 216 27 659 384 27 945 571 
S. cerevisiae (%) 17.76 18.59 22.63 24.59 
Duplicated paired reads 54.07 51.56 55.33 55.16 
GEO number  GSM4471397  GSM4471398  GSM4471399  GSM4471400  
 
Table S7. Sequencing statistics for the ChIP-seq data used in this analysis. Related to Results section 5 and 
Figure S8. 
Two replicates are indicated as “rep 1” and “rep 2”. Paired-end libraries (2 x 75 bp for Pol II and 2 x 42 bp for 
CycT1) were sequenced on the Illumina NextSeq500. Pol II and CycT1 IP were performed in distinct experiments 
and therefore were generated two input samples. The percentage of deduplicated reads corresponds to the 
percentage of distinct reads, formed by singletons (reads found one single time) and distinct duplicated reads 
(distinct reads duplicated n times). Uniquely mapped reads number correspond to the paired reads mapped to the 
human hg38 (GRCh38) and D. melanogaster dm6 (BDGP6.28) combined genome with STAR (Dobin et al., 2013) 
and filtered with Samtools (Li et al., 2009). Duplicated paired reads were calculated with Picard tools (Broad 
Institute, 2019). 
Sample Treatment Sequenced reads 
Deduplicated sequenced 
reads (% read 1, read 2) 
Duplicated  
paired reads 
GEO number  
input 1 
DMSO rep 1 42 143 914 95.38, 95.48 2.91 GSM4970218  
DMSO rep 2 41 068 397 95.70, 95.70 2.93 GSM4970219  
Pla-B rep 1 43 973 742 95.25, 95.33 3.32 GSM4970220  
Pla-B rep 2 55 890 334 95.08, 95.14 3.31 GSM4970221  
Pol II 
DMSO rep 1 19 135 434 92.93, 93.61 7.81 GSM4970222  
DMSO rep 2 19 431 013 93.37, 93.92 6.77 GSM4970223  
Pla-B rep 1 29 352 773 92.01, 92.59 8.09 GSM4970224  
Pla-B rep 2 10 024 957 94.23, 94.91 5.98 GSM4970225  
input 2 
DMSO rep 1 31 787 818 94.20, 94.37 2.69 GSM4970226  
DMSO rep 2 32 0544 51 94.71, 94.64 2.35 GSM4970227  
Pla-B rep 1 40 785 308 93.89, 93.88 2.75 GSM4970228  
Pla-B rep 2 42 160 671 94.01, 93.89 2.78 GSM4970229  
CycT1 
DMSO rep 1 30 000 866 93.36, 93.04 3.66 GSM4970230  
DMSO rep 2 31 438 774 93.07, 93.17 3.57 GSM4970231  
Pla-B rep 1 40 730 438 92.46, 92.64 3.23 GSM4970232  
Pla-B rep 2 28 048 798 93.27, 93.43 3.61 GSM4970233  
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Table S8. Reads distribution per genome. Related to Results section 5. 
Uniquely mapped reads number correspond to the paired reads mapped to the genome with STAR (2.6.0, 
RRID:SCR_015899) (Dobin et al., 2013) and filtered with Samtools (1.3.1, RRID:SCR_002105) (Li et al., 2009).  
Sample Treatment 
Uniquely mapped reads 
Total Human Human (%) D. melanogaster D. melanogaster (%) 
Input 1 
DMSO rep 1 38494817 38458645 99.91 36172 0.09 
DMSO rep 2 37717106 37668833 99.87 48273 0.13 
Pla-B rep 1 40165741 40120100 99.89 45641 0.11 
Pla-B rep 2 51112255 51067169 99.91 45086 0.09 
Pol II 
DMSO rep 1 14152608 14077899 99.47 74709 0.53 
DMSO rep 2 13297544 13245849 99.61 51695 0.39 
Pla-B rep 1 22928355 22823066 99.54 105289 0.46 
Pla-B rep 2 5915592 5896421 99.68 19171 0.32 
Input 2 
DMSO rep 1 28595714 28517919 99.73 77795 0.27 
DMSO rep 2 28796195 28731252 99.77 64943 0.23 
Pla-B rep 1 36576410 36500999 99.79 75411 0.21 
Pla-B rep 2 37926653 37842232 99.78 84421 0.22 
CycT1 
DMSO rep 1 26304890 26191607 99.57 113283 0.43 
DMSO rep 2 27615374 27503670 99.60 111704 0.40 
Pla-B rep 1 35460620 35326434 99.62 134186 0.38 
Pla-B rep 2 24344919 24259236 99.65 85683 0.35 
 
 
Table S9. Overview of upregulated genes between 1 h DMSO or 1 M Pla-B treatment. Related to Results 
section 7 and Figure 23C. 
Gene description from Ensembl annotation. BST2 gene was also upregulated genes upon 30 min HS. 
Transcript 
identifier 
Gene name Gene description 
NM_012094 PRDX5 peroxiredoxin 5 [Source:HGNC Symbol;Acc:HGNC:9355] 
NM_001003 RPLP1 ribosomal protein lateral stalk subunit P1 [Source:HGNC 
Symbol;Acc:HGNC:10372] 
NM_005332 HBZ hemoglobin subunit zeta [Source:HGNC Symbol;Acc:HGNC:4835] 
NM_194434 VAPA VAMP associated protein A [Source:HGNC Symbol;Acc:HGNC:12648] 
NM_001863 COX6B1 cytochrome c oxidase subunit 6B1 [Source:HGNC 
Symbol;Acc:HGNC:2280] 
NM_198589 BSG basigin (Ok blood group) [Source:HGNC Symbol;Acc:HGNC:1116] 
NM_000041 APOE apolipoprotein E [Source:HGNC Symbol;Acc:HGNC:613] 
NM_001172667 FAM178B FAM178B family with sequence similarity 178 member B 
[Source:HGNC Symbol;Acc:HGNC:28036] 
NM_004335 BST2 bone marrow stromal cell antigen 2 [Source:HGNC 
Symbol;Acc:HGNC:1119] 
NM_017854 TMEM160 transmembrane protein 160 [Source:HGNC Symbol;Acc:HGNC:26042] 
NM_013335 GMPPA GDP-mannose pyrophosphorylase A [Source:HGNC 
Symbol;Acc:HGNC:22923] 
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Table S10. Overview of upregulated genes between 4 h DMSO or 1 M Pla-B treatment. Related to Results 
section 7 and Figure 23D. 
Gene description from Ensembl annotation. ARL6IP5, MSMO1 and SQLE genes were also upregulated upon 30 
min HS treatment. 
Transcript 
identifier 
Gene name Gene description 
NM_194434 VAPA VAMP associated protein A [Source:HGNC Symbol;Acc:HGNC:12648] 
NM_002167 ID3 inhibitor of DNA binding 3, HLH protein [Source:HGNC 
Symbol;Acc:HGNC:5362] 
NM_001305066 TMEM59 transmembrane protein 59 [Source:HGNC Symbol;Acc:HGNC:1239] 
NM_021970 LAMTOR3 late endosomal/lysosomal adaptor, MAPK and MTOR activator 3 
[Source:HGNC Symbol;Acc:HGNC:15606] 
NM_001330663 HMGCS1 3-hydroxy-3-methylglutaryl-CoA synthase 1 [Source:HGNC 
Symbol;Acc:HGNC:5007] 
NM_005648 ELOC elongin C [Source:HGNC Symbol;Acc:HGNC:11617] 
NM_006407 ARL6IP5 ADP ribosylation factor like GTPase 6 interacting protein 5 
[Source:HGNC Symbol;Acc:HGNC:16937] 
NM_006745 MSMO1 methylsterol monooxygenase 1 [Source:HGNC 
Symbol;Acc:HGNC:10545] 
NM_003129 SQLE squalene epoxidase [Source:HGNC Symbol;Acc:HGNC:11279] 
 
 
Table S11. Overview of upregulated genes between 1 h DMSO or 30 ng/mL SSA treatment. Related to 
Results section 7 and Figure 23E. 
Gene description from Ensembl annotation. 
Transcript 
identifier 
Gene name Gene description 
NM_017828 COMMD4 COMM domain containing 4 [Source:HGNC Symbol;Acc:HGNC:26027] 
NM_005332 HBZ hemoglobin subunit zeta [Source:HGNC Symbol;Acc:HGNC:4835] 
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Table S12. Overview of upregulated genes between 1 h 75 μM Ctr AMO or 75 μM U2 AMO treatment. 
Related to Results section 7 and Figure 23F. 




Gene name Gene description 
NM_005252 FOS Fos proto-oncogene, AP-1 transcription factor subunit [Source:HGNC 
Symbol;Acc:HGNC:3796] 
NM_014117 C16orf72 chromosome 16 open reading frame 72 [Source:HGNC 
Symbol;Acc:HGNC:30103] 
NM_000981 RPL19 ribosomal protein L19 [Source:HGNC Symbol;Acc:HGNC:10312] 
NM_194434 VAPA VAMP associated protein A [Source:HGNC 
Symbol;Acc:HGNC:12648] 
NM_014280 DNAJC8 DnaJ heat shock protein family (Hsp40) member C8 [Source:HGNC 
Symbol;Acc:HGNC:15470] 
NM_024700 SNIP1 Smad nuclear interacting protein 1 [Source:HGNC 
Symbol;Acc:HGNC:30587] 
NM_001354602 TMEM269 transmembrane protein 269 [Source:HGNC 
Symbol;Acc:HGNC:52381] 
NM_001009899 USF3 upstream transcription factor family member 3 [Source:HGNC 
Symbol;Acc:HGNC:30494] 
NM_005908 MANBA mannosidase beta [Source:HGNC Symbol;Acc:HGNC:6831] 
NM_005275 GNL1 G protein nucleolar 1 (putative) [Source:HGNC 
Symbol;Acc:HGNC:4413] 
NM_001527 HDAC2 histone deacetylase 2 [Source:HGNC Symbol;Acc:HGNC:4853] 
NM_002489 NDUFA4 NDUFA4, mitochondrial complex associated [Source:HGNC 
Symbol;Acc:HGNC:7687] 
NM_015713 RRM2B ribonucleotide reductase regulatory TP53 inducible subunit M2B 
[Source:HGNC Symbol;Acc:HGNC:17296] 
NM_001301668 AZIN1 antizyme inhibitor 1 [Source:HGNC Symbol;Acc:HGNC:16432] 
NM_001206 KLF9 Kruppel like factor 9 [Source:HGNC Symbol;Acc:HGNC:1123] 
NM_033198 PIGS phosphatidylinositol glycan anchor biosynthesis class S 
[Source:HGNC Symbol;Acc:HGNC:14937] 
NM_000998 RPL37A ribosomal protein L37a [Source:HGNC Symbol;Acc:HGNC:10348] 
NM_015508 TIPARP TCDD inducible poly(ADP-ribose) polymerase [Source:HGNC 
Symbol;Acc:HGNC:23696] 
NM_001319236 RPL34 ribosomal protein L34 [Source:HGNC Symbol;Acc:HGNC:10340] 
NM_018321 BRIX1 BRX1, biogenesis of ribosomes [Source:HGNC 
Symbol;Acc:HGNC:24170] 
NM_001964 EGR1 early growth response 1 [Source:HGNC Symbol;Acc:HGNC:3238] 
NM_004282 BAG2 BCL2 associated athanogene 2 [Source:HGNC 
Symbol;Acc:HGNC:938] 
NM_006716 DBF4 DBF4 zinc finger [Source:HGNC Symbol;Acc:HGNC:17364] 
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